close

Joan J. Dean

Generic drugs

Global Generic Drugs Market Report 2022-2026

Dublin, Aug. 12, 2022 (GLOBE NEWSWIRE) — The Generic Drugs – Global Market Trajectory & Analytics report has been added to ResearchAndMarkets.com’s offer.

Global generic drug market to reach $507.8 billion by 2026

Amid the COVID-19 crisis, the global generic drug market estimated at US$402.9 billion in 2022 is expected to reach a revised size of US$507.8 billion by 2026, growing at a CAGR of 5.6% over the analysis period.

A key advantage for generic drug manufacturers is that they do not need to invest time and money in drug R&D and marketing efforts, as generic drug prices are significantly lower compared to their branded counterparts.

Generic small molecules, one of the segments analyzed in the report, is expected to grow at a CAGR of 5.2% to reach US$325.7 billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and the induced economic crisis, the growth of the biosimilars segment is readjusted to a revised CAGR of 6.3% for the next 7-year period.

This segment currently accounts for a 37.7% share of the global generic drug market. With several factors encouraging growth contributing to wider adoption, biosimilars are poised to increase their share of the global generic drug market in the coming years. The rise of biosimilars has notably reduced overall drug spending in recent years, a trend that is expected to continue for the foreseeable future.

The emergence of biosimilars in the market leads to increased competition, the next generation of biologics under development aims to improve safety, efficacy and cost factors compared to the drugs of the previous generation, which further adds to the competitive heat in the market.

The US market is estimated at $121.8 billion in 2022, while China is expected to reach $91.2 billion by 2026

The generic drug market in the United States is estimated to be worth US$121.8 billion in 2022. The country currently accounts for a 30.46% share of the global market. China, the world’s second largest economy, is expected to reach an estimated market size of US$91.2 billion in 2026 growing at a CAGR of 7.2% over the analysis period.

Other noteworthy geographic markets include Japan and Canada, each forecasting growth of 3.8% and 5% respectively over the analysis period. In Europe, Germany is expected to grow at a CAGR of approximately 4.3%, while the rest of the European market (as defined in the study) will reach US$97.6 billion by the end of the outlook period. ‘to analyse.

The market is expected to be driven by the ever increasing risk of various chronic diseases such as hypertension, obesity and diabetes. Although pharmaceutical companies continue to develop branded drugs due to the shortage of new blockbuster drugs coming to market, generic drugs are expected to continue to meet the majority of these therapeutic needs of the population, especially the elderly population. in expansion.

With the high cost of brand name drugs becoming a financial burden on people, efforts have intensified to develop cost-effective generic variants. Many branded drugs are unable to extend their exclusivity, resulting in the loss of patents and making way for affordable generics to be manufactured. Major application areas of generic drugs include cardiology, anti-infection, anti-arthritis, CNS, anti-cancer, and respiratory, among others.

Generic drugs for cardiovascular diseases currently represent the dominant segment, accounting for the majority share of the overall market. Cardiovascular diseases such as heart failure, high blood pressure, circulatory disorders, dyslipidemia, cholesterol, arrhythmias, strokes and angina pectoris are the leading causes of death worldwide.

The cardiovascular segment is expected to cover a larger portion of the global generic drugs market owing to several patent expirations of these drugs. Generic drugs for infectious diseases would gain popularity over the next few years, mainly due to the increasing number of cases around the world.

The COVID-19 pandemic has emerged as a significant growth driver for the generic drug market over the past year. As nations’ economies collapsed due to rising unemployment, the demand for cheaper substitutes for brand name drugs grew.

What’s new for 2022?

  • Global competitiveness and percentage market shares of main competitors
  • Market presence in multiple geographies – Strong/Active/Niche/Trivial
  • Peer-to-peer collaborative online interactive updates
  • Access to digital archives
  • Free updates for one year

Main topics covered:

I. METHODOLOGY

II. ABSTRACT

1. MARKET OVERVIEW

  • Generic drugs – Percentage of market share of the main global competitors in 2022 (E)
  • Progress on vaccinations, why should companies care?
  • These are times when questions abound and answers are few.
  • With the IMF’s upward revision of global GDP forecasts for 2021, most businesses are optimistic about a global economic comeback.
  • A strong economic rebound in 2021 based on pent-up demand comes as relief for struggling industries and markets
  • How has the healthcare industry been and continues to be impacted by the pandemic and what is the new normal?
  • With the COVID-19 pandemic exposing the lack of global health care preparedness, policies are increasingly focused on restarting health systems around the world: current and required health expenditure as % of GDP
  • Impact of the COVID-19 crisis on the generic drugs market
  • Demand for generic painkillers is increasing
  • A prelude to generic drugs
  • The generic drug market is poised for rapid growth
  • US dominates, Asia-Pacific shows fastest growth
  • India – An important market
  • Market constraints
  • Competition
  • Recent market activity

2. FOCUS ON CERTAIN PLAYERS (Total 42 Featured)

  • Abbott Laboratories
  • Apotex Inc.
  • ASKA Pharmaceutical Co., Ltd.
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca Plc
  • Baxter International Inc.
  • Dr. Reddy’s Laboratories Limited
  • Eli Lilly and company
  • Endo International plc
  • Fresenius Kabi
  • GlaxoSmithKline Plc.
  • H.Lundbeck A/S
  • Hospira
  • Lupine Pharmaceuticals, Inc.
  • Mylan S.A.
  • Novartis International SA
  • Novo Nordisk A/S
  • F. Hoffmann-La Roche SA
  • Sandoz International GmbH
  • Sanofi-Aventis US LLC
  • STADA Arzneimittel AG
  • Sun Pharma
  • Teva Pharmaceutical Industries Ltd.

3. MARKET TRENDS AND DRIVERS

  • Patent expirations expected to expand potential generic drug market
  • Expiry of patents for certain drugs in 2020
  • Expiry of patents for certain drugs in 2021
  • Expiry of patents for certain drugs in 2022
  • Expiration of patents for certain major drugs in the United States: 2020-2022
  • High demand for pharmaceutical drugs drives demand for generic drugs
  • Cost containment measures focus on generics
  • Small molecule generics are the dominant segment
  • Increased demand for biosimilars, driven by expiring patents for key biopharmaceutical drugs
  • Expiration of patents for major biopharmaceutical drugs in the United States and Europe
  • A progressive regulatory framework accelerates product approvals and subsequently market revenue
  • Specific guidelines for biosimilars in various countries with year of publication
  • Biosimilar regulators in selected regional markets
  • US biosimilar approvals (as of February 2021)
  • Biosimilar approvals in Europe (from January 2021)
  • Rising healthcare costs drive demand for generic drugs
  • An aging population to propel demand for generic drugs
  • Growing prevalence of chronic diseases is driving demand for generic drugs
  • Global cost of chronic diseases (in billions of US dollars) for the years 2018 and 2030
  • Deaths by heart disease – Estimated percentage distribution for cardiovascular disease, ischemic heart disease, stroke and other

4. GLOBAL MARKET OUTLOOK

III. REGIONAL MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/q8s3o4

  • Global Generic Drugs Market


        
read more
Prescription drugs

High school seniors playing contact sports more likely to abuse prescription drugs in their 20s – The Hill

The story at a glance


  • Researchers collected data from more than 4,000 high school students from 2006 to 2017, then followed them for a decade to measure the relationship between sports participation and prescription drug abuse.

  • The team looked at contact, semi-contact and non-contact sports, and found that athletes are more likely than non-athletes to abuse prescription stimulants.

  • About 31% of people aged 17 to 18 reported abusing prescription drugs in the last year of the study period.

High school students who play sports are more likely than non-athletes to abuse prescription stimulants during their 20s, but those who play contact sports are even more likely than their peers to do so, according to a new study.

Researchers at the University of Michigan collected data from 4,777 12e students from 2006 to 2017 and then followed them for a decade to measure the relationship between high school sports participation and prescription drug abuse.

The team looked at contact, semi-contact and non-contact sports, and found that athletes are more likely than non-athletes to abuse prescription stimulants. They found that seniors who play contact sports are 50% more likely than those who haven’t played contact sports to abuse prescription stimulants over the next decade.

Additionally, the percentage of athletes involved in contact athletics who reported using prescription stimulants as seniors increased by 7% between the ages of 21 and 22. About 31% of people aged 17 to 18 reported abusing prescription drugs in the last year of the study period. .

America is changing faster than ever! Add Change America to your Facebook Where Twitter stream to stay up to date with the news.

The study’s lead author, Philip Veliz, an associate research professor at the University of Michigan School of Nursing, said that while opioid use among athletes in contact sports was higher , participation did not trigger any abuse.

Veliz said the abuse of opioids and stimulants has declined over the decade, “the study found that certain types of former high school athletes are at greater risk of abusing these drugs and initiate in early adulthood”.

The researchers said the study results “strengthen screenings” for monitoring drug abuse among high school athletes.

“Increased abuse of prescription stimulants after high school warrants continued monitoring into adulthood, especially in athletes,” Sean Esteban McCabe, lead author and director of DASH, the Center for the Study of Drug, Alcohol, Smoking, and Health from the University of Michigan. School of Nursing, said in the statement.

Posted on August 11, 2022

read more
Medical products

Fake test kits, seized medical products

Police show off falsely labeled ATKs, face masks and other goods seized in raids on premises in Nakhon Pathom and Nonthaburi on Thursday. (Photo: Wassayos Ngamkham)

Fake Covid-19 antigen test kits and other medical equipment, worth around 2 million baht, were seized in raids by police in Nakhon Pathom and Nonthaburi provinces on Thursday.

Teams of Consumer Protection Police Division (CPPD) officers and Food and Drug Administration (FDA) officials first searched a commercial building in tambon Naraphirom of Bang Len district in Nakhon Pathom .

They seized tens of thousands of antigen test kits (ATKs) that were falsely labeled with brand names such as Testsealabs Gica, Testsealabs Nex and Zybio, along with face masks and other products.

A woman identified only as Anusara admitted to owning the goods and the building, Central Bureau of Investigation Commissioner Lt. Gen. Jirabhob Bhuridej said.

The second raid took place at a tambon Bang Khen house in Muang district of Nonthaburi. There they seized ATKs falsely labeled as Testsealab Gia, Testsealabs Nex, Greenspring, Singclean, Seinofy, Hip, Deepblue, Humansis, Bioteke and Ustar, as well as medical gloves, oximeters and Chinese herbal products.

A woman identified only as Patyaphorn admitted to owning the house and property.

The items seized from the two locations were worth around 2 million baht in total, the CIB chief said.

The raids followed complaints that unscrupulous people were selling unapproved products falsely labeled with FDA-approved brand names.

CPPD Branch 4 Chief Pol Col Neti Wongkulab said a police investigation revealed that falsely labeled ATKs were being sold at low prices through Facebook accounts run by the two women since April. They sold ATKs for 40 to 45 baht each, cheaper than brands normally sold, Pol Col Neti said.

The police posed as customers, buying the ATKs from a shop near the site of the first raid in Nakhon Pathom. They then searched the nearby commercial building and found the same products packaged and ready for distribution. This led to the raid on the house in Nonthaburi.

Pol Col Neti said the next step would be to arrest the Chinese national who allegedly supplied these counterfeit products. Investigators believed at least four people were involved.

FDA Secretary General Paisarn Dunkum said oximeters and ATKs are medical devices. Tampering with medical equipment affects quality and safety and poses a danger to medical staff and patients.

Tampering with medical equipment is punishable by up to 10 years in prison and/or a fine of one million baht, Dr Paisarn said.

read more
Medical supplies

Key to Automated Payments for Medical Supplies

PYMNTS recently met with two of the players in the health sector.

On the purchase side, Huntington Healthwhich is affiliated with the Cedars-Sinai Health System in California, shared how faster and more efficient delivery of vital medical supplies is occurring despite limited supplies and other recently exposed system weaknesses.

From a financial point of view, American Express shared his perspective on the history, status quo and future of digitization and automation of payments in the healthcare sector, which accounts for nearly 20% of gross domestic product (GDP).

Read more: B2B Payments in Healthcare Tracker®

The buy side

Like many other health systems, Huntington Health faces payment issues when purchasing medical supplies, seeking faster and more efficient payment processes instead. Embracing technology and trusted financial partnerships can ease friction.

Huntington buys about $100 million worth of supplies and equipment a year – even bandages. The pandemic has tested purchases with a mad rush for specialized types of equipment, such as N95 masks and ventilators, which are not normally stocked in bulk or available in large quantities from medical supply suppliers. trusted or even government stocks.

The pandemic presented a unique day-to-day scenario where the hospital needed to be prepared to write a check or quickly transfer money outside of its normal purchasing systems, which required manual billing, shipping, and Accounts Payable (AP) .

Slowly, this is changing as hospitals are beginning to see the benefits of using enterprise resource planning (ERP) solutions to streamline different processes and work towards achieving overall organizational efficiency. Still, it takes time to implement new technologies in large healthcare organizations, and Huntington is about three years away from full adoption.

The use of electronic payments is also growing. The number of ACH healthcare payments in the second quarter of 2022 was 113.7 million, an increase of 5.3% compared to the 108 million ACH healthcare payments in the second quarter of 2021, according at Nasha.

Yet while providers prefer ACH payments and direct deposits, their customers are making up to 85% of their payments by check or other paper-based methods, as shown in the B2B Payments in Healthcare Tracker, a collaboration between PYMNTS and American Express.

The healthcare industry is also facing staffing shortages in many different disciplines. Huntington is working to adopt artificial intelligence and robotics technology that can help reduce the need for human effort.

The Financial Sector Perspective

American Express believes that automation can improve medical supplies procurement and supplier relationships. The shape of things to come implies a future in which automation will continue as procurement ensures supply chain efficiency.

Healthcare is particularly sensitive to pandemic issues, and many back-office employees are still inclined to work from home. Digital access to physical assets, such as ledgers, invoices and checks, widely adopted during shutdowns, continues to enable this trend, helping to address labor shortages while reducing workforces by maximizing efficiency and effectiveness.

Remote back office work also frees up facility space for clinical and wellness revenue generating uses.

See also: Health accounts for 20% of GDP which desperately needs payment efficiency

Automated billing creates a backbone of supply support to deliver critical medical supplies on time. Fully automated AP and Accounts Receivable (AR) processes with electronic invoicing can eliminate friction by correcting discrepancies.

Hospitals have embraced AP automation solutions, which conversely have vendors looking for AR solutions and payment portals to maximize receivable collection rates and treasury applications while using solutions supply chain finance.

The challenges of travel

The journey to the promised land necessarily requires a trek through the desert. Supply is challenged by a myriad of factors, especially when visibility into hospital inventory is poor.

Internally, data management can be difficult when working on decentralized legacy systems. Teams that can still take very manual steps to place orders will cause delivery delays, further blurring visibility into inventory levels, orders, and delivery schedules.

Externally, ongoing changes in regulatory requirements are impacting on-demand medical supplies that need to be stocked. Additional tension occurs when demand spikes, bidding processes lack transparency, and supply chain procurement logistics come to a halt.

Concentration remains a problem. While nothing focuses the mind quite as wonderfully as the prospect of a pandemic, hospitals and healthcare systems are still focused on other priorities, including clinics, compliance, revenue cycle management, and consolidation. after the merger and acquisition.

A common goal

Huntington looks forward to the time when direct payments to overseas suppliers can be made by machines that can instantly account for supply chain delays. By using pre-authorized payment methods such as virtual cards, machines can ensure a steady flow of supplies and pay for them in local currency.

Meanwhile, American Express envisions the convergence of buyers and suppliers under the umbrella of automation. FinTechs and financial institutions will be instrumental in providing the healthcare industry with the payment digitization and automation solutions it needs to succeed in this matter of life and death.

For all PYMNTS B2B coverage, subscribe daily B2B Newsletter.

——————————

NEW PYMNTS SURVEY FINDS 3 IN 4 CONSUMERS HAVING HIGH DEMAND FOR SUPER APPS

About: Results from PYMNTS’ new study, “The Super App Shift: How Consumers Want To Save, Shop And Spend In The Connected Economy,” a collaboration with PayPal, analyzed responses from 9,904 consumers in Australia, Germany, UK and USA. and showed strong demand for one super multi-functional app rather than using dozens of individual apps.

read more
Prescription drugs

Passage of the Cut Inflation Act includes cutting the cost of prescription drugs

AARP in the Virgin Islands

AARP – in the Virgin Islands shares a statement released by AARP CEO Jo Ann Jenkins following the historic vote to pass the Cut Inflation Act. The message was released on August 7 immediately after the Senate vote. The Senate voted to pass the Cut Inflation Act of 2022, a bill that includes several key provisions to drive down prescription drug prices. AARP thanked all of the senators who voted to support this essential legislation and move closer to real relief for seniors.

The Inflation Reduction Act includes key AARP priorities that will go a long way in reducing drug prices and out-of-pocket costs. AARP fought for provisions in the bill that:

  • Finally allow Medicare to negotiate drug prices
  • Cap annual prescription drug spending in Medicare Part D at $2,000
  • Hold drug companies accountable when they raise drug prices faster than the rate of inflation, and
  • Cap the insulin co-pay to a maximum of $35 per month in Part D.

Jo Ann Jenkins, executive director of AARP, released a statement in reaction to the Senate vote:

“Since AARP’s inception, we have fought to ensure seniors have access to affordable health care, including prescription drugs. And we’ve worked for nearly two decades to allow Medicare to negotiate the price it pays for drugs. Thanks to today’s historic vote in the Senate, millions of Americans over 50 are one step closer

to real relief from runaway prescription drug prices. This bill will save Medicare hundreds of billions of dollars and give seniors peace of mind knowing there is an annual limit on what they have to pay out of pocket for drugs. Lowering prescription drug prices is a top priority for Americans, with more than 80% of people from all political parties supporting the measure. We thank all senators who voted today to lower drug prices.

“We are also thrilled that the bill will keep health insurance affordable for millions of Americans who buy their coverage in the market, especially consumers between the ages of 50 and 64, including more than one million got more affordable options.

Printable, PDF and email version
read more
Medical products

Growing medical device maker with 110 new jobs in Houston County

Mark Fellows, vice president of GRI-APS, said the additional 110 jobs in Houston County will increase over the next 90 days.

“These growth plans for Global Resources International and Advanced Product Solutions represent a significant development for the Wiregrass region,” said Greg Canfield, Secretary of the Alabama Department of Commerce.

“This expansion will enhance domestic production of much-needed products for Alabama and nationwide customers, while strengthening GRI-APS’ presence in Wiregrass.”

GROWTH PLANS

In a joint statement, Dothan Mayor Mark Saliba and Houston County Commission Chairman Mark Culver praised GRI-APS’ continued investment and said they are “incredible examples of partners community trade”.

Columbia Mayor Cas Haddock said the GRI-APS project is a “breath of fresh air” for the Houston County community of 800.

“We are grateful that they chose Columbia, Alabama for this sophisticated operation,” he added.

GRI, headquartered in Flowery Branch, Georgia, is a privately held manufacturing and supply company specializing in the design, manufacture, sterilization and distribution of products for the healthcare, medical and medical markets. industry and animal care.

A long-standing GRI affiliate, based in Ashland, Alabama Eastern Technologies Inc.. produces protective equipment for workers in industries such as nuclear power, chemicals and defence. (Learn more about ETI’s efforts at the start of the pandemic.)

A broad partnership of state and local agencies supported the project. At the state level, these include the governor’s office; the Alabama Department of Commerce; AIDT, the state’s main workforce development agency; and Southeastern Alabama works.

The City of Dothan, Houston County Commission, City of Columbia, Dothan Industrial Development Council, and Dothan Chamber/Grow Dothan Development Team also supported the project, as did Dothan Utilities, Alabama Municipal Electric Authority. and Southeast Gas.

read more
Medical supplies

Global Medical Supplies Market Report 2022, Trends and Opportunities to 2030 – Shanghaiist

published by researchreports.xyz

Comprehensive analyzes of the fastest growing medical supplies market provide insights that help stakeholders identify opportunities and challenges. The 2022 markets could be another big year for medical supplies. This report provides an overview of the company’s activities and financial situation (a company profile is required if you want to raise capital or attract investors), recent developments (mergers and acquisitions) and recent SWOT analyses. This report focuses on the medical supplies market over the assessment period 2030. The report also provides an analysis of the growth of the medical supplies market which includes Porter’s five factor analysis and analysis of the Supply Chain.

Click here to access the sample report: researchreports.xyz/Request-For-Sample-Report?/Medical-Supplies&id=9403

This Medical Supplies analysis report also provides in-depth insights into other upcoming trends and challenges that will have a tremendous effect on the growth of the market. Get detailed insights into trends and challenges, which will help businesses assess and develop strategies for growth.

Who are the main suppliers of medical supplies?

Medtronic plc (Ireland), Cardinal Health, Inc. (USA), Becton, Dickinson and Company (USA), Johnson & Johnson (USA), B. Braun (Germany), Boston Scientific Corporation (USA), USA), Thermo Fisher Scientific (USA), Baxter International Inc. (USA), Halyard (USA), 3M (USA)

Detailed segmentation:

By TypeDiagnostic ProductsDialysis ConsumablesTrauma ConsumablesRadiation Related ConsumablesInfusion Related ProductsBy ApplicationUrologyWound CareRadiologyAnesthesiaSterilizationCardiologyOphthalmologyOther ApplicationsBy End UsersHospitalsClinicsOtherBy Distribution ChannelOnline ChannelOffline Channel

Get 30-50% off various types of licenses when buying it now (use corporate email id for higher priority) @researchreports.xyz/Check-Discount-On-Report?/ Medical-Supplies&id=9403

Competitive landscape highlighting important parameters players are gaining with market shifts and developments:

• % market share, SWOT analysis, segment revenue for each company profile.
• Overview of the activity and classification of the products or services.
• Latest developments (product launches, technological advances, manufacturing, expansion plans and research and development)
• Matrix of products or services.
• Capacity, consumption and production of players.

Quantitative data:

1. Market Revenue and Growth Rate by Type (Historical and Forecast)
2. Market revenue and growth rate by application, such as food, beverage, pharmaceutical, industrial & chemical, cosmetic & personal care, agriculture, etc.
3. Market Revenue, Growth Rate, Volume, Type and Application by Each Country (Historical and Forecast)
4. Revenue, volume and annual growth rate per player (reference year).

Qualitative data:

It contains sections related to market dynamics and trending factors that are influencing or driving market growth. To list some names of the sections covered:

• Overview of the global medical supplies industry.
• Global market growth drivers, opportunities and restraints.
• Gaps and opportunities in the medical supplies market
• Market entropy (suppression of aggressiveness and strategic moves by industry players).
• Analysis of Porter’s five forces (potential new market entrants, competitive competitors, alternative customers and products).
• PESTLE analysis (360 degree view of the market).
• Analysis of trademarks and patents.
• Competitive analysis (of each player and manufacturer featured in the report) SWOT analysis display).
• Medical supplies market developments and insights innovations, and new product or service launches.
• Investment and project feasibility study.

We also offer customization of reports based on specific customer requirements:

– Free country-level analysis for the 5 countries of your choice.
– Free competitive analysis of 5 key market players.
– 40 hours of free analysis to cover any other data point.

For a custom report, click @ researchreports.xyz/Reports-Description-And-Details?/Medical-Supplies&id=9403

All of the reports we list tracked the impact of COVID-19. The upstream and downstream of the entire supply chain were taken into account during this operation. Additionally, where possible, we will provide an additional COVID-19 update supplement/report to the third quarter report, please check with the sales team.

About Us:

researchreports.xyz is the credible source for getting the research reports that will provide you with the direction your business needs. The market is changing rapidly with the continuous expansion of the industry. Technological advancements have provided today’s businesses with multi-faceted benefits driving daily economic changes. Thus, it is very important for a business to understand the patterns of market movements in order to better strategize. An effective strategy gives companies a head start in planning and an advantage over their competitors.

Contact us

Research reports

Phone (UK): +44 141 628 5998

Email: [email protected]

Web: https://www.researchreports.xyz

read more
Prescription drugs

Hyperlipidemia Prescription Drugs Market Research Report 2022

Global Prescription Drugs for Hyperlipidemia Market is expected to grow at a CAGR of 14.5% to reach xx Million USD through 2029

Prescription drugs for hyperlipidemia Market overview

The Prescription Drugs for Hyperlipidemia market research report includes all the necessary details. By providing accurate data to its clients, it helps them make important decisions and gives market forecasts. This study, which combines primary and secondary research, provides market size, share, trends and forecasts for important segments and sub-segments. This market research monitors all the latest developments and changes in the industry. It provides information on the obstacles encountered when starting a business and offers advice on how to deal with impending difficulties.

Browse the full report at:

https://pharmaresearchconsulting.com/reports/hyperlipidemia-prescription-drugs-market-global-growth-trends-and-forecast-2022-2029-by-type-hmg-coa-reductase-inhibitors-fibric-acid-derivatives- nicotinic-acid-by-hospital-clinical-application-and-by-regions

Report scope

The research analysis of the Global Prescription Drugs for Hyperlipidemia Market takes a close look at the market size, trends, and potential opportunities. By offering in-depth details of technology expenditure for the projection year, this research provides a unique perspective on the global Prescription Hyperlipidemia Drugs market across various categories. Clients can learn more about the potential and limitations of the industry by reading the study on Global Prescription Drugs for Hyperlipidemia Market. The study discusses in detail a number of factors that have been identified as influencing the growth trajectory of the market. The issues facing the market are also identified in the study.

Profile of key companies in the report:

Amgen, are Eli Lilly, GlaxoSmithKline Pharmaceuticals, Isis Pharmaceuticals, Merck, Dr. Reddy’s Laboratories, Immuron Limited, Esperion Therapeutics and Pfizer, Formac Pharmaceuticals and others.

Prescription drugs for hyperlipidemia Market segmentation :

By Type, it is segmented into

HMG COA reductase inhibitors

Fibric acid derivatives

nicotinic acid

Bile acid sequestering agents

Cholesterol absorption inhibitors

Combination drug therapy

By Application, it is segmented into

Hospital

Clinical

Others

Regional Analysis Of Prescription Drugs For Hyperlipidemia Market

The research mentions the regional scope of the market, mainly focusing on the following areas:

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia, etc.)

Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa)

Points covered in the report

It includes a detailed description of each company. Along with these factors, the study also covers their capacity, production, price, revenue, cost, gross margin, sales volume, revenue, consumption, growth rate, import , their exports, supply, future plans and technological advancements. This study forecast and reviewed data for the past 12 years.

There is a detailed discussion of the market growth factors, along with a detailed explanation of each of the market end users.

The data and information is broken down by market player, region, type, application etc. and also by custom

Prescription drugs for hyperlipidemia Market Players and Competitor Analysis:

The research includes company profile, product specifications, production/sales capacity, revenue, price and gross margin 2022-2029, and sales by type for major market players.

Regional and global market research Global and regional market status and outlook for 2022-2029 are included in the report. The report also includes breakdown information for each region and country it covers. identifying the number of sales and revenue projections, as well as its production, consumption, imports and exports.

Market analysis by product type: The study covers the majority of product types used in the Prescription Drugs for Hyperlipidemia market, along with product details for each major player, volume and sales by volume and value.

Market analysis by type of application: The market is further subdivided into numerous key applications of its industry based on the Prescription Hyperlipidemia Drugs market and its applications. It offers market size, CAGR, and forecast information for each application in the industry.

Market trends: Two major market trends are the escalation of competition and continuous innovation.

Main highlights of the Prescription drugs for hyperlipidemia Market report:

– Overall assessment of the parent market
– Evolution of the significant aspects of the market
– Industry-wide survey of market segments
– Assessment of the value and volume of the market over the past, present and forecast years (2022-2029)
– Market share assessment
– Tactical approaches from market leaders
– Money-making strategies to help companies strengthen their position in the market

Click the link for a free sample copy of the report:

https://pharmaresearchconsulting.com/reports/veterinary-therapeutics-market-global-growth-trends-and-forecast-2022-2029-by-type-by-distribution-channel-by-regions-by-key-players- zoetis-inc-merck-animal-health-elanco-animal-health-boehringer-ingelheim-gmbh/request

Contents:

Chapter 1: Introduction, Market Driver Product Research and Research Objectives Scope of Prescription Drugs for Hyperlipidemia Market

Chapter 2: Exclusive Summary – Basic Information on the Prescription Drugs for Hyperlipidemia Market.

Chapter 3: Revealing Market Dynamics – Drivers, Trends and Challenges

Chapter 4: Prescription drugs for hyperlipidemia Introducing Porters Five Forces Market Factor Analysis, Supply/Value Chain, Pestel Analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: View by Type, End User and Region 2022-2029

Chapter 6: Evaluating Hyperlipidemia Prescription Drugs Market Key Manufacturers Including Competitive Landscape and Company Profiles

Chapter 7: To assess the market by segments, countries and manufacturers, with revenue sharing and sales by key countries for these various regions.

Chapters 8 and 9: Appendix, methodology and data source display

About Us

Pharma Research Consulting (An Improve Digital Consultancy Pvt Ltd Group Company) provides

syndicated market research reports to industries, organizations or even individuals to help them

their decision-making process

Contact us: –

Phone number+1 (704) 266-3234 | [email protected]

read more
Generic drugs

Generic Inhalation and Nasal Spray Market Segmentations, Trends, Share, Size, Major Key Players and Forecast to 2030 – Instant Interview

The Generic Inhalation and Nasal Spray market report is provided here in USD Million. The report will provide insightful data related to the growth rates represented in terms of CAGR % over the projected years. The report will discuss which strategies to adopt after COVID-19, along with a comprehensive analysis of the growth factors, types, applications, impending challenges, competitive landscape, key trends to watch, PEST analysis and overall market dynamics. The main objective of the Inhalation And Nasal Spray Generic Drugs market report is to analyze the impact of COVID-19 on the market and the opportunities to be exploited in the future. The Generic Inhalation and Nasal Spray Drugs Market study examines the market performance for the top 20 countries and understands the growth potential in these countries.
For More Details, Download Free Sample of Generic Inhalation and Nasal Spray Drugs Market: https://healthcaremarketreports.com/sample-request/inhalation-and-nasal-spray-generic-drugs-market/170/

Global Generic Inhalation and Nasal Spray Drugs Market: Major Key Players
Novartis AG (Sandoz International GmbH)
cipla ltd.
Allergan AG
Nephron Pharmaceutical Company
Ranbaxy Laboratories Ltd.
Teva Pharmaceutical Industries Ltd.
Beximco Pharmaceuticals
Mylan AG
Roxane Laboratories, Inc.

Global Generic Inhalation and Nasal Spray Drugs Market by Types
Generic Nasal Spray Drugs
Generic inhaled drugs

Global Generic Drugs for Inhalation and Nasal Spray Market: By Applications
Asthma
COPD
Allergic rhinitis

Global Generic Drugs for Inhalation and Nasal Spray Market by Country
United States
Canada
Germany
UK
France
Italy
Spain
Russia
China
Japan
South Korea
Australia
Thailand
Brazil
Argentina
Chile
South Africa
Egypt
United Arab Emirates
Saudi Arabia

The global healthcare industry has been growing at a CAGR of around 5% and is expected to produce even more in the future. The healthcare industry is growing at a steady pace and is expected to move up the growth ladder in the future. The healthcare sector consists of several main areas including healthcare services and facilities, hospital supplies, medical equipment, pharmaceuticals and drugs and we provide comprehensive information on these sectors with utmost accuracy. .

Healthcare organizations are now working in a dynamic environment, undergoing seismic transformations following the introduction of innovative medical treatments and increased use of the internet. This, combined with unrivaled online access to incredible amounts of information, has made astute patients more cautious. As a result, the demand for smart, affordable and personalized healthcare services has exploded. The COVID-19 pandemic has further led to an increase in demand for healthcare and related products and services, further bolstering the performance of the entire healthcare industry.
Our specialized reports offer information tailored to the unique needs of all important stakeholders. Our reports come with market assessments that provide our clients with useful information on market size, current competition, and other factors. The reports also estimate the burden of common and unusual medical conditions based on prevalence and cost of care. The reports also include an executive-level market plan and valuable insights to help establish effective expansion plans. Healthcare reports also provide an in-depth look at the research and development landscape of a market. These data pointers and analytics provide in-depth research of pipeline product distribution by clinical trial stage, therapeutic region, indication and other factors.

Buy Direct Inhalation and Nasal Spray Generic Drugs Market Research Report: https://healthcaremarketreports.com/purchase/inhalation-and-nasal-spray-generic-drugs-market/170/

FAQs
• What is the driving factor for the growth of the Inhalation And Nasal Spray Generic Drugs market?
• What impact will COVID-19 pandemic have on demand and consumption for the Inhalation And Nasal Spray Generic Drugs Market?
• What is the major application area of ​​the Inhalation And Nasal Spray Generic Drugs market?
• Who are the manufacturers of generic inhalers and nasal sprays in the world?
• Which geographical area is predominant in the Inhalation And Nasal Spray Generic Drugs market?
• Who are the leading industry players in the Generic Inhalation and Nasal Spray Drugs Market?

About Us:
The healthcare industry is certainly facing disruption, with global economies placing great importance on individual health. In this scenario, we expect our customers to get deep insights to propel their innovations in the right direction. We have closely followed the changes and modifications that occur in the field of health. According to our understanding, these alterations are active and unexampled.

read more
Prescription drugs

Senate lawmaker weakens plan of Senate prescription drug bill, climate change initiatives remain intact

WASHINGTON– On Saturday, the Senate congressman struck a blow to the Democrats’ plan to cut drug prices, but left the rest of their sprawling economic bill largely untouched as party leaders geared up for early votes on a package containing many of President Joe Biden’s major national goals.

Elizabeth MacDonough, the nonpartisan arbiter of the chamber rules, said lawmakers must remove language imposing stiff penalties on drugmakers who raise prices above inflation in the private insurance market. . These were the bill’s main rate protections for the roughly 180 million people whose health coverage comes from private insurance, either through work or purchased on their own.

Other important provisions remained intact, including giving Medicare the power to negotiate what it pays for pharmaceuticals for its 64 million elderly beneficiaries, a longtime goal for Democrats. Penalties on manufacturers for overshooting inflation would apply to drugs sold to Medicare, and there is a $2,000 annual cap on free drug and vaccine costs for Medicare beneficiaries.

RELATED | Democrats say they have reached an agreement on the climate and the tax bill

His decisions came as Democrats planned to begin votes in the Senate on Saturday on their sweeping agenda covering climate change, energy, health care costs, taxes and even deficit reduction. Party leaders said they believe they have the unity they will need to push the legislation through the Senate 50-50, with Vice President Kamala Harris’s deciding vote and a strong Republican opposition.

“This is a major victory for the American people,” Senate Majority Leader Chuck Schumer, DN.Y., said of the bill, which both parties are using in their election campaigns to blame the worst period of inflation in four years. decades. “And a sad commentary on the Republican Party as it actively fights cost-cutting provisions for the American family.”

In response, Senate Minority Leader Mitch McConnell, R-Ky., said Democrats are “misinterpreting the outrage of the American people as a mandate for another reckless fiscal and spending spree.” He said Democrats “have already robbed American families once through inflation and now their solution is to rob American families a second time.”

Abandoning penalties on drugmakers reduces incentives for pharmaceutical companies to restrict what they charge, which increases costs for patients.

RELATED | PACT Act: Senate passes healthcare for veterans exposed to toxic burning stoves amid protests

Erasing that language will reduce the $288 billion in 10-year savings that Democrats’ blanket drug restrictions were meant to generate — a reduction of perhaps tens of billions of dollars, analysts say.

Schumer said MacDonough’s private insurance price cap decision was “an unfortunate decision.” But he said the lingering drug pricing language represented “a major victory for the American people” and that the overall bill “remains largely intact.”

The decision followed a 10-day period in which Democrats resurrected key elements of Biden’s agenda that seemed dead. In quick deals with the Democrats’ two most unpredictable senators — first conservative Joe Manchin of West Virginia and then Arizona centrist Kyrsten Sinema — Schumer pieced together a vast package that, although a fraction of earlier versions bigger than Manchin has derailed, would give the party a feat in the context of the legislative elections this fall.

The parliamentarian also signed a levy on excess emissions of methane, a potent contributor of greenhouse gases, from oil and gas drilling. She also left environmental grants to minority communities and other carbon reduction initiatives, said Senate Environment and Public Works Committee Chairman Thomas Carper, D-Del.

She approved a provision requiring union-wide wages to be paid if energy efficiency projects are to qualify for tax credits, and another that would limit electric vehicle tax credits to cars and trucks. assembled in the USA.

The blanket measure faces unanimous Republican opposition. But assuming Democrats fight an unbroken “vote-a-rama” of amendments — many of which are designed by Republicans to derail the measure — they should be able to force the measure through the Senate.

The switch to the House could take place when that House returns briefly from recess on Friday.

“What the vote-a-rama will look like. It’ll be like hell,” Sen. Lindsey Graham of South Carolina, the top Republican on the Senate Budget Committee, said Friday of the approaching GOP amendments. He said that by supporting the Democratic bill, Manchin and Sinema are “strengthening legislation that will make life harder for the average person” by forcing energy costs with tax increases and making it harder for businesses to hire workers.

The bill proposes spending and tax incentives to switch to cleaner fuels and support coal with help to reduce carbon emissions. The expiration of subsidies that help millions pay private insurance premiums would be extended by three years, and $4 billion is earmarked to help Western states fight drought.

There would be a new minimum tax of 15% on certain corporations that earn more than $1 billion a year but pay significantly less than the current corporate tax of 21%. There would also be a 1% tax on companies buying back their own shares, traded after Sinema refused to back higher taxes for private equity firm executives and hedge fund managers. The IRS budget would be inflated to strengthen its tax collections.

While the final costs of the bill are still being determined, overall it would spend more than $300 billion over 10 years to slow climate change, which analysts say would be the country’s biggest investment in this. effort, and billions more for health care. This would raise more than $700 billion in taxes and government drug cost savings, leaving about $300 billion for deficit reduction – a modest portion of projected 10-year deficits of several trillions of dollars. dollars.

Democrats are using special procedures that would allow them to pass the measure without having to achieve the 60-vote majority that legislation often needs in the Senate.

It is the parliamentarian’s job to decide whether parts of the legislation should be dropped for violating these rules, which include the requirement that the provisions are intended primarily to affect the federal budget, not to impose new policy.

Copyright © 2022 by The Associated Press. All rights reserved.

read more
Generic drugs

Global generic drug market to reach $631.58 billion by 2027

DUBLIN, August 5, 2022 /PRNewswire/ — The report “Global Generic Drugs Market (2022-2027) by Category, Applications, End User, Geography, Competitive Analysis and Covid-19 Impact with Ansoff Analysis” has been added to from ResearchAndMarkets.com offer.

The global generic drug market is estimated at $374.14 billion in 2022 and should reach $631.58 billion by 2027 at a CAGR of 11.04%.

Market segmentation

The global generic drugs market is segmented on the basis of category, applications, end-user, and geography.

  • By category, the market is categorized into biosimilars and small molecule generics.
  • By applications, the market is categorized into Anti-Arthritis Drugs, Anti-Cancer Drugs, Anti-Infection Drugs, Cardiovascular Drugs, Central Nervous System Drugs, and Respiratory Drugs.
  • By end-user, the market is categorized into pharmacies, hospitals, pharmacies, private clinics, and retail pharmacies.
  • By geography, the market is categorized into Americas, Europe, Middle East & Africa and Asia Pacific.

Countries studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United StatesRest of the Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Swiss, UKRest of Europe)
  • Middle East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emiratesrest of the MEA)
  • Asia Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, TaiwanRest of Asia Pacific)

Competitive quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and assess the position of companies based on their industry position score and market performance score. The tool uses various factors to classify players into four categories. Some of these factors considered for analysis are financial performance over the past 3 years, growth strategies, innovation score, new product launches, investments, market share growth, etc

Ansoff analysis

The report presents a detailed analysis of the Ansoff matrix for the global generic drugs market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design business growth strategies. The matrix can be used to assess approaches in four strategies viz. Market development, market penetration, product development and diversification. The matrix is ​​also used for risk analysis to understand the risk associated with each approach. The analyst analyzes the global generic drugs market using the Ansoff Matrix to provide the best approaches a company can take to improve its position in the market. Based on the SWOT analysis done on the industry and industry players, the analyst has designed appropriate strategies for market growth.

Why buy this report?

  • The report offers a comprehensive assessment of the global generic drugs market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and market size projections. Projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The main research is done through interviews, surveys and observations of renowned personnel in the industry.
  • The report includes in-depth market analysis using Porter’s 5 forces model and Ansoff’s matrix. Additionally, the impact of Covid-19 on the market is also presented in the report.
  • The report also includes the regulatory scenario in the industry, which will help you to make an informed decision. The report discusses the major regulatory bodies and major rules and regulations imposed on this industry across various geographies.
  • The report also contains competitive analysis using Positioning Quadrants, the analyst’s proprietary competitive positioning tool.

Report Highlights:

  • A comprehensive analysis of the market, including the parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current and projected market size based on value and volume
  • Market shares and strategies of the main players
  • Recommendations for companies to strengthen their presence in the market

Market dynamics

Drivers

  • Low cost of generic drugs compared to brand name drugs
  • Robust M&A activity in the generic drug market
  • Growing incidences of chronic diseases

Constraints

  • Strong commercialization of brand name drugs eclipses generic drugs

Opportunities

  • 3D manufacturing technology boosts
  • Increase collaboration on generic drug research

Challenges

  • Inactive ingredients or excipients are different

Main topics covered:

1 Description of the report

2 Research methodology

3 Executive summary

4 Market dynamics

5 Market Analysis

6 Global Generic Drugs Market, by Category

7 Global Generic Drugs Market, by Applications

8 Global Generic Drugs Market, By End User

9 Americas Generic Drugs Market

ten Europe Generic drugs market

11 Middle East and africa Generic drugs market

12 APAC Generic Drugs Market

13 Competitive landscape

14 company profiles

15 Appendix

Companies cited

  • Abbott Healthcare Pvt. ltd.
  • Allergan PLC
  • Amneal Pharmaceuticals, Inc.
  • Aspen Pharmacare Holdings Ltd.
  • Aurobindo Pharma Ltd.
  • Baxter International Inc.
  • Cipla inc.
  • Eli Lilly and company
  • Endo Pharmaceuticals Inc.
  • Fresenius medical care
  • GSK-API
  • Apotex Inc.
  • Lupine Ltd.
  • Mylan AG
  • Novartis International
  • Pfizer Inc.
  • Sandoz International GmbH
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/7zc1v9

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

read more
Medical supplies

Medical supplies market worth $163.5 billion by 2027 –

Chicago, Aug. 05, 2022 (GLOBE NEWSWIRE) — The medical supplies market is expected to grow from USD 138.4 billion in 2022 to USD 163.5 billion by 2027, at a CAGR of 3.4% from 2022 to 2027 according to a new report from MarketsandMarkets™. The growth of this market can be attributed to the expanding geriatric population, increasing investment in research, high volume of surgical procedures, and high prevalence of chronic diseases.

Download the PDF brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64344238

Browse the in-depth table of contents at “Medical supplies market
174 – Tables
39 – Numbers
281 – Pages

In 2021, intubation and ventilation supplies accounted for the largest share of the medical supplies market, by type.

By Type, the medical supplies market is segmented into diagnostic supplies, dialysis consumables, wound care consumables, radiology consumables, disinfectants, infusion and injectable supplies, intubation and ventilation supplies, personal protective equipment , sterilization consumables, catheters, sleep apnea consumables and other medical equipment. In. The intubation and ventilation supplies segment held the highest share, which is attributed to its massive demand amid the novel coronavirus outbreak. The overwhelming influx of COVID-19 patients has created a huge demand for intubation and ventilation supplies which has fueled the market share.

By other application accounted for the largest market share in 2021.

Based on application, the medical supplies market is segmented into urology, wound care, radiology, respiratory, infection control, cardiology, IVD and other applications. The other application segment held the largest share. Other application areas include dentistry, neurology, gastroenterology, orthopedics and waste management applications. The segment market share is driven by high number of surgeries and increasing prevalence of neurological disorders, dental diseases, gastrointestinal disorders and others.

By end user, hospitals accounted for the largest market share in 2021.

Based on end-user, the market is segmented into hospitals, clinics/doctor’s offices, and other end-users. In 2021, the hospital segment accounted for the largest market share. This can be attributed to increased investment in healthcare and state-of-the-art infrastructure.

Request sample pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=64344238

North America was the largest regional market for the medical supplies market in 2021.

The medical supplies market is segmented into five major regions, namely North America, Europe, Asia Pacific and Rest of the World. North America held the largest market share in 2021, followed by Europe. The largest North America market share is driven by high incidence of strong presence of industry players, high prevalence of chronic and infectious diseases and advanced healthcare infrastructure in the region.

Some of the major players operating in the medical supplies market are Medtronic plc (Ireland), Cardinal Health (US), BD (US), Johnson & Johnson, Inc. (US), B. Braun Melsungen AG (Germany), Boston Scientific Corporation (US ), Thermo Fisher Scientific, Inc. (USA), Baxter (USA), 3M (USA), Smith & Nephew (Ireland), Convatec Inc. (UK), Abbott (USA) , Cook Medical (USA), Merit Medical Systems (USA), Stryker (USA), Terumo Corporation (Japan), Teleflex Incorporated (USA), Fresenius Medical Care AG & Co. KGaA (Germany) , Coloplast Group (Denmark), Hamilton Medical (Switzerland), ACell, Inc. (USA), Invacare Corporation (USA), Medline Industries, LP. (USA), DeRoyal Industries, Inc. (USA), Shenzhen MedRena Biotech Co., Ltd. (China), Kerecis (USA) and Whiteley (Australia).

Get 10% free customization on this report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=64344238

Browse the adjacent market: Research reports and advice on the medical device market

Related reports:

Infection Control Market by product [Sterilization (Steam, Hydrogen Peroxide, EtO), Disinfection (Wipes, Liquids, Disinfectors), Services, E-beam, Face Masks]End user (Hospitals, Pharmaceutical companies) (2022 – 2026)


        
read more
Medical products

Inequalities in access to COVID-19 medical products persist as corporate power expands : Peoples Dispatch

Cases of COVID-19 persist around the world, raising particular concern in regions with low immunization rates due to unequal access to vaccines. As the pandemic continues, analyzes of the global response continue to underscore the dangers of prevailing multi-partisan campaigns. One of the latest of these analyzes is a report published by Transnational Institute and Friends of the Earth International in July. It examines how transnational corporations (TNCs) seized the opportunity to gain more power over international institutions and expand markets during the COVID-19 pandemic.

During the launch of the report, Lauren Paremoer of the People’s Health Movement pointed out that the capture of the multilateral system by TNCs and private philanthropies was already underway before the pandemic, but extraordinary circumstances have led to an unforeseen expansion. In the report itself, Harris Gleckman, former head of the New York office of the United Nations (UN) Conference on Trade and Development, highlights how a response to the pandemic is building on multi-stakeholder initiatives such as the The COVID-19 Tool Access Accelerator (ACT-A) has essentially resulted in an international response driven by TNC interests rather than global solidarity.

As demonstrated in previous instances, the report says the COVID-19 pandemic has been a source of record profits for major pharmaceutical and biotech producers. Most strikingly, this suggests that the inclusion of TNCs in pandemic response mechanisms, in combination with their quest to protect and expand markets, has resulted in the prioritization of market opportunities over people’s lives.

In addition to issues around access to COVID-19 vaccines in the Global South, the report highlights examples of inequitable access to COVID-19 tests, personal protective equipment (PPE) and therapeutics – from Essential products highly inaccessible in developing countries due to prohibitive prices. Also among those products is medical oxygen, which about 15% of all COVID-19 patients need while on treatment, according to the nonprofit organization PATH.

In low- and middle-income countries, this translates to around 500,000 people needing a million cylinders of oxygen every day, an amount that exceeds what was defined in contracts signed before the start of COVID-19. . Since the start of the pandemic, oxygen shortages have been recorded in Jordan, Nigeria, Pakistan and Zimbabwe, among others. And although the shortages presented a direct threat to the health and lives of thousands of people in the Global South, some oxygen producers continued to insist on contractual clauses prohibiting the supply of oxygen from other sources. sources, including local extraction.

Among other things, ACT-A was supposed to examine and close the gaps between oxygen supply and need through an emergency task force coordinated by Unitaid, an intergovernmental funding agency, and the Wellcome Foundation based United Kingdom. But instead of developing approaches that would ensure rapid and accessible deployments of supplemental oxygen supplies when needed, the task force “focused on arranging grants and loans from OECD countries, from the World Bank, regional development banks and private foundations to enable local health authorities to purchase supplemental oxygen.

According to the report, there is concern that a similar procedure may have been put in place with regard to the purchase and distribution of PPE through ACT-A. A strategic plan from October 2021 to October 2022 remains silent on the more practical aspects of delivering PPE to the 92 priority countries. Reviewing the oxygen supply experience, the report states that it is “reasonable to assume that this objective and the related market expansion would be achieved, if at all, by increased debt or grants to institutions in developing countries”.

As Gleckman pointed out at the launch, this is a well-known pattern of the COVID-19 vaccine procurement process: countries that lacked the resources to pay the high prices set by producers vaccines were forced to take out loans around the world. Bank and the International Monetary Fund. This means that they will have to allocate even more money to debt service instead of strengthening health and social security systems, which will compromise their ability to respond to future crises.

Due to the effects of loans from international financial institutions on the stability of health systems in developing countries, debt and debt cancellation should be a major focus in future phases of the COVID-19 discussion, suggested Lauren Paremoer. With this element missing from the conversation, developing countries face the same grim no-access scenario they faced in the case of vaccines.

Read more articles from the latest edition of the People’s Health Dispatch and subscribe to the newsletter here.

read more
Generic drugs

Global Generic Drugs Market Report (2022-2027): Low Cost of Generic Drugs Compared to Branded Drugs and Robust M&A Activities in Generic Drugs Market Driving Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Generic Drugs Market (2022-2027) by Category, Applications, End User, Geography, Competitive Analysis and Covid-19 Impact with Ansoff Analysis” report has been added to from ResearchAndMarkets.com offer.

The global generic drugs market is estimated at USD 374.14 billion in 2022 and is projected to reach USD 631.58 billion by 2027, growing at a CAGR of 11.04%.

Market segmentation

The global generic drugs market is segmented on the basis of category, applications, end-user, and geography.

  • By category, the market is categorized into biosimilars and generics of small molecules.

  • By applications, the market is categorized into Anti-Arthritis Drugs, Anti-Cancer Drugs, Anti-Infection Drugs, Cardiovascular Drugs, Central Nervous System Drugs, and Respiratory Drugs.

  • By end-user, the market is categorized into pharmacies, hospitals, pharmacies, private clinics, and retail pharmacies.

  • By geography, the market is categorized into Americas, Europe, Middle East & Africa, and Asia-Pacific.

Countries studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)

  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)

  • Middle East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)

  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and assess the position of companies based on their industry position score and market performance score. The tool uses various factors to classify players into four categories. Some of these factors considered for analysis are financial performance over the past 3 years, growth strategies, innovation score, new product launches, investments, market share growth, etc

Ansoff analysis

The report presents a detailed analysis of the Ansoff matrix for the global generic drugs market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design business growth strategies. The matrix can be used to assess approaches in four strategies viz. Market development, market penetration, product development and diversification. The matrix is ​​also used for risk analysis to understand the risk associated with each approach. The analyst analyzes the global generic drugs market using the Ansoff Matrix to provide the best approaches a company can take to improve its position in the market. Based on the SWOT analysis done on the industry and industry players, the analyst has designed appropriate strategies for market growth.

Why buy this report?

  • The report offers a comprehensive assessment of the global generic drugs market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and market size projections. Projections are calculated using proven research methodologies.

  • The report has been compiled through extensive primary and secondary research. The main research is done through interviews, surveys and observations of renowned personnel in the industry.

  • The report includes in-depth market analysis using Porter’s 5 forces model and Ansoff’s matrix. Additionally, the impact of Covid-19 on the market is also presented in the report.

  • The report also includes the regulatory scenario in the industry, which will help you to make an informed decision. The report discusses the major regulatory bodies and major rules and regulations imposed on this industry across various geographies.

  • The report also contains competitive analysis using Positioning Quadrants, the analyst’s proprietary competitive positioning tool.

Report Highlights:

  • A comprehensive analysis of the market, including the parent industry

  • Important market dynamics and trends

  • Market segmentation

  • Historical, current and projected market size based on value and volume

  • Market shares and strategies of the main players

  • Recommendations for companies to strengthen their presence in the market

Market dynamics

Drivers

  • Low cost of generic drugs compared to brand name drugs

  • Robust M&A activity in the generic drug market

  • Growing incidences of chronic diseases

Constraints

  • Strong commercialization of brand name drugs eclipses generic drugs

Opportunities

  • 3D manufacturing technology boosts

  • Increase collaboration on generic drug research

Challenges

  • Inactive ingredients or excipients are different

Main topics covered:

1 Description of the report

2 Research methodology

3 Executive Summary

4 Market dynamics

5 Market Analysis

6 Global Generic Drugs Market, by Category

7 Global Generic Drugs Market, by Applications

8 Global Generic Drugs Market, By End User

9 Americas Generic Drugs Market

10 European Generic Medicines Market

11 Middle East & Africa Generic Drugs Market

12 APAC Generic Drugs Market

13 Competitive landscape

14 company profiles

15 Appendix

Companies cited

  • Abbott Healthcare Pvt. ltd.

  • Allergan PLC

  • Amneal Pharmaceuticals, Inc.

  • Aspen Pharmacare Holdings Ltd.

  • Aurobindo Pharma Ltd.

  • Baxter International Inc.

  • Cipla inc.

  • Eli Lilly and company

  • Endo Pharmaceuticals Inc.

  • Fresenius medical care

  • GSK-API

  • Apotex Inc.

  • Lupine Ltd.

  • Mylan AG

  • Novartis International

  • Pfizer Inc.

  • Sandoz International GmbH

  • STADA Arzneimittel AG

  • Sun Pharmaceutical Industries Ltd.

  • Teva Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/6dznz2

read more
Prescription drugs

Navigating High Prescription Drug Prices

Steven and Jenna Emerson are the two faces of type 1 diabetes. They need thousands of dollars in drugs and supplies to stay alive.

“I would say $15 to $30,000 a year, depending on the year,” said their mother, Kelly Emerson.

That’s what the Emerson family pays after the insurance.

“Some days you have to rob Peter to pay Paul so you can afford to keep your kids alive,” she said. “When you have a child who is sick or needs medicine, you do whatever you have to do, and they know it.”

Emerson answers calls from creditors, chooses one need over another, and manages to keep his house whole. She is one of more than 100 million Americans working to cover up what will save someone’s life.

Marta Wosinska has spent more than two decades studying drug pricing and policy. She says prices are dictated by a web of interests that aren’t always aligned with those in need.

“Insurance companies are responsible for designing insurance benefits. List prices for drugs are set by pharmaceutical companies. Pharmacy benefit managers negotiate discounts, but they work for insurance companies,” Wosinska said. “Employers are the ones who select which plans to offer, often focusing on those that cost them the least.”

Wosinska said everyone has an incentive to embrace a system that sometimes works against them, with no federal solution in sight. But a partial answer may come from an unlikely source: nonprofit drug companies. They are popping up all over the country and competing with big pharma.

Allan Coukell is Senior Vice President at Civica RX. It’s one of many companies making deals with hospitals and winning federal grants. They are trying to create competition and ultimately drive down the price of generic drugs.

“Our first drug will actually launch this summer. Our insulins will hit the market in early 2024. And our goal is to make them available through a variety of mail-order channels and brick-and-mortar pharmacies,” Coukell said.

In the meantime, Emerson continues to search for elusive relief. Until then, she says, she will continue to answer calls from creditors, make tough decisions and take nothing for granted.

“You never know what the future holds. Things can change in no time,” she said. “But I want to give my children the best opportunity to live their best life.”

read more
Prescription drugs

Sue Menegat: Making prescription drugs affordable |

SUE MENEGAT

A recent editorial by Drew Johnson (Missoulian July 27) demonstrates that a barking dog can’t bite when it has false teeth, and Johnson’s statistics are ill-fitting dentures. With strategically played stats, anyone can twist a topic from their own point of view, especially if they have an agenda. Mr Johnson’s agenda appeared to be for “Big Pharma” and against improving health care for Americans. Statistics are everywhere – any statistic one wants to prove any desired point, whether accurate or not, can be found. The problem is that statistics are flexible, but facts are stubborn things. The truth will come out.

The statistics I found in a quick Google search point to a different conclusion than Mr. Johnson. One set, from the Kaiser Foundation, notes that, since 2014, drug prices have increased by 35% compared to a much smaller price increase of 19% for all other products. Another set of statistics, that of the AMA, points out that between 2008 and 2021, the cost of each newly introduced drug has increased by 11% per year. And a Medicare study found that the price of half of all drugs rose faster than the rate of inflation.

People also read…

Johnson is trying to dissuade readers from supporting President Biden’s Build Back Better plan, which would increase funding for Medicaid and allow Medicare to negotiate drug prices with “Big Pharma.” The reasons for the changes proposed by the President are simple; 90% of seniors and 50% of adults take prescription drugs, and 18 million Americans cannot afford their medications. Another 118 million people cannot afford health care, let alone insurance – ahhh, statistics again. Let’s make it more personal. People who can’t afford the necessary health care and necessary medication live shorter lives, can get sick and sometimes die Yes, people are dying.

Think of older couples who split pills into 2 or 3 to reduce drug costs. How about the woman who asks her pharmacist to fill only 1/4 of her prescription because she can’t afford the cost of $270/month. (Others pay $0 to $4 through insurance.) Think Lisa Ann. After seeing insulin prices rise every year, she tried to increase the doses, but was reluctant to tell anyone about her situation. She worked two jobs all her life, but had no drug coverage. She died, alone, of insulin shock at the age of 60. Or think of Jan. She had lower back pain and thought it was a bad disc from lifting heavy things at work. Years before, a non-cancerous cyst had been removed from her neck. After that, her husband’s insurance classified her as having a “pre-existing condition” and declined additional coverage (this was before Obamacare). She postponed her visit to the doctor, waiting to be eligible for Medicare, after all, it was a disc problem. But that was not the case. Jan died of colon cancer four months before her 65th birthday.

A death is a tragedy; a million deaths is a statistic, and statistics erase names. Millions of people are in the same boat, and they all have names. Johnson calls Democrats socialists because they want all Americans to have access to health care. Yet, in reality, various federal, state, and local government programs and policies are, by definition, socialist…the public school system, state universities, national parks and national forests, the military, the AV, police and firefighters, Social Security, Medicaid and Medicare, agricultural subsidies, oil subsidies, all paid for in a “socialist” way by our taxes. All were proposed and instituted by Republicans and Democrats. Slinging tags and calling names is useless and doesn’t solve any problems.

Yes, the poor are and will always be with us. But our society has the means to lighten people’s burdens. Why do prescriptions for Americans cost so much more than the same drug in Canada, Mexico, European countries and for the VA? Why is the life expectancy of Americans ranked 46th among the nations of the world?

If billionaires can spend their money building spaceships just to personally experience weightlessness, Americans can solve our health care debacle. Mr. Johnson, can’t America, the land of the free and the brave, afford to build back better? There, but for the grace of God, I go, or any of us.

Sue Menegat is a retired historian and special education teacher. She volunteers at the Missoula Senior Center.

You must be logged in to react.
Click on any reaction to connect.
read more
Medical supplies

Gambia: WHO hands over medical supplies and equipment to Moh

The World Health Organization (WHO) handed over medical supplies and equipment to the Ministry of Health last Friday during a handover ceremony held at the Central Medical Store in Kotu.

Items vary in size and value and include surgical masks and disposable gloves, triple-wrapped insulated cryobox and freezer boxes. The items, hailing from various countries, namely China, India and the United Arab Emirates, cost more than two hundred and seventeen thousand dollars (US$217,000).

Welcoming the gathering, Babanding Sabally, director of pharmaceutical services at the ministry, reiterated that quality health services mean availability of essential drugs and medical products.

He praised the WHO for its consistent support since the start of the pandemic, acknowledging that the UN agency has also played a crucial role in advocating for support from other partners to complement the government in the fight against the disease. pandemic.

“Our partners are aware of this fact and therefore they always come to our aid to complement whatever the government is doing.”

The UN agency, he added, has been supporting the country’s health care sector not only technically, but by providing much-needed financial support to the country.

Introducing the papers, Dr Desta Tiruneh, WHO Representative to The Gambia, recalled that with the onset of the Covid-19 pandemic, the past few years have been a difficult journey for people in The Gambia and around the world. .

He observed that since the start of the pandemic, WHO has worked in tandem with the government, the United Nations system, the private sector and multilateral and bilateral partners to support the development and implementation of a strong strategy and guidelines for the response to the pandemic.

“The close collaborative partnerships we have fostered have fostered a rapid scale-up of the pandemic response in the country and helped us cushion the drastic blow of Covid-19.”

Dr Tiruneh described that the event was not only a celebration of such fruitful partnerships across sectors, but also a move to further cement the relationship in a demonstration of shared commitment to improving public health in The Gambia. .

“I would like to take this opportunity to sincerely thank our esteemed partners for their continued support of WHO’s emergency work in The Gambia. In particular, we would like to thank our most generous partners, including the governments of the United Kingdom, from Canada, the United States, Germany, France, the Netherlands and Azerbaijan.”

On receiving the articles, Dr Ahmad Lamin Samateh, Minister of Health, hailed the long-standing partnership between the Gambian government and WHO.

This mutual partnership, he noted, is growing stronger, recognizing that the WHO, as a global leader in the health sector, has truly done its job as expected by the peoples of the world.

“All over the world, there must certainly be coordination of every activity of life, otherwise countries and people will have their own notions, norms and ways of doing things. But we are lucky to have an institution like the WHO which harmonizes all of this and sets out benchmarks that countries could use as standards and guidelines to measure performance, productivity and all the parameters that need to be measured.”

The WHO office in The Gambia, Minister Samateh acknowledged, has really fulfilled this role, adding that since the start of the Covid-19 pandemic, the WHO country office and the entire United Nations system in The Gambia have worked harmoniously exchanging ideas to ensure that the country responds adequately to Covid-19.

read more
Medical supplies

Research Segments by Global Emergency Medical Supplies Market Size, Industry Trends, Share and Forecast 2022-2028 | Bound Tree Medical, Henry Schein, Inc.

Emergency Medical Supplies Market

The recent research report on Global Emergency Medical Supplies Market 2022-2028 explains current market trends, possible growth rate, differentiable industry strategies, future prospects, significant players and their profiles, regional analysis and industry shares along with forecast details. The detailed study offers a wide range of considerable information which also emphasizes the significance of key parameters of the global Emergency Medical Supplies Market.

The emergency medical supplies market is expected to grow at a CAGR of 16% during the forecast period.

Click Here For Free Sample PDF Copy Of Emergency Medical Supplies Market 2022 Latest Research Before Purchase: @ https://www.theresearchinsights.com/request_sample.php?id=531281&mode=07RJ

Top Key Players are covered in this report:

Bound Tree Medical, Henry Schein, Inc., McKesson Medical-Surgical, Inc., Medline Industries, Inc., Stryker Corporation, Emergency Medical Products, Inc., Cardinal Health, Smiths Medical, Inc., Life-Assist, Medtronic plc. among others.

On the basis of product, the emergency medical supplies market is primarily split into:

By Product (Life Support and Emergency Resuscitation, Patient Monitoring Systems, Wound Care Consumables, Patient Treatment Equipment, Infection Control Supplies, Other EMS Products)

KBased on end users/application, this report covers

N / A

Market segment by region/country comprising:

Asia Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America[United States, Canada, Mexico]
Middle East and Africa[GCC, North Africa, South Africa]
South America[Brazil, Argentina, Columbia, Chile, Peru]

Key Highlights of the Emergency Medical Supplies Market report study:
• A detailed overview of the global emergency medical supplies industry
• The report analyzes the global emergency medical supplies market and provides its stakeholders with important actionable insights
• The report has considered all the major developments in the recent past, helping the users of the report with the latest industry updates
• The study of the report should help the key decision makers in the industry to help them in the decision-making process
• The study includes data on Emergency Medical Supplies market intelligence, changing market dynamics, current and forecasted market trends, etc.
• The report includes an in-depth analysis of macroeconomic and microeconomic factors affecting the global emergency medical supplies market
• Market ecosystem and adoption in all market regions
• Key trends shaping the global emergency medical supplies market
• Historical and forecast size of the emergency medical supplies market in terms of revenue (USD Million)

SPECIAL OFFER: GET UP TO 30% OFF THIS REPORT: https://www.theresearchinsights.com/ask_for_discount.php?id=531281&mode=07RJ

The Emergency Medical Supplies Market report provides a primary review of the industry along with definitions, classifications, and the form of the business chain. Market analysis is provided for global markets which includes improving trends, assessment of hostile views and development of key regions. Development policies and plans are discussed in addition to manufacturing strategies and royalty systems are also analyzed. This file also indicates import/export consumption, supply and demand, expenses, sales and gross margins.

Browse the full report at:https://www.theresearchinsights.com/reports/global-emergency-medical-supplies-market-growth-2022-2028-531281?mode=07RJ

Research covers the following objectives:
– To study and analyze the global Emergency Medical Supplies consumption by key regions/countries, product type and application, history data from 2016 to 2022, and forecast to 2026.
– To understand the structure of Emergency Medical Supplies by identifying its various subsegments.
– Focuses on the key global Emergency Medical Supplies manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, Five Forces Analysis of Porter, SWOT analysis and development plans over the next few years.
– To analyze the Emergency Medical Supplies with respect to individual growth trends, future prospects, and their contribution to the total market.
– Share detailed information about key factors influencing market growth (growth potential, opportunities, drivers, industry-specific challenges, and risks).
– To project the consumption of Emergency Medical Supplies submarkets, with respect to key regions (along with their respective key countries).
Report customization:
Emergency Medical Supplies, the report can be customized to suit your business needs as we recognize what our customers want, we have extended customization by 25% at no additional cost to all of our customers for any of our syndicated reports .
In addition to customizing our reports, we also offer fully customized research solutions to our clients across all industries we track.
Our research and insights help our clients identify compatible business partners.
To note: All of the reports we list tracked the impact of COVID-19 on the market. In doing so, the upstream and downstream flows of the entire supply chain have been taken into account. Additionally, where possible, we will provide an additional COVID-19 update report/supplement to the Q3 report, please check with the Commercial team.

About Us:
The Research Insights – A world leader in analysis, research and advice that can help you renew your business and change your approach. With us, you will learn to make decisions without fear. We make sense of disadvantages, opportunities, circumstances, estimates and information using our experienced skills and verified methodologies. Our research reports will give you an exceptional experience of innovative solutions and results. We have effectively led businesses around the world through our market research reports and are in an excellent position to lead digital transformations. Therefore, we create greater value for customers by presenting advanced opportunities in the global market.

Contact us:
robin
Commercial director
Contact number: +91-996-067-0000
[email protected]
https://www.theresearchinsights.com

read more
Medical products

Kenya and Novo Nordisk sign MoU to provide medical products to children with diabetes

The Government of Kenya and Novo Nordisk, a Danish multinational pharmaceutical company, have signed a memorandum of understanding for the supply of medical products to improve the treatment and self-management of type 1 diabetes in children.

Speaking at the ceremony, Cabinet Secretary for Health Mutahi Kagwe said the long-term aspiration of the program was not only to improve the lives of children enrolled in the project, but also to find ways to integrate the components of the program into the delivery of health care in the country.

He said the parties have entered into a partnership to use their respective skills and strengths to improve the well-being of people living with diabetes in Kenya through sustainable partnerships and collaborations, as well as to improve the diabetes care for children with type 1 diabetes in Kenya. the country.

“We welcome you and thank you for your support. Your partnership is important and we value it. We invite you to think about investing in the country in terms of manufacturing,” said the Health CS.

To reach more children with diabetes, Kenya needs to establish additional type 1 diabetes clinics and build the capacity of health workers, with Novo Nordisk committing two billion shillings to support the program for the next 3 years.

The two parties have agreed on how to improve and establish the infrastructure of diabetes clinics and the provision of medical and laboratory equipment, training and education of health professionals working on diabetes in type 1 in children and adolescents, the provision of human insulin and blood glucose monitoring equipment and supplies at no cost to children and adolescents. They also agreed to educate children and teens with type 1 diabetes and their families, create a registry for children and teens with type 1 diabetes, and share ideas and results for improvement. Continuation of the Changing Diabetes in Children Project between parties. .

In the agreement, the Government of Kenya will be obliged, among other things, to gradually integrate the Changing Diabetes in Children program into the national health system and to ensure that diabetes and specifically type 1 diabetes is included in the national non-communicable disease agenda. consistent with the Sustainable Development Goals.

Novo Nordisk, in turn, will have to provide the diagnostic, screening and monitoring equipment necessary for the organization and operation of diabetes clinics and the patient registry, provide free human insulin to cover diabetes treatment needs type 1 in children and adolescents up to 25 years old in the health structures supported by the CDiC project.

The company will also have to support the training of health professionals in the management of type 1 diabetes in children and adolescents, support awareness campaigns in collaboration with various stakeholders, support education on diabetes self-management for children, adolescents and their families, including development The CDiC project provides educational materials to patients and supports the improvement of infrastructure in some of the diabetes clinics, as determined by the ministry of Health.

The MoU was signed by Vinay Ransiwal, Managing Director and Vice President on behalf of Novo Nordisk and CS Mutahi Kagwe on behalf of the Government of Kenya and in the presence of Danish Ambassador to Kenya Ole Thonke.

The Changing Children’s Diabetes program was launched in Kenya in 2012 to ensure that children with type 1 diabetes have access to appropriate treatment and support. The partnership was between Novo Nordisk, the Government of Kenya, Roche Diabetes and the Kenya Diabetes Management and Information Center (DMI). It was created to identify solutions that can lead to an integrated approach to the diagnosis, treatment and control of diabetes in children with type 1 diabetes.

(With contributions from APO)

read more
Medical supplies

Darlington man Ken Longstaff struggles to get NHS medical supplies

The wife of a man who needs round-the-clock care after being struck down with a rare disease has raised concerns after struggling to get the medical supplies he needs to stay alive.

Ken Longstaff, of Darlington, depends on care for his daily needs after being diagnosed with Guillain Barre syndrome in 2012.

The condition left him locked up for seven weeks and the 64-year-old, who has discovered a talent for art since his diagnosis, is now confined to a wheelchair and requires round-the-clock care.

Read more: How good is it? Brilliant mural appears in Darlington to celebrate women’s football

His wife Beverley, 62, has raised concerns about obtaining essential medical supplies for the past six months via the Darlington District Nursing Team, through whom she is believed to be able order them.

County Durham and the Darlington NHS Foundation Trust, which is leading the team, said global logistics issues were having a “significant impact” on the supply of some items in the North East – but decided to reassure patients that the trust was working to ensure patients were never deprived of essential equipment.

Ken Longstaff of Darlington

Mrs Longstaff wants to raise awareness of the issue after struggling to get replacement tubes for her husband’s tracheostomy, which he needs to help him breathe, as well as a special type of essential water for his ventilator , which he needs at night .

He usually keeps a spare game in his bag, which accompanies him everywhere, as well as two at home.

However, the couple struggled to replace the kit as it is used and recently recorded backup compliance due to difficulty obtaining the tracheostomy tube.

She said: “I had an incident where they said they couldn’t have a tracheotomy. I kept trying and trying, then they sent me one that was completely different.

“We got to the stage about a week ago where we only had one left, which is the one he wears all the time.”

Recalling an incident last week, she said she was called at 5 a.m. by her carer to help as he was struggling to breathe.

After being unable to clear her airway by suction, she feared having to use the unknown tracheotomy, and would then find herself in a position where she would have no reserve in case of another emergency. Fortunately, after several attempts, they managed to clear the airways.

She added: “My problem is that if we were to use the other one and it hadn’t worked, I would have a dead man on my hands.”

Darlington and Stockton Times: Ken Longstaff has discovered a talent for art since his diagnosis Ken Longstaff has discovered a talent for art since his diagnosis

Mrs. Longstaff, who works as a receptionist at Woodland Hospital, at Darlington, spent several days last week trying to get supplies, which she managed to get to intensive care from James Cook University Hospital, Middlesbrough and Darlington Memorial Hospital.

To get more Darlington stories straight to your email basket, click here

She said, “The only reason we have them is because I begged and borrowed and stole from other people. I got them from the intensive care units, but that means they no longer have those supplies.

“There will be people like us who will struggle to get supplies and they won’t have the contacts we have.”

She added: “We’re lucky because where I work I have contacts. What about an OAP who doesn’t know who to ask for help? danger.

“It shouldn’t be something I deal with at all. People need to know that’s a problem.

A spokesperson for County Durham and Darlington NHS Foundation Trust, said: “The current global manufacturing and logistics issues are having a significant impact on the supply of certain clinical and other items across the NHS. We are working closely with the NHS supply chain to find alternative products if needed.

“Our patients always come first and we fully understand Mr Longstaff’s family’s concern that certain equipment is not currently as readily available as it once was and we apologize for the concern this has caused them. We are in close contact with Mr. Longstaff’s family to ensure they have the equipment he needs.

Read next:

If you want to read more great stories, why not subscribe to your Northern Echo for as little as £1.25 a week. Click here

read more
Medical products

Physical testing for 3D printed medical products

Image Credit: Stable Micro Systems Ltd

3D printing has become a niche manufacturing method, allowing consumers to design and manufacture their own products. As such, it now occupies an important place in the manufacturing industry. Objects can be constructed in almost any format the consumer desires, and this has overcome the early limitations of certain groups of polymers as a building material. It’s now a potential tool in many industries, including bone and organ replacements, meat manufacturing, and even customizable baking.

Stable Micro Systems manufactures instruments that measure the tensile and compressive properties of 3D printed parts. As with any manufacturing innovation, the final product must go through a quality control process to assess its physical properties. A Texture Analyzer is a crucial part of this procedure, providing a reliable way to test the mechanical properties of 3D printed objects by applying a choice of compression, tension, extrusion, adhesion, bending or cutting tests to measure the resistance of a product physical properties for example tensile strength, flexural modulus, fracturability, compressibility, to name but a few.

3D Printing Materials Test Example – Extrusion

The printability of materials used in extrusion 3D printing is one of the most important properties, especially when manufacturing objects with architectural complexities. This parameter is influenced by several factors (temperature, components and additives), which makes a thorough evaluation and classification difficult. Interest in 3D printing for biomedical applications is growing and the pharmaceutical industry is beginning to explore how 3D printing can help us deliver better medicines. Achieving reproducibility in 3D printing of biomaterials requires a robust polymer synthesis method to reduce batch-to-batch variation as well as methods to ensure thorough characterization throughout the manufacturing process. In particular, biomaterial inks containing large solid fractions such as ceramic particles, often required for bone tissue engineering applications, are prone to inhomogeneity from improper mixing or particle aggregation which can lead to inconsistent print results. The production of such ink can be optimized to ensure consistent and repeatable print results by using a TA.XTPlusC Texture Analyzer to perform extrusion force measurements to predict the printability of inks. To read a sample post of this texture analyzer app at ETH Zurich, Click here.

Direct extrusion test on a texture analyzer. Image Credit: Stable Micro Systems Ltd

3D Printing Materials Test Example – Compression

Due to the low price of 3D printing equipment and its versatility, materials such as antioxidant PLA composites containing lignin can be used in hospitals to print dressings for patients on demand. 3D printing can also benefit plastic and reconstructive surgeries by fabricating patient-specific tissue substitutes with tissue-like functions and mechanical properties. A texture analyzer can be used to perform compression test on samples to characterize their mechanical properties which are important for their structural integrity. To read a sample post of this Texture Analyzer app at the University of Nottingham, Click here.

Unconfined compression on a texture analyzer. Image Credit: Stable Micro Systems Ltd

3D Printing Materials Test Example – Bending and Bending

3D printing offers a new approach to the fabrication of drug-eluting implantable medical devices, as it allows complex and custom shapes of tissue scaffolds to be flexibly extruded. Given the simplicity, it can be easily transferred to a clinical setting, where implants could be designed on demand to meet patient needs after surgery. These implants may be suitable for administering drugs for localized treatment. For example, chemotherapy agents, antibiotics or local anesthetics. Alternatively, they could be adapted by coating them for prolonged administration of drugs for the treatment of chronic diseases.

Compared to other printable biomaterials, polyurethane elastomers have several advantages, including excellent mechanical properties and good biocompatibility. However, some intrinsic behaviors, especially high melting point and slow degradation rate, hinder their application in 3D printed tissue engineering. The development of a 3D printable amino acid modified biodegradable water-based polyurethane means that the flexibility of this material provides better tissue compliance during implantation and prevents high modulus grafts from scratching tissue surrounding. The use of a texture analyzer to perform flexibility measurements (three-point curvature) on 3D printed samples allows to evaluate if this can be used as an alternative biomaterial for tissue engineering with low temperature printing, biodegradability and compatibility. To read a sample post of this texture analyzer app at Beijing Science and Technology University, Click here Where Click here to see similar work at Queen’s University Belfast.

3-point flexibility and bending test on a texture analyzer. Image Credit: Stable Micro Systems Ltd

Example of testing 3D printing materials – Perforation, Elongation and Tension:

Orodispersible films (ODF) are promising dosage forms for children or the elderly who may have swallowing problems with solid oral dosage forms. By printing active pharmaceutical ingredients on orodispersible films, the flexibility of drug dosing is increased and offers potential for personalized drugs. Warfarin is an example of a drug with a narrow therapeutic index which requires a personalized dosage which is not currently achieved by marketed products. 3D printing by extrusion can be used to produce transparent, smooth and thin, yet flexible and resistant orodispersible films containing therapeutic doses. Using a texture analyzer, films can measure their properties of burst strength and flexibility as part of their critical physical characteristics that could impact their usability.

To read a sample post of this texture analyzer app at Heinrich Heine University Dusseldorf Click hereWhere Click here for similar work done at Åbo Akademi University.

Bursting strength, tensile strength and film flexibility on a texture analyzer. Image Credit: Stable Micro Systems Ltd

How a Texture Analyzer Can Assess the Flow of Base Powder

Texture analysis can also be used at other stages of the 3D printing process, not just to measure the properties of the final product. For example, the properties of the base powder used in selective laser sintering affect the sintering process as well as the properties of the final product. The flow of the powder is one of these properties. As each new layer of powder is swept over the sinter bed, the layer should be even and of the correct thickness and distribution. A Powder flow analyzer (PFA) is a very useful addition to a Texture Analyzer Plus to help measure these flow properties.

PFA proves to be an accurate and reliable method for measuring the flow characteristics of dry and wet powders, with the ability to measure cohesion, clumping and velocity flow dependence as well as bulk density and other properties. It can be quickly retrofitted to a TA.XTPlusC Texture Analyzer, allowing manufacturers to assess and avoid typical issues such as batch and source variation of ingredients, clumping during storage/transportation and problems unloading hoppers or bins, as well as 3D printing. specific properties of the powder. The powder is conditioned at the start of each test to eliminate any load variation and the patented precision blade is then rotated through the sample causing a controlled flow.

Image Credit: Stable Micro Systems Ltd

The need to measure dimensional profiles

If you designed a product and then print it, one of the concerns will be whether what was printed matches what you designed. In many cases you will need your printed object to be dimensionally accurate and printing iterations of your design are almost inevitable to adjust the print settings to achieve a dimensionally accurate product. A precise numerical evaluation of the physical dimensions thus becomes a necessity. A Volscan Profiler provides such a solution – a benchtop laser scanner that measures the volume, density and dimensional profiles of solid products. Rapid three-dimensional scanning of products allows for the automatic calculation of several detailed dimension-related parameters, the results of which can be mathematically manipulated for immediate use or future retrieval in a variety of data formats for your printed objects.

Volscan Profiler models for measuring volume, density and dimensional profiles. Image Credit: Stable Micro Systems Ltd

Bone sample ready for scanning and an archived scan of the sample. Image Credit: Stable Micro Systems Ltd

The medical industry is increasingly dependent on the TA.XTmoreC Texture Analyzer as a tool for measuring all types of physical/mechanical properties.

See a wider range of test and measurement possibilities in this area.

read more
Prescription drugs

Prescription Hyperlipidemia Drugs Market Size by Share, Growth and Forecast 2029 – Instant Interview

Global Prescription Drugs for Hyperlipidemia Market is expected to grow at a CAGR of 14.50% to reach USD xx million through 2029

Overview of the Prescription Drugs for Hyperlipidemia Market

Prescription Drugs for Hyperlipidemia research report includes all the necessary details. By providing accurate data to its clients, it helps them make important decisions and gives market forecasts. This study, which combines primary and secondary research, provides market size, share, trends and forecasts for important segments and sub-segments. This market research monitors all the latest developments and changes in the industry. It provides information on the obstacles encountered when starting a business and offers advice on how to deal with impending difficulties.

Download a sample exclusive report:

https://pharmaresearchconsulting.com/reports/hyperlipidemia-prescription-drugs-market-global-growth-trends-and-forecast-2022-2029-by-type-hmg-coa-reductase-inhibitors-fibric-acid-derivatives- nicotinic-acid-by-hospital-clinical-application-and-by-regions/demand

Report scope

The research analysis of the Global Prescription Drugs for Hyperlipidemia Market takes a close look at the market size, trends, and potential opportunities. By offering in-depth details of technology expenditure for the projection year, this research provides a unique perspective on the global Prescription Hyperlipidemia Drugs market across various categories. Clients can learn more about the potential and limitations of the industry by reading the study on the Global Prescription Drugs for Hyperlipidemia Market. The study discusses in detail a number of factors that have been identified as influencing the growth trajectory of the market. The issues facing the market are also identified in the study.

Key companies influencing this market include:

Amgen, are Eli Lilly, GlaxoSmithKline Pharmaceuticals, Isis Pharmaceuticals, Merck, Dr. Reddy’s Laboratories, Immuron Limited, Esperion Therapeutics and Pfizer, Formac Pharmaceuticals and others.

Global Prescription Hyperlipidemia Drugs Market Segmentation:

By Type, it is segmented into

  • HMG COA reductase inhibitors
  • Fibric acid derivatives
  • nicotinic acid
  • Bile acid sequestering agents
  • Cholesterol absorption inhibitors
  • Combination drug therapy

By Application, it is segmented into

Regional coverage:

The research mentions the regional scope of the market, mainly focusing on the following areas:

  1. North America (United States, Canada and Mexico)
  2. Europe (Germany, France, UK, Russia and Italy)
  3. Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
  4. South America (Brazil, Argentina, Colombia, etc.)
  5. Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa)

Buy a full copy of Prescription Drugs for Hyperlipidemia Market report:

https://pharmaresearchconsulting.com/reports/hyperlipidemia-prescription-drugs-market-global-growth-trends-and-forecast-2022-2029-by-type-hmg-coa-reductase-inhibitors-fibric-acid-derivatives- nicotinic-acid-by-hospital-clinical-application-and-by-regions.

Key information covered Hyperlipidemia Prescription drugs Market research:

  • Manufacturers Production Capacity Analysis of Prescription Hyperlipidemia Drugs
  • Key factors shaping the growth of the Prescription Hyperlipidemia Drugs Market
  • Hyperlipidemia Prescription Drugs Industry Segmentation Analysis
  • Competitive Mapping for Key Players in the Prescription Hyperlipidemia Drugs Market
  • Prescription Drugs for Hyperlipidemia Market Growth to 2029
  • Analysis of Direct and Indirect Sales of Prescription Drugs for Hyperlipidemia
  • Hyperlipidemia Prescription Drugs Industry Share 2022
  • Distribution Channel Analysis of Prescription Drugs for Hyperlipidemia

Contents:

Chapter 1: Introduction, Market Driver Product Research and Research Objectives Scope of Prescription Drugs for Hyperlipidemia Market

Chapter 2: Exclusive Summary – Basic Information on the Prescription Drugs for Hyperlipidemia Market.

Chapter 3: Revealing Market Dynamics – Drivers, Trends and Challenges

Chapter 4: Presenting the Porters Five Forces Prescription Hyperlipidemia Drugs Market factor analysis, supply/value chain, Pestel analysis, market entropy, patent/trademark analysis.

Chapter 5: View by Type, End User and Region 2022-2029

Chapter 6: Evaluation of the Prescription Drugs for Hyperlipidemia Market leading manufacturers including competitive landscape and company profiles

Chapter 7: To assess the market by segments, countries and manufacturers, with revenue sharing and sales by key countries for these various regions.

Chapters 8 and 9: Appendix, methodology and data source display

Contact us: –
Phone number+1 (704) 266-3234

Send mail to: [email protected]

read more
Prescription drugs

Board can make prescription drugs more affordable in New Mexico | My opinion

read more
Prescription drugs

Prescription drugs are expensive. New Ohio bill could bring relief | Health

For many Ohioans, prescription drugs are just too expensive, even with insurance. Co-pay assistance programs can offer some financial relief, but often patients end up paying all the freight anyway, since the costs covered by these programs are not factored into their deductible.

This means that even if they don’t pay the full cost of their prescriptions, they end up paying that cost on other medical care until they hit their deductible.

A bill at the Ohio House aims to change that.

Bill HB 135 would allow patients to count co-pay assistance programs toward their deductible, the amount a person must pay out of pocket before insurance begins to pay. Proponents say it would allow patients to better afford care and alleviate some real hardships some people face when they get sick and can’t afford their medication.

“Health care in general is very expensive,” said Leo Almeida, director of government relations for the American Cancer Society, which advocates for legislative change.

And co-pay assistance programs, which are supposed to help alleviate some of that cost, aren’t always helpful.

“Let’s say you take a prescription and your out-of-pocket payment for that prescription is $500. You have this co-payment assistance. The pharmacy applies the $500, so you get that drug for free that month,” he said. “But your insurance company doesn’t apply that $500 to your annual deductible. So it’s a benefit over the counter at the pharmacy, but it’s not a long-term benefit because you’re still paying your same deductible through your insurance. So you basically just pay it down the road.”

Julie Turner from Tipp City, Ohio is a cancer survivor. After her chemotherapy and radiation treatments, she lost her bone density, she said.

She is now taking medication to treat this side effect, but the medication is very expensive, so she applied for and received co-payment assistance through her medication manufacturer.

But the copay assistance program didn’t help her at all, she says.

“The help I was so excited about — being a retired person on a fixed income — was going to help me, but in essence it was no help at all,” Turner said. “Because later in the year, I was paying back the $1,500 of my maximum outlay.

This reality can be particularly costly for people with chronic conditions. According to an article in the Journal of the American Medical Association (JAMA), the average spending by people with diabetes in 2018 was over $2,000. For about 8% of people, personal expenses amount to more than $5,000.

Insulin – a life-saving drug for people with diabetes – accounts for 18% of all out-of-pocket expenses.

The PAN Foundation – which provides co-payment assistance – said it has helped people with rheumatoid arthritis, people who need medication to improve their mental health and people with all types of cancers.

The situation for some may be so dire that the organization said it has encountered people considering taking out a second mortgage on their home to pay for medication or skipping medication before finding co-payment assistance. Nearly 60% of Americans have delayed or gone without essential medical care due to high costs, and Medicare patients paid an average of $8,000 per person for drugs in 2019, according to the foundation.

A recent survey found that 51% of cancer patients and survivors had taken on debt to cover the cost of their cancer care, Almeida said.

“So if you think about that 51%, there are people deciding between putting food on the table for their family or paying for their prescription,” he said.

HB 135 would help anyone whose medications are so expensive they need a co-payment assistance program, Almeida said. But advocates say they fear the bill will be stalled.

In March, state lawmakers in the House voted unanimously to pass the bill, meaning it has bipartisan support. Since then, he has served on the Senate Health Committee.

Copyright 2022 WKSU. To learn more, visit WKSU.
read more
Prescription drugs

Medicare patients may soon pay less for prescription drugs – FOX13 News Memphis

WATCH: Bipartisan agreement reached on proposal to allow Medicare to negotiate drug prices WATCH: Bipartisan agreement reached on proposal to allow Medicare to negotiate drug prices

MEMPHIS, Tenn. — At 84, Marcia Dunlap depends on Medicare and private insurance to get the medications she needs.

“I have type 1 diabetes and getting insulin is very expensive,” she told FOX13 after picking up her prescription at a Midtown Walgreens.

The long-time diabetic said the price of the insulin she needed to survive had skyrocketed.

According to the Health Policy Institute, nearly two-thirds of Americans rely on prescription drugs to survive. Additionally, Americans are spending ten times more on prescription drugs than they did 30 years ago, according to the Congressional Budget Office.

On Wednesday night, Democrats reached a deal with U.S. Senate Republicans that could lower prescription drug prices. The proposal will allow Medicare to negotiate prescription prices with drug companies.

READ MORE: Manchin and Schumer in surprise health, energy and tax deal

“When it comes to the cost of living and the expenses families face, many of these families had to choose between their money or their lives,” said U.S. Sen. Dick Durbin (D-Chicago). “(They need) to buy drugs that doctors have told them are essential for their survival.”

Republicans believed the proposal would only interfere with a free market.

“Democrats in Washington are working right now to find ways to put more bureaucracy between American patients and the treatments that are allowed to them,” argued Senate Minority Leader Mitch McConnell (R-Kentucky).

“Senator Hagerty does not believe in giving government more control over drugs and the personal medical decisions of Americans and crushing vital pharmaceutical innovation in the process,” a spokeswoman for U.S. Senator Bill Hagerty wrote. (R-Tennessee). “This is yet another power grab by the Democrats in Washington that is mistakenly viewed as beneficial to the American people.”

However, Dunlap has applauded the legislation, which she hopes will make her insulin cheaper.

“Ten years ago, insulin was affordable,” Dunlap said. “About – maybe five years ago, it became incredibly unaffordable.”


Download the FOX13 Memphis app to receive alerts on breaking news in your neighborhood.

CLICK HERE TO DOWNLOAD


Trending Stories:

read more
Prescription drugs

Boots becomes the first pharmacy to provide drone delivery of prescription drugs

Boots has become the first community pharmacy in the UK to drone prescription-only medicines. The company revealed today that it had carried out a test flight which carried the drugs from the British Army’s Baker Barracks on Thorney Island, near Portsmouth, to St Mary’s Hospital on the Isle of Wight.

Boots uses drones to deliver prescription drugs to Isle of Wight residents. (Photo courtesy of Boots)

Working with medical drone start-up Apian, Boots secured permission from the Civil Aviation Authority (CAA) to fly the drones in a separate airspace between the mainland and the island.

Why does Boots use drones for prescription drug delivery?

Boots says he is assessing the potential wider use of drones for the delivery of prescription drugs, joining the Isle of Wight NHS Trust, which is testing the use of unmanned aerial vehicles (UAVs) to take delivery of medicines. Portsmouth chemotherapy treatments. The pilot, which was announced on the NHS’ 74e anniversary, also involves Apian as a private partner.

Boots CIO Rich Corbridge said today that drones have huge potential in the delivery of medicines and the company is delighted to be the first pharmacy in the UK to transport them in this way. He also explained that the Isle of Wight was a ‘smart place to start a drone trial’ because of the obvious value of delivering medicine to remote locations.

The CIO goes on to say that Boots is studying the time it can save by using drones in its supply chain as well as economic efficiencies: “We want to prepare now for the wider use of this technology in the future.”

The Boots trial uses rotary-wing drones. These are particularly useful for landing in areas where space is limited, says Dr Reza Mohammadkhani, assistant professor at the University of Sussex’s School of Engineering and Computer Science. “Rotary-wing drones are more popular because they can take off and land vertically – no launcher or runway needed,” he says. “They are best suited for more precise handling applications.”

However, says Dr. Mohammadkhani, these types of drones “require more mechanical and electronic complexity, leading to more complicated maintenance, decreased uptime and increased cost.”

Remote islands using state-of-the-art technology for reliability and connectivity

Remote areas are unsurprisingly popular when it comes to testing the potential of drones. The NHS pilot project on the Isle of Wight was launched because the island’s hospital trust believes it can be more effective with treatments, which have a short shelf life, and reduce delivery times of four hours to 30 minutes, while saving fuel. Each drone delivery replaces at least two car trips and one hovercraft or ferry trip per delivery.

Content from our partners
What finance leaders are wrong about digital transformation
Data and Network Recovery Key for Cyber ​​Resilience

Royal Mail is also testing drone technology for deliveries to the Shetland Islands, Orkney Islands, Isles of Scilly and Isle of Mull. He said the use of drones increases delivery reliability, especially in foggy conditions, while providing additional connectivity for remote communities.

Research has found that drones also emit less carbon than conventional air cargo and other traditional forms of transport such as cars and ferries.

Drones are not a ‘one-size-fits-all approach’

The NHS and Royal Mail are just two examples of businesses using drones for delivery, but some fear the companies are taking a tech-driven approach to solving a business problem.

According to McKinsey, over the past three years, there have been more than 660,000 commercial drone deliveries to customers — not including test flights. He also estimates that more than 2,000 drone deliveries took place every day in 2022, but said the rate of growth is accelerating every week.

“We expect there will be nearly 1.5 million deliveries in 2022 as a whole, compared to just under half a million in 2021,” Mckinsey said in a blog post.

However, as the drone economy looks set to take off, McKinsey warns that there will be three determining factors in future adoption: how drones are regulated; whether the public accepts them; and the cost of delivery by drone.

Seb Robert, CEO and founder of Gophr, says drones are unlikely to be a “silver bullet” for deliveries in hard-to-reach areas. “There are some amazing examples of drone delivery working well and providing a vital service – medical deliveries in the Australian bush for example,” he says. “The Isle of Wight trial location makes perfect sense; hard-to-reach areas are where drones come into their own.

However, he fears that those attracted to the benefits of drones will use the technology in places where it is not suitable, such as in urban areas: experienced pilot to avoid unexpected obstacles,” adds Robert. “It’s not a one-size-fits-all approach.”

Read more: UK spent £1bn on drones to spot migrants in the canal

read more
Medical supplies

When is stocking up on medical supplies worth it?

The US supply chain has shown major vulnerabilities during the pandemic. Long reliant on a just-in-time (JIT) approach to stockpiling, the industry began to feel the pinch when demand exceeded availability. The result has been major shortages, inventory and a ripple effect that many supply chain experts have been predicting for years. To make matters worse, medical supplies were at the center of massive shortages, leading to limited availability of personal protective equipment (PPE) and other essential items for frontline healthcare workers.

It’s easy to look back and say what should have been done. But companies must prepare for the future, by addressing systemic challenges. Now is the time to adopt strategies that set health facilities up for success, whether there is a surplus or a shortage of essential medical supplies.

As COVID-19 spread around the world, the medical supply chain began to scramble. It quickly became apparent that the JIT delivery model that many hospitals, especially smaller rural facilities, had adopted could not withstand high demand during a catastrophic pandemic. Stories of frontline workers reusing PPE supplies or even making their own have captured national attention and led to a wake-up call throughout the supply chain.

So how did this happen? Along with hospitals not having a stockpile of supplies to fall back on, other supply chain factors were also fueling the problem. Manufacturers, distributors, and group purchasing organizations (GPOs) relied on a single source for supplies and materials, and when those vendors were forced to close, it resulted in shortages down the line. The lack of supplier diversity has wreaked havoc within the industry, forcing many to rethink the partners they rely on and the strategies they use to stock essential supplies.

Unfortunately, there’s no way to tell when or where the next global crisis will occur, but if 2020 has taught us anything, it’s that a crisis can strike when you least expect it. As supply chain industry leaders, we must prepare and implement the strategic lessons of the past to conquer the future.

Storing medical supplies presents a variety of challenges, but there are a few instances when it makes sense for hospitals to have excess stock on hand. Just as consumers stock up on paper towels, toilet paper, and non-perishable food, hospitals can maintain a repository of in-demand supplies with extended expiration dates and fewer complex storage requirements. This includes masks, gloves and gowns which are always in demand and do not require refrigeration to stock. Additionally, PPE protects frontline workers and, as we’ve seen with COVID-19, keeping them healthy during a pandemic is crucial to fighting a silent killer like a highly contagious virus.

Beyond everyday essentials like PPE, it’s difficult for hospitals to stockpile medical supplies. This is largely because it is impossible to predict which products will be in short supply. Still, there are tactics that can be implemented to help hospitals be better prepared without having to stockpile.

The best way to prepare for future global disasters is to ask manufacturers, distributors and GPOs how they are preparing for the next shortage. Their responses should center on diversifying sources of supply to overcome potential shortages, as well as adopting proactive initiatives to supplement products when they are or will be in high demand.

If we’ve learned anything from recent supply chain shortages, it’s that suppliers shouldn’t depend on a single source for goods. Rather, they should have multiple options for sourcing materials and supplies to ensure a steady flow through the supply chain.

Throughout the ups and downs of the past two years, the US supply chain has proven its resilience by pivoting and innovating to create new partnerships and reinvent existing ones. From sourcing to manufacturing to transporting supplies, there are operational and economic efficiencies to be gained when finding the right supply chain partners.

Mike Palazzini is Executive Vice President of Operations at triose.

read more
Generic drugs

Generic Drugs Market to Register Growth of $138.9 Billion – Technavio Identifies North America as a Key Growth Region

NEW YORK, July 27, 2022 /PRNewswire/ — The “Generic Drugs Market by Type and Geography – Forecast and Analysis 2021-2025“a Technavio report expects the market size to increase by $138.9 billion between 2020 and 2025. The market grew at a CAGR of 5.95% in 2021 and the growth momentum is expected to accelerate at a CAGR of 6.33% during the forecast period. The report provides a comprehensive analysis of recent developments, new product launches, major revenue-driving segments, and market behavior across all geographies. Download sample PDF report here

Technavio has announced its latest market research report titled Generic Drugs Market by Type and Geography – Forecast and Analysis 2021-2025

The global generic drugs market is fragmented and characterized by global and regional vendors. Suppliers partner with research organizations and hospitals for R&D and participate in various scientific conferences to showcase their products and explore long-term development opportunities. The major vendors in the global generic drugs market are focusing on product approvals, mergers and acquisitions, and product launches to gain a competitive edge in the market. Inorganic growth strategies, robust R&D and pricing strategies will also increase the competition among these vendors.

Technavio identifies Amgen Inc., Dr. Reddys Laboratories Ltd., Fresenius SE and Co. KGaA, Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. among the major players in the market. Although the availability of low-cost alternatives, increased outsourcing of drug discovery and development, and increasing drug patent expirations will provide immense opportunities for growth, growing credibility issues, side effects growth and strict regulations will test the growth of market players. To make the most of the opportunities, sellers in the market should focus more on growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. Download sample report now

The generic drugs market is segmented as follows:

The small molecule generics segment will hold the largest market share. The availability of generic drugs at discounted prices is driving the growth of the segment. In addition, the emergence of super generics, the lower investment required by manufacturers and the simplification of synthetic chemical reactions to produce exact copies of the product are contributing to the growth of the segment.

39% of market growth will come from North America during the forecast period. The presence of a large number of key vendors who offer a variety of highly differentiated products is driving the growth of the regional market. Additionally, the increase in the prevalence of major health disorders is mainly due to lifestyle changes, and the increase in the consumption of alcohol and tobacco in the United States will have a positive impact on the growth of the market. generic drugs in the United States. North America. Technavio presents a detailed picture of the market through study, synthesis and summation of data from multiple sources. Our Generic Drugs Market report covers the following areas:

Generic Drugs Market 2021-2025: Vendor Analysis

We provide a detailed analysis of around 25 vendors operating in the generic drug market, including some of the dominant vendors. Leveraging on competitive intelligence and benchmarking, our Generic Drugs Market research report is designed to provide entry assistance, customer profiling and M&A as well as strategy support of placing on the market.

Generic Drugs Market 2021-2025: Key Highlights

  • Market CAGR over the forecast period 2021-2025

  • Detailed information on the factors that will contribute to the growth of the generic drugs market over the next five years

  • Estimation of the generic drugs market size and its contribution to the parent market

  • Predictions on upcoming trends and changes in consumer behavior

  • The growth of the generic drug market

  • Market Competitive Landscape Analysis and Detailed Vendor Information

  • Comprehensive details of the factors that will challenge the growth of the Generic Drugs Market vendors

Related reports:

Generic Drugs Market Scope

Report cover

Details

Page number

120

base year

2020

Forecast period

2021-2025

Growth momentum and CAGR

Accelerate at a CAGR of 6.33%

Market Growth 2021-2025

$138.9 billion

Market structure

Fragmented

Annual growth (%)

5.95

Regional analysis

North America, Europe, Asia and ROW

Successful market contribution

North America at 39%

Main consumer countries

United States, Germany, China, Japan and United Kingdom

Competitive landscape

Leading companies, competitive strategies, scope of consumer engagement

Profiled companies

Amgen Inc., Dr. Reddys Laboratories Ltd., Fresenius SE and Co. KGaA, Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. and Viatris Inc..

Market dynamics

Parent market analysis, market growth drivers and barriers, analysis of fast growing and slow growing segments, impact of COVID 19 and future consumer dynamics, and analysis of market conditions for the forecast period.

Personalization area

If our report does not include the data you are looking for, you can contact our analysts and customize the segments.

Contents:

1. Summary

2 Market landscape

3 Market sizing

4 Five forces analysis

5 Market Segmentation by Type

6 Customer Landscape

7 Geographic landscape

8 drivers, challenges and trends

9 Supplier landscape

10 Vendor Analysis

11 Appendix

About Us

Technavio is a global leader in technology research and consulting. Their research and analysis focuses on emerging market trends and provides actionable insights to help companies identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialist analysts, Technavio’s reporting library consists of over 17,000 reports and counts, spanning 800 technologies, spanning 50 countries. Their customer base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing customer base relies on Technavio’s comprehensive coverage, in-depth research, and actionable market intelligence to identify opportunities in existing markets and potentials and assess their competitive positions in changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Manager
USA: +1 844 364 1100
UK: +44 203 893 3200
E-mail: [email protected]
Website: www.technavio.com/

Technavio (PRNewsfoto/Technavio)

Technavio (PRNewsfoto/Technavio)

Quote

Quote

See original content to download multimedia: https://www.prnewswire.com/news-releases/generic-drugs-market-to-record-usd-138-9-bn-growth–technavio-identifies-north- america-as-a-key-growth-region-301593342.html

SOURCETechnavio

read more
Prescription drugs

Senator Cortez Masto says Nevada’s new prescription drug ad is fake

As elected officials and would-be politicians campaign, how do Nevada voters know what’s factual and what’s campaign?

Senator Catherine Cortez Masto called out Big Pharma today for spreading misinformation about its stance on prescription drug prices.

The ad currently airing in Nevada claims lawmakers are considering “cutting millions of dollars” that could help Nevadans with prescription drug costs.

On Tuesday in the Senate, Cortez Masto told his colleagues that the ad was patently false. And she said that although it’s said to be produced by the American Prosperity Alliance, it’s unclear who is actually funding it, but she has her suspicions.

“We don’t know who actually funded this ad, and the organization that wrote the check doesn’t have to disclose that information, and therefore no one can be held responsible. And that’s part of the problem,” he said. she declared. “And that’s why I called for accountability and transparency and who is funding these ads. is “Big Pharmacy.”

Cortez Masto said she wants her colleagues and Nevada voters to know the opposite is true with lawmakers like her working to lower prescription drug prices by capping out-of-pocket costs and allowing the government to directly negotiate prescription drug prices.

read more
Medical products

Sentinel Node Biopsy Market Is Booming Globally | Devicor Medical Products, Inc., CR Bard, Inc. (USA), INTRAMEDICAL IMAGING LLC (USA)

Global Sentinel lymph node biopsy The market report is an objective and in-depth study of the current state aimed at the key drivers, Sentinel Node Biopsy market strategies and growth of Sentinel Node Biopsy key players. The Sentinel Node Biopsy study also involves the significant achievements of the Sentinel Node Biopsy market, Sentinel Node Biopsy research and development, Sentinel Node Biopsy new product launch, Sentinel Node Biopsy product responses and Sentinel Node Biopsy industry regional growth of key competitors operating in the market globally and locally. The structured analysis contains a graphical and schematic representation of the global Sentinel Node Biopsy market with its specific geographical regions.

[Due to the pandemic, we have included a special section on the pre-post Impact of COVID 19 on the @ Market which would mention How the Covid-19 is Affecting the Sentinel Node Biopsy

Get Sentinel Node Biopsy sample copy of report @ jcmarketresearch.com/report-details/73152/sample

** The Values marked with XX is confidential data. To know more about Sentinel Node Biopsy industry CAGR figures fill in your information so that our JCMR business development executive can get in touch with you.

Global Sentinel Node Biopsy (Thousands Units) and Revenue (Million USD) Market Split by following coverage:- 

[Segments]

The Sentinel Node Biopsy research study is segmented by Application such as Laboratory, Sentinel Node Biopsy Industrial Use, Sentinel Node Biopsy Utilities and Others with historical and projected market share and a compound annual growth rate.
Global Sentinel Node Biopsy by Region (2022-2030)

Sentinel Node Biopsy Market Segmentation By Regions 2015 2017 2019 2020 CAGR (%) (2022-2030)
North America xx xx xx xx% xx%
Europe xx xx xx xx% xx%
AEM xx xx xx xx% xx%
APAC and rest of the world xx xx xx xx% xx%
Total xx xx xx xx% xx%

Geographically, this Sentinel Node Biopsy report is segmented into several key Regions, with production, consumption, revenue (Million USD) and market share of Sentinel Node Biopsy and growth rate of Sentinel Node Biopsy of the sentinel lymph node in these regions, from 2015 to 2030 (forecast) covering .

Additionally, sentinel node biopsy export and import policies can have an immediate impact on sentinel node biopsy. This Sentinel Node Biopsy study contains an EXIM* related chapter on Sentinel Node Biopsy Market and all its associated companies with their profiles, which provides valuable data regarding their outlook in terms of industry financials Node Biopsy, Sentinel Node Biopsy Product Portfolios, Sentinel Node Biopsy Investment Plans, Sentinel Node Biopsy Marketing and Sentinel Node Biopsy Business Strategies. The Sentinel Node Biopsy report is an important document for all market enthusiasts, policy makers, investors, and players.

Key questions answered in this Sentinel Node Biopsy Industry Report – 2030 Data Survey Report

What will be the size of the Sentinel Node Biopsy market in 2030 and what will be the growth rate?
What are the key trends in the Sentinel Node Biopsy market?
What motivates sentinel lymph node biopsy?
What are the growth challenges of the Sentinel Node Biopsy market?
Who are the leading providers of sentinel lymph node biopsy in space?
What are the key market trends impacting the growth of Sentinel Node Biopsy?
What are the main results of the analysis of the five forces of the sentinel lymph node biopsy?

Get Attractive Discount on Sentinel Node Biopsy Report with Extra Customization @ jcmarketresearch.com/report-details/73152/discount

There are 15 chapters to view Sentinel Node Biopsy.

Chapter 1, to describe Definition, Specifications and Classification of Sentinel Node Biopsy, Applications of Sentinel Node Biopsy, Market Segment by Regions;

Chapter 2, to analyze the Sentinel Node Biopsy manufacturing cost structure, Sentinel Node Biopsy raw material and suppliers, Sentinel Node Biopsy manufacturing process, manufacturing chain structure sentinel lymph node biopsy industry;

Chapter 3, to view the Technical Data and Manufacturing Plants Analysis of Sentinel lymph node biopsysentinel node biopsy capacity and commercial production date, distribution of sentinel node biopsy manufacturing plants, sentinel node biopsy R&D status and technology source, sentinel node biopsy raw material source analysis;

Chapter 4, to show the Global Sentinel Node Biopsy Market Analysis, Sentinel Node Biopsy Capacity Analysis (Company Segment), Sentinel Node Biopsy Sales Analysis (Company Segment), Sentinel Node Biopsy Sales Price Analysis (Company Segment);

Chapter 5 and 6, to show the Regional Sentinel Node Biopsy Market Analysis that includes North America, Europe, Asia-Pacific etc, Market Analysis of Biopsy Segment from the sentinel lymph node by various segments;

Chapter 7 and 8, to analyze the Sentinel Node Biopsy Segment Market Analysis (by Application) Major Manufacturers Analysis of Sentinel Node Biopsy;

Chapter 9, Sentinel Node Biopsy Market Trend Analysis, Regional Market Trend, Market Trend by Product Types, Market Trend by Applications;

Chapter 10, Sentinel Node Biopsy Regional Marketing Type Analysis, Sentinel Node Biopsy International Trade Type Analysis, Sentinel Node Biopsy Supply Chain Analysis;

Chapter 11, to analyze consumer analysis of sentinel lymph node biopsy;

Chapter 12, to describe Sentinel Node Biopsy Research Findings and Conclusion, Appendix, methodology and data source;

Chapter 13, 14 and 15, to describe Sentinel Node Biopsy sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Purchase an instant copy of the full Sentinel Node Biopsy Research Report: @ jcmarketresearch.com/checkout/73152

Find more research reports on Sentinel node biopsy industry. By JC Market Research.

Thank you for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About the Author:
JCMR’s global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities, but also to empower and inspire you to create visionary growth strategies for the future, through our extraordinary depth and breadth of thought leadership, research, tools, events and experience. that help you make goals a reality. Our understanding of the interplay between industry convergence, megatrends, technologies and market trends provides our clients with new business models and opportunities for expansion. We are focused on identifying the “Accurate Forecast” in each industry we cover so that our clients can reap the benefits of being early market entrants and can achieve their “Goals and Objectives”.

Contact us:
JCMARKETRESEARCH
Mark Baxter (Business Development Manager)
Call:
+1 (925) 478-7203
Email: [email protected]

Connect with us at – LinkedIn

read more
Generic drugs

DTI will push investments in the manufacture of generic drugs


The Department of Trade and Industry (DTI) is committed to making more generic medicines available on the market in line with its priority of promoting life sciences and health.

Responding to President Ferdinand Marcos Jr.’s call in his first State of the Nation (SONA) address on Monday for more accessible and cheaper drugs, DTI Secretary Alfredo Pascual at the post-SONA economic briefing , said yesterday that the agency would encourage the entry of more generic drugs in two ways.

One is through multinational companies whose drugs will be formulated and manufactured locally under subcontracting agreements with local companies.

The second way is to encourage the local pharmaceutical industry to launch into the production of generics.

In a statement, Johannes Bernabe, OCI chairman of the Philippine Competition Commission (PCC), said the agency has been advocating since its inception for measures that will remove barriers to entry and viability for manufacturers of generic drugs in the country.

Bernabe said the production of unbranded generic drugs in the country lags behind even among other developing countries.

The Commission has also been constantly monitoring and reviewing possible anti-competitive situations, including cartels, that may exist in the different segments of the pharmaceuticals supply chain, Bernabe said.

“The Philippines is known to have one of the highest drug costs in Asia,” Bernabe said.

Bernabe expressed the CCP’s commitment to continue with even more determination the investigation of the pharmaceutical sector, in addition to its current efforts in this priority sector and to uphold its mandate to crack down on cartels and abusive behavior in different industries. , including this sector.

read more
Medical supplies

Medical supplies market worth $163.5 billion by 2027

CHICAGO, July 26, 2022 /PRNewswire/ — Medical supplies market should go from $138.4 billion in 2022 at $163.5 billion by 2027, at a CAGR of 3.4% from 2022 to 2027 according to a new report from MarketsandMarkets™. The growth of this market can be attributed to the expanding geriatric population, increasing investment in research, high volume of surgical procedures, and high prevalence of chronic diseases.

Download the PDF brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64344238

Browse the in-depth table of contents at “Medical Supplies Market”

174 – Tables
39 – Numbers
281 – Pages

In 2021, intubation and ventilation supplies accounted for the largest share of the medical supplies market, by type.

By Type, the medical supplies market is segmented into diagnostic supplies, dialysis consumables, wound care consumables, radiology consumables, disinfectants, infusion and injectable supplies, intubation and ventilation supplies, personal protective equipment , sterilization consumables, catheters, sleep apnea consumables and other medical equipment. In. The intubation and ventilation supplies segment held the highest share, which is attributed to its massive demand amid the novel coronavirus outbreak. The overwhelming influx of COVID-19 patients has created a huge demand for intubation and ventilation supplies which has fueled the market share.

By other application accounted for the largest market share in 2021.

Based on application, the medical supplies market is segmented into urology, wound care, radiology, respiratory, infection control, cardiology, IVD and other applications. The other application segment held the largest share. Other application areas include dentistry, neurology, gastroenterology, orthopedics and waste management applications. The segment market share is driven by high number of surgeries and increasing prevalence of neurological disorders, dental diseases, gastrointestinal disorders and others.

By end user, hospitals accounted for the largest market share in 2021.

Based on end-user, the market is segmented into hospitals, clinics/doctor’s offices, and other end-users. In 2021, the hospital segment accounted for the largest market share. This can be attributed to increased investment in healthcare and state-of-the-art infrastructure.

Request sample pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=64344238

North America was the largest regional market for the medical supplies market in 2021.

The medical supplies market is segmented into five major regions, namely, North America, Europe, Asia PacificRest of the world. North America held the largest market share in 2021, followed by Europe. The largest market share of North America is driven by the high incidence of a strong presence of industry players, the high prevalence of chronic and infectious diseases, and the state-of-the-art healthcare infrastructure in the region.

Some of the major players operating in the medical supplies market are Medtronic plc (Ireland), Cardinal Health (USA), BD (USA), Johnson & Johnson, Inc. (USA), B. Braun Melsungen AG (Germany), Boston Scientific Corporation (USA), Thermo Fisher Scientific, Inc. (USA), Baxter (USA), 3M (USA), Smith & Nephew (Ireland), Convatec Inc. (UK), Abbott (US), Cook Medical (US), Merit Medical Systems (US), Stryker (US), Terumo Corporation (Japan), Teleflex Incorporated (USA), Fresenius Medical Care AG & Co. KGaA (Germany), Coloplast Group (Denmark), Hamilton Medical (Swiss), ACell, Inc. (USA), Invacare Corporation (USA), Medline Industries, LP. (USA), DeRoyal Industries, Inc. (USA), Shenzhen MedRena Biotech Co., Ltd. (China), Kerecis (United States) and Whiteley (Australia).

Get 10% free customization on this report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=64344238

Browse the adjacent market: Medical Devices Market Research reports and advice

Related reports:

Infection Control Market by product [Sterilization (Steam, Hydrogen Peroxide, EtO), Disinfection (Wipes, Liquids, Disinfectors), Services, E-beam, Face Masks]End user (Hospitals, Pharmaceutical companies) (2022 – 2026)

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats that will impact 70%-80% of global business revenue. Currently serving 7,500 customers worldwide, including 80% of global Fortune 1000 companies as customers. Nearly 75,000 senior executives from eight industries around the world approach MarketsandMarkets™ for their revenue decision issues.

Our 850 full-time analysts and MarketsandMarkets™ SMEs track global high-growth markets by following the “Growth Engagement Model – GEM”. The GEM aims for proactive collaboration with customers to identify new opportunities, identify most important customers, write “Attack, Avoid and Defend” strategies, identify additional sources of revenue for the company and its competitors. MarketsandMarkets™ now offers 1,500 MicroQuadrants (positioning top performers among Leaders, Emerging Companies, Innovators, Strategic Players) each year in high-growth emerging segments. MarketsandMarkets™ is determined to benefit over 10,000 companies this year for their revenue planning and help them bring their innovations/disruptions to market by providing research ahead of the curve.

MarketsandMarkets’ flagship competitive intelligence and market research platform, “Knowledge Store”, connects over 200,000 markets and entire value chains for a deeper understanding of unmet information, as well as market sizing and niche market forecasts.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Office 430
Northbrook, IL 60062
UNITED STATES: +1-888-600-6441
E-mail: [email protected]
Research overview: https://www.marketsandmarkets.com/ResearchInsight/medical-supplies-market.asp
Visit our website: https://www.marketsandmarkets.com/
Source of content: https://www.marketsandmarkets.com/PressReleases/medical-supplies.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE Markets and Markets

read more
Medical supplies

Medical Supplies Market Supply Chain Analysis, Growth Opportunities, Top Companies, Report Revenue Growth by 2027

Emerging research logo

Medical Supplies Market Rising demand for the disinfection and IASS containment product is propelling the demand in the medical supplies market.

Medical Supplies Market Size – USD 126.57 Billion in 2019, Market Growth – CAGR of 4.5%, Market Trends – COVID-19 Virus Outbreak.

— Emerging research

VANCOUVER, BC, CANADA, July 26, 2022 /EINPresswire.com/ —
The Global Medical supplies market is expected to be worth $180.89 billion by 2027, according to current analysis by Emergen Research. Rising incidence of chronic diseases due to poor lifestyle habits is expected to drive the demand for medical supplies over the forecast period. The report covers the currently fluctuating market scenario along with the current and future assessment of the impact of COVID-19. The report includes historical data, company overview, financial status and necessary information about the new key players in the market.

In addition, the report also provides an overview of product portfolios, costs, sales, production capacity, and market players. Raw materials, demand analysis, product flows, and distribution channels have been researched and researched in detail in this research report. Key trends and growth opportunities are offered through in-depth market investigation and review. A detailed development course is offered in the report along with related business information including local firms, industries, organizations, suppliers and manufacturers.

Get a sample report @ https://www.emergenresearch.com/request-sample/380

Some highlights of the report

Growing level of worker health and safety awareness and rising fatalities, especially in emerging countries, is creating a need for personal protective equipment, thus fueling the demand for the segment.
The increase in the geriatric population at high risk for chronic wounds will support demand for the advanced wound care segment. The growing number of patients with chronic injuries places significant financial burdens on healthcare systems around the world.
Hospitals held the largest share of the medical supplies market. This is due to increased investment in the healthcare system and the growing prevalence of chronic and infectious diseases.
The report covers the key points of the market including the standards, regulations and policy changes applied by the government on the industry for the coming years. The report encompasses in-depth research conducted through the application of advanced analytical tools such as SWOT analysis and Porter’s Five Forces analysis to identify trends and growth patterns. Factors likely to influence market growth, current trends, opportunities, restraining factors, and the business landscape are thoroughly discussed in the market study.

The report offers a comprehensive breakdown of the regional analysis of the market and subsequent analysis by country. The regional market analysis includes information on production volume, consumption volume and patterns, revenue and growth rate for the forecast period 2020-2027.

According to the regional analysis, the market is primarily split across the key geographical regions as follows:
North America (USA, Canada)
Europe (UK, Italy, Germany, France, Rest of EU)
Asia-Pacific (India, Japan, China, South Korea, Australia, rest of APAC)
Latin America (Chile, Brazil, Argentina, Rest of Latin America)
Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa, Rest of MEA)

The report offers a comprehensive overview of the competitive landscape and covers company profiles, production and manufacturing capacity, product portfolio, expansion strategies and business initiatives such as mergers and acquisitions, joint ventures, collaborations, partnerships, product launches and brand promotions, among others. .

Ask for a discount on the report @ https://www.emergenresearch.com/request-discount/380

Leading Players Analyzed in the Report:
Medtronic Plc, Becton, Dickinson And Company, B. Braun Melsungen Ag, Cardinal Health, Inc., Johnson & Johnson, Boston Scientific Corporation, Baxter International, Inc., 3M Company, Abbott and Avanos Medical, Inc., among others.

To learn more about the report, visit @ https://www.emergenresearch.com/industry-report/medical-supplies-market

Further, the report divides the medical supplies market into key segments and sub-segments to offer an analysis of product type and industry application spectrum. It also offers predictions on which segments are expected to show significant growth over the forecast period.

For the best solutions on the market, visit the link below:
https://www.emergenresearch.com/industry-report/medical-supplies-market

For the purposes of this report, Emergen Research has segmented the global medical supplies market on the basis of type, application, end-user, and region:

Type Outlook (Revenue, USD Billion; 2017-2027)
Diagnostic supplies
Blood Collection Consumables
Other
Infusion and injectable supplies
Intubation and ventilation supplies
Disinfectants
Hand sanitizers
Skin disinfectants
Surface disinfectants
Instrument disinfectants
Individual protection equipment
Hand and arm protection equipment
Eye and face protection equipment
Protective clothing
Foot and leg protection equipment
Surgical drapes
Other protective equipment
Sterilization consumables
Consumables for wound care
Advanced dressings
Surgical wound care
Traditional wound care
Dialysis consumables
Hemodialysis consumables
Consumables for peritoneal dialysis
Radiology consumables
Catheters
Cardiovascular catheters
IV catheters
Urological catheters
Specialty catheters
Neurovascular catheters
Consumables for sleep apnea
Other medical supplies

Application Outlook (Revenue, USD Billion; 2017-2027)
Urology
Wound care
Radiology
Respiratory
infection control
Cardiology
DIV
Other Apps

End User Outlook (Revenue, USD Billion; 2017-2027)
Hospitals
Clinics
Others

Medical Supplies Market Report Overview:
Introduction, Product Scope, Market Overview and Opportunities
Manufacturers Analysis with Sales, Revenue and Price Analysis
Complete analysis of the competitive landscape
Detailed profiling of key competitors along with their business strategies and market size
Regional analysis of the market along with sales, revenue, market share and global position
Country-wise analysis of the market along with types, applications, and manufacturing
Strategic recommendations to established players as well as new entrants
In-depth analysis of Medical Supplies industry risks, restraints and limitations

Request report customization @ https://www.emergenresearch.com/request-for-customization/380

Thank you for reading our report. Please contact us for more information about the report or report customization. Our team will ensure that the report is best suited to your needs.

Explore More Emergen @ Research Report www.emergenresearch.com

artificial intelligence and advanced machine learning market-https://www.emergenresearch.com/industry-report/artificial-intelligence-and-advanced-machine-learning-market

photolithography equipment market-https://www.emergenresearch.com/industry-report/photolithography-equipment-market

environmental testing equipment market-https://www.emergenresearch.com/industry-report/environmental-testing-equipment-market

drone parcel delivery market-https://www.emergenresearch.com/industry-report/drone-package-delivery-market

power monitoring market-https://www.emergenresearch.com/industry-report/power-monitoring-market

bariatric surgery market-https://www.emergenresearch.com/industry-report/bariatric-surgery-market

auto-injector market-https://www.emergenresearch.com/industry-report/autoinjectors-market

green technology and sustainability market-https://www.emergenresearch.com/industry-report/green-technology-and-sustainability-market

About Us:
Emergen Research is a market research and consulting firm that provides syndicated research reports, custom research reports, and consulting services. Our solutions are uniquely focused on your goal of locating, targeting and analyzing changes in consumer behavior across demographics, across industries, and helping customers make smarter business decisions. We offer market intelligence research ensuring relevant and factual research across multiple sectors including health, touchpoints, chemicals, types and energy. We are constantly updating our search offerings to ensure that our clients are aware of the latest trends existing in the market. Emergen Research has a strong base of experienced analysts from a variety of areas of expertise. Our industry experience and ability to develop a workable solution to any research problem gives our clients the ability to secure an edge over their respective competitors.

Read the full press release @ https://www.emergenresearch.com/press-release/global-medical-supplies-market

Contact us:

Eric Lee
Emerging research
+91 90210 91709
write to us here
Visit us on social media:
Facebook
Twitter
LinkedIn

read more
Prescription drugs

High heat can impact the effectiveness of prescription medications and cause side effects | Local News

The heat wave continues across the country, in the United States and locally. And with temperatures in the region consistently staying in the 80s to 90s, experts warn of more than just heatstroke and sunburn.






Scott room


Scott Hall, senior director of clinical practice for pharmacy in the Southwest Region of the Mayo Clinic Health System, says heat can impact medication effectiveness. The chemicals they contain can be degraded when stored at very high or even very cold temperatures.

“We really need to make sure that these drugs retain their strength, potency, and effectiveness regardless of the condition they’re trying to treat,” Hall says. “The temperature can really impact all the medications people take.”

Insulin is a drug that can be particularly heat-sensitive, Hall says, as can nitroglycerin tablets and epinephrine injectors.

People also read…

To maintain medication effectiveness, medications should not be stored in a vehicle, bathroom, or near stoves and ovens, where moisture, steam, and heat from cooking and baking can have a negative effect on the pills. Especially for those who do not have air conditioning in their homes, medicines should be kept in a cool, dry place. Medicines should also be kept in their original packaging.

“Whether it’s the bottle the medicine originally came in or the bottle the pharmacist put it in at the pharmacy, keeping it in those bottles where they can stay sealed will really help prevent any side effects. heat negative,” Hall said. said.

Medications should not, Hall says, be stored in the refrigerator unless directed by a pharmacist or doctor.

In addition to affecting medications, heat can also impact the patient’s tolerance to medications and have adverse effects. Certain medications, especially those classified as diuretics, such as blood pressure medications, can make patients more susceptible to dehydration.

“Their intended effect is to increase urination and, through this, help lower blood pressure,” says Hall. “But this increased urination can lead to dehydration.”

Beta-blockers and antihistamines, Hall adds, “can inhibit the body’s ability to sweat and therefore make patients more susceptible to the effects of heat.” And some psychiatric drugs can interfere with body temperature regulation.

“I would say the basic common practice is that if you’re on these types of medications, limit the amount of time you’re outside,” advises Hall. Those who have to stay outdoors for a long time should stay in the shade as much as possible and drink enough water.

Says Hall, “Make sure you’re proactively taking care of yourself so you don’t end up in a tough spot.”

Those who have questions about storing their medications, or if they have been affected by any heat-related side effects, should talk to their pharmacist.

read more
Medical supplies

Tomlin Medical offers affordable medical supplies

Tomlin Medical, a reputable medical equipment supplier in Australia, offers quality and affordable patient monitors and alarms online.

Medical practitioners need quality equipment and tools to perform complicated procedures efficiently. Thorough research and caution become imperative when selecting aids used in these practices. With the help of trusted medical equipment distributors, this can be achieved seamlessly. Tomlin Medical is a trusted medical equipment supplier in Australia with half a century of experience in the industry. They dedicate their expertise to providing healthcare professionals with a wide range of medical and surgical equipment. So customers can be sure to get multiple products, including microscopes, ultrasound, x-ray, patient monitors, operating tables, infusion pumps, endoscopy equipment, autoclaves, equipment anesthesia, electrosurgical equipment, surgical tools and other general equipment.

In response to a question about their services and products, the spokesperson for Tomlin Medical said, “We are always excited to provide our customers with high quality, durable and affordable products. We carefully select our products and offer both new and used products, which our in-house bio-engineer carefully approves. Therefore, rest assured that you can find exactly what you are looking for in our warehouse at an affordable price. Do not hesitate to make an appointment with us to discover our new and used equipment throughout our warehouse in Moorabbin.

A wide range of medical products are available on the Tomlin Medical website. As a family business, they focus on building long-term business relationships with customers. Their delivery procedures are also very meticulous, as they always ensure that large and fragile medical products arrive at their clients’ clinic or hospital in one piece. For all their online medical supplies australia, they offer customers a 12-month warranty on new products and a 6-month warranty on used medical equipment. Customers can also receive competitive pricing on all of their medical products and equipment.

The spokesperson added: “On our website you will find new and used patient monitors. They are very resourceful for various clinical situations, and we have a variety of monitors for every occasion. These monitors have the standard settings to meet your needs. We have portable ones and ones you can mount on a wall.

Doctors who need patient monitors in australia can contact Tomlin Medical. These products can be used in operating theaters, emergency rooms, intensive care centers and intensive care units.

About Tomlin Medical:

Tomlin Medical is a professional medical equipment supplier and distributor in Australia. Customers can also be sure to get alarms and patient monitors at very affordable rates.

Contact information:

Tomlin Medical

31 Levanswell Moorabbin Road,

CIV 3189

Telephone: 03 9555 1010

Website: https://www.tomlinmedical.com.au/

Media Contact
Company Name: Tomlin Medical
E-mail: Send an email
Call: (03)95551010
Address:31 Levanswell Road
Town: Moorabbi
State: CIV 3189
Country: Australia
Website: https://www.tomlinmedical.com.au/

read more
Medical supplies

Medical Supplies Market Size, Scope, Growth Opportunities, Trends by Manufacturers and Forecast to 2029 – This Is Ardee

New Jersey, United States – The Medical supplies market research guides new entrants to obtain accurate market data and communicates with customers to learn about their needs and preferences. He identifies direct business opportunities and helps bring new products to market. It identifies opportunities in the market. It aims to make changes in the business to make business procedures smooth and business moving forward. It helps business players make informed decisions. The Medical Supplies market report assists in reducing business risks and provides means for facing upcoming challenges. The market information provided here helps new entrants make informed decisions. It emphasizes on major global regions such as Europe, North America, Asia-Pacific, Middle East, Africa, and Latin America along with their market size .

Such a unique research report on Medical Supplies Market offers detailed strategic plans that help players to face the current market situation and take a position. This helps strengthen your trading position. It provides a better understanding of the market and keeps perspective to help stay ahead in this competitive market. Organizations can gaze and compare their presentation with others in the market based on this quick market report. This market report offers a clarified picture of the various market tactics and thus helps the business organizations to earn bigger profits. You get a clear idea about product launches, trade regulations, and market expansion through this market report.

Get Sample Full PDF Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.verifiedmarketresearch.com/download-sample/?rid=144345

Key Players Mentioned in the Medical Supplies Market Research Report:

Johnson & Johnson, Coloplast Group, Fresenius Medical care AG & Co. KGaA, Teleflex Incorporated, Terumo Japan, Stryker, Merit Medical Systems, Cook Medical, Abbott ConvaTec Group Plc.

The Medical Supplies Market report embraces significant data regarding the entire market environment for products or services offered by different industry players. It allows industries to know the market scenario of a particular product or service including demand, supply, market structure, price structure, and trend analysis. It is of great help in developing the product market. It further outlines essential data regarding customers, products, competition, and market growth factors. Medical supplies market research is very helpful in making the right decision. Future trends are also revealed for particular products or services to help business players make the right investment and launch products in the market.

Medical Supplies Market Segmentation:

Medical Supplies Market, By Type

• Individual protection equipment
• Disinfectants
• Intubation and ventilation supplies
• Infusion and injectable supplies
• Diagnostic supplies
• Others

Medical Supplies Market, By Application

• Cardiology
• Infection control
• Respiratory
• Radiology
• Wound care
• Others

Medical Supplies Market, By End User

• Hospitals
• Clinics/Doctors’ offices
• Others

Inquire for a discount on this Premium Report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=144345

To prepare the table of contents, our analyst did extensive research on the following:

Presentation of the report: It includes key Medical Devices Market players covered in research study, research scope, market segments by Type, market segments by Application, years considered for research study, and objectives of the report.

Global Growth Trends: This section focuses on industry trends where market drivers and key market trends are shed light on. It also provides growth rates of major producers operating in the medical supplies market. Also, it offers production and capacity analysis where trends of marketing price, capacity, production, and production value of the Medical Equipment market are discussed.

Market Share by Manufacturers: Here, the report provides details of manufacturers’ revenue, manufacturers’ production and capacity, prices by manufacturers, expansion plans, mergers and acquisitions and products, market entry dates, distribution and market areas of major manufacturers.

Market Size by Type: This section focuses on the product type segments where production value market share, price and production market share by product type are discussed.

Market Size by Application: Besides an overview of the Medical Supplies market by application, it gives a consumption study on the Medical Supplies market by application.

Production by region: Here, production value growth rate, production growth rate, import and export, and key players in each regional market are provided.

Consumption by region: This section provides consumption information in each regional market studied in the report. Consumption is discussed according to country, application and product type.

Company Profiles: Almost all the major players of the Medical Supplies Market are profiled in this section. The analysts provided information on their recent developments in the Medical Supplies market, products, revenue, production, activities and company.

Market forecast by production: The production and production value forecasts included in this section are for the medical supplies market as well as major regional markets.

Market forecast by consumption: Consumption and consumption value forecasts included in this section are for Medical Supplies market as well as major regional markets.

Value chain and sales analysis: It provides an in-depth analysis of customers, distributors, sales channels and the value chain of Medical Devices market.

Main findings: This section provides a quick overview of important findings from the research study.

For more information or query or customization before buying, visit @ https://www.verifiedmarketresearch.com/product/medical-supplies-market/

About Us: Verified Market Research®

Verified Market Research® is a leading global research and advisory firm that for over 10 years has provided advanced analytical research solutions, personalized advice and in-depth data analysis to individuals and businesses seeking accurate research, reliable and up to date. data and technical advice. We provide insight into strategic and growth analytics, the data needed to achieve business goals, and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecasts, capitalize on future opportunities, and maximize efficiency by working as a partner to deliver accurate and valuable insights. The industries we cover span a wide spectrum, including technology, chemicals, manufacturing, energy, food and beverage, automotive, robotics, packaging, construction, mining and the gas. Etc.

At Verified Market Research, we help in understanding holistic market indicator factors and most current and future market trends. Our analysts, with their deep expertise in data collection and governance, use industry techniques to gather and review data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject matter expertise and years of collective experience to produce informative and accurate research.

Having served over 5000 clients, we have provided reliable market research services to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the world’s leading consulting firms such as McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for companies around the world.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research®

USA: +1 (650)-781-4080
UK: +44 (753)-715-0008
APAC: +61 (488)-85-9400
US Toll Free: +1 (800)-782-1768

E-mail: [email protected]

Website:- https://www.verifiedmarketresearch.com/

read more
Prescription drugs

The cost of prescription drugs is the topic of today’s editorial board meeting streamed live on Facebook

Prescription drug prices in the United States are too high. And too many people find themselves unable to pay for their medications and keep food on the table. That’s according to the Pennsylvania Health Access Network (PHAN), which is meeting with PennLive’s editorial board at 2 p.m. Thursday, July 21, in an event that will be streamed live on Pennlive’s Facebook page.

The Organization for Economic Co-operation and Development (OECD) says Americans spend more on prescription drugs than anyone else in the world. And the prices in this country of life-saving drugs keep rising. With inflation impacting almost every aspect of American life, PHAN members argue that something needs to be done to help the elderly and others who depend on lifesaving drugs but are increasingly struggling. to pay for them.

PHAN members will discuss what they see as the reasons for the high drug prices in this country and what they have proposed to do to reduce them.

PHAN participants will include Executive Director Antoinette Kraus; policy analyst Jennifer Wolff; Policy Director Patrick Keenan; Director of Communications Shana Jalbert and William Leachman, a consumer concerned about the high cost of prescription drugs in the United States.

PHAN will focus specifically on what can be done in Pennsylvania to support President Joe Biden’s administration’s efforts to reduce the cost of prescription drugs.

Bring your respectful comments and questions to our discussion today on the cost of prescription drugs in America.

Joyce M. Davis is PennLive’s Awareness and Opinion Editor. Follow her on Facebook and Twitter @byjoycedavis.

Quality local journalism has never been more important. You deserve the best. Not yet subscribed? Please consider support our work.

read more
Prescription drugs

John Williamson: Driving while taking prescription drugs

Roadside drug testing will become another tool for police to tackle impaired driving alongside breath testing. Photo/NZME

OPINION

Six weeks ago I had a knee replacement. The operation had been planned 16 months earlier, but the surgeon had health problems and only now has he returned to work.

Both knees are done now and I look forward to a pain free future. The first game of bowls is this week, so things are going well.

I was sent home with a bag of medicine. Antibiotics just in case of infection, anti-inflammatories as well, plus three different painkillers depending on the levels of pain expected at different stages.

They say the pain of knee replacement surgery is worse than that of childbirth, but it’s hard to imagine.

The pain is not excruciating, but with increased activity it persists for some time. However, with the increase in activity you feel more capable and I was physically able to drive.

What held me back though was trying to figure out what level of pain relief makes you potentially impaired while driving, and it’s very hard to find out.

Driving under the influence of drugs has long been a difficult problem to solve, especially when the drugs involved are prescribed by a doctor and dispensed by a pharmacist without a clear warning.

In my case, the most potent drugs had warnings that “this drug may make you drowsy and make it dangerous to drive or use machinery – limit your alcohol intake”.

It is a precautionary signal that does not make driving illegal. There’s a clear message that drinking alcohol while taking prescription drugs just isn’t smart.

From April next year, police will have the authority and tools to be able to randomly road test via a saliva sample for the presence of the 25 most common drugs that could be in the drug system. a driver.

The bulk of them will be prescription drugs. You would like to think that the real target of these tests are illegal and recreational drugs such as cannabis, MDMA (ecstasy) and methamphetamine. These are well-known problematic drugs, especially when mixed with alcohol.

The problem with random road tests for these problematic drugs is that they are illegal, and the law as it stands now confirms that any confirmed presence of these drugs in a person’s system while driving is an automatic condemnation.

Research is sparse on what level of attendance makes the driver intoxicated, but the law says it doesn’t matter – any level is illegal.

Research is conclusive, however, that the presence of alcohol in combination with these drugs multiplies the level of impairment. This makes the conviction appropriate, even though the driver’s blood alcohol level may be below the legal limit.

Zero tolerance for illicit drugs sends a clear signal that these drugs and driving are incompatible.

But what about the driver who took appropriately prescribed medication, with no alcohol present, but no special knowledge of his inebriated state, other than a strongly qualified label on his medication?

Here we have a vast lack of knowledge, about which the police will have to have some discretion during road tests.

There’s no doubt that certain medications prescribed at certain levels can cause driving problems, and they can be scary.

In fact, one of the biggest public health issues in the United States is the epidemic of accidental opioid-related deaths. People taking prescribed drugs, ostensibly for pain but in fact to get high, have caused more than 600,000 premature deaths over the past 20 years from overdoses.

A 2013 report titled “The Wolff Report on Driving Under the Influence of Drugs” attempted to categorize the range of painkillers, antidepressants and sedatives according to power level and level of driving impairment. .

This is an attempt to give guidance to the authorities on the legal limits. Fentanyl, by the way, is considered 80 times more potent than morphine, and its prescription requires great caution.

Random roadside drug testing is an additional tool in the toolbox to make our roads safer.

Common sense as well as better education and knowledge of prescription drugs, especially mixed with alcohol, are also crucial parts of this mix.

read more
Prescription drugs

White House hits back at prescription drugs, accuses McConnell of supporting Big Pharma ‘welfare’

NEWYou can now listen to Fox News articles!

EXCLUSIVE: The White House is hitting back at Senate Minority Leader Mitch McConnell’s criticism of the Democrats’ spending bill — particularly on prescription drugs — accusing him of supporting ‘big social welfare’. pharmaceutical companies,” while saying President Biden is committed to middle-class families and reducing the deficit.

The White House comments came after McConnell, R-Ky., spoke in the Senate on Monday, criticizing the Democrats’ reconciliation plan that would allow Medicare to regulate prescription drug prices.

McConnell said the Biden administration and congressional Democrats “want to impose socialist price controls between America’s innovators and new cures for debilitating diseases.”

In response, White House Deputy Press Secretary Andrew Bates told Fox News on Tuesday that McConnell was “resorting to talking points that Big Pharma is spending millions on airwaves in opposition to the anti- President’s inflation, which would reduce the deficit and finally allow Medicare to negotiate down the exorbitant prescription drug costs that have driven so many American families out of business.”

Senate Minority Leader Mitch McConnell has said the Democrats’ reconciliation plan will negatively impact the country, while President Biden is urging Congress to pass the bill.
(AP Photo/J. Scott Applewhite | Anna Moneymaker/Getty Images)

SENATE READY FOR VOTE ON SEMICONDUCTOR BILL AFTER MANCHIN SHRINKS DEMS RECONCILIATION PACKAGE AGAIN

“The American people are forced to pay two to three times what citizens of other countries do for these drugs, and for too long Medicare has been barred by law from using their leverage to save consumers money and of taxpayers – the welfare of big pharma that the industry has lobbied and Senator McConnell has supported for nearly two decades,” Bates said.

Bates added, “When it comes to choosing between the bottom line of middle-class families or special interests driving up hard-working prices to boost record profits, the president knows exactly where he stands.”

As for prescription drugs in the reconciliation package, Democrats seek to give Medicare the power to negotiate a better deal on some of the most expensive drugs. Currently, Medicare does not have the right to negotiate drug prices.

The legislation would also require rebates from pharmaceutical companies that raise prices faster than inflation and impose caps on recipients of $2,000 per year. One official said the provision would give Americans “the financial security of knowing their pharmacy fees are capped.”

The United States Capitol building in Washington, November 2, 2020.

The United States Capitol building in Washington, November 2, 2020.
(AP Photo/Patrick Semansky, File)

Democrats also say the legislation would help reduce the deficit.

But McConnell and Republicans warn that the bill is waging a “war” on America’s medical innovation sector.

“Democrats in Washington are working right now to find ways to put more bureaucracy between American patients and the treatments they rely on,” McConnell said in his speech on the floor Monday. “They want to put socialist price controls between American innovators and new cures for debilitating diseases.”

McConnell warned that with “one-party democratic control of government, they could get away with it.”

McConnell also pointed out that the provisions would have “extremely, extremely negative consequences” for the country.

“The American people know that government can’t magically cut costs by passing laws saying things should cost less,” McConnell said, warning that “the bill will go to the American people who are living with real health issues. health”.

“The price of bigger government will be fewer lifesaving cures, less innovation in the future,” McConnell added, saying the legislation would ultimately shrink the pipeline of new therapies for patients with chronic conditions.

BIDEN SAYS HE WILL TAKE EXECUTIVE ACTION TO ADDRESS CLIMATE CHANGE IF CONGRESS DOESN’T ACT

“Prescription drugs with socialism would have devastating and aggravating effects,” he said.

Meanwhile, Democrats hoped pass a scan packet to brag about midterm, but in light of recent inflation numbers, Sen. Joe Manchin, DW.Va., last week officially rejected efforts to raise taxes or pass energy and climate policies in the reconciliation package.

Senator Joe Manchin has criticized Democrats' policies on climate change.

Senator Joe Manchin has criticized Democrats’ policies on climate change.
(AP Photo/J. Scott Applewhite)

Manchin, instead, said he would only support a bill that includes a provision to reduce prescription drug prices and a two-year extension of Affordable Care Act grants.

That leaves Democrats, in the Senate 50-50, with only prescription drug provisions and the expansion of the Affordable Care Act (ACA) in their legislation.

Democrats hope to pass the bill using the Senate Reconciliation Process to circumvent the filibuster threshold of 60 votes. This will give them a much-needed victory to bring to voters before members head home to campaign in August ahead of November’s midterm elections, even if it’s a far cry from the $3 trillion-plus bill. dollars that they originally wanted to pass last year.

Fox News’ Tyler Olson and Jason Donner contributed to this report.

read more
Prescription drugs

Syracuse Hospital will provide free prescription drugs to uninsured residents of Onondaga County

Syracuse, NY – Uninsured Onondaga County residents with limited income will be able to get free insulin and other prescription medications starting July 24 at the Upstate Community Hospital Outpatient Pharmacy at 5000 West Seneca Turnpike.

Upstate will get the drugs from the Dispensary of Hope, a national nonprofit drug distributor that collects billions of doses of excess drugs that would otherwise be destroyed and donates them to those in need.

To be eligible, patients must be uninsured and have an income at or below 300% of the federal poverty level. For a single person, 300% of the federal poverty level means an annual income of $40,770.

Eligible patients must also have a prescription to obtain the drugs.

Darryl Geddes, a spokesperson for Upstate, said the program would be a great option for people who don’t qualify for Medicaid, the government’s health insurance program for low-income and disabled people. Medicaid serves patients at or below 133% of the federal poverty level.

About 5% of Onondaga County residents under age 65 are uninsured, according to U.S. Census data.

Medications available will include drugs to treat high blood pressure, high cholesterol, stomach ulcers, diabetes and more.

One of the medications available will be insulin, a diabetes medication that can cost up to $300 per vial.

Upstate said in an announcement that its hospital and clinics often see patients who cannot afford medication.

Dispensary of Hope was started in Nashville, Tennessee in 2003 by a doctor who worked with the local medical community to donate unused drug samples to free clinics and pharmacies. It now receives donated drugs directly from manufacturers and distributors and distributes them to more than 200 sites nationwide.

Upstate will become the state’s first Dispensary of Hope site outside of New York, which has five sites.

Patients who wish to participate should send their prescriptions to the pharmacy, located across from Upstate Community Hospital.

More information about the program can be obtained by emailing Upstate at [email protected]

James T. Mulder covers health. Do you have a topical tip? Contact him at (315) 470-2245 or [email protected]

read more
Medical products

Pharmaceuticals and medical products boosted Irish exports by a third in May – The Irish Times

The value of Irish goods exports jumped by a third to €18 billion in May from the same month last year, driven mainly by growth in exports of medical and pharmaceutical products, according to the latest data. from the Central Statistics Office.

The data also shows that the year-on-year value of merchandise exports for the first five months of 2022 increased by a third to 88.1 billion euros.

Exports of medical and pharmaceutical products increased by almost two-thirds to reach 7.1 billion euros. This represented 39 percent of total exports. Exports of professional, scientific and control devices increased by a third to 733 million euros.

Exports of food and live animals increased by 28% to €1.3 billion, while exports of machinery, appliances, appliances and electrical parts increased by 19% to €1.2 billion .

Strong increases were also seen on the import side, with the unadjusted value rising by 46% to €12.8 billion. The value of goods imports for the period from January to May increased by 36% to 53.6 billion euros.

Imports from Great Britain increased by 71% to reach 2 billion euros. CSO statistician Ciarán Counihan said this was partly explained by the relatively low level of imports in May 2021, which was the fifth month in which post-Brexit customs documentation was required for UK trade.

The value of goods imports from Britain in the first five months of the year is 76% higher than last year, at 9.3 billion euros.

Exports to Great Britain increased by 27% to reach 1.5 billion euros. The main change was an increase in exports of chemicals and related products, as well as machinery and transport equipment. Exports to Britain accounted for 8% of total exports in May. The value of goods exports to Britain from January to May rose 32% to €6.9 billion.

Imports from Northern Ireland were up 23% on a year ago in the five months to May, to 1.9 billion euros. Exports to Northern Ireland for the same period increased by 42% to €2 billion.

The European Union accounted for 35% of total merchandise exports in May, of which 2 billion euros went to Germany, 1.3 billion euros to the Netherlands and 1.2 billion euros to the Belgium. Total EU exports increased by 15% compared to May 2021.

The United States was the main destination outside the EU, accounting for 30 percent of total exports. The EU accounted for 27%, an increase of 1% from May 2021.

The United Kingdom with 2.4 billion euros (19%), the United States with 1.9 billion euros (15%) and China with 1.6 billion euros (12%) were main sources of non-EU imports.

read more
Medical products

US Treasury says agricultural and medical products not part of Russian sanctions

The US Treasury Department clarified on Thursday that it had not imposed any sanctions on the production, manufacture, sale or transport of agricultural products (including fertilizers), agricultural equipment or drugs linked to Russia.

In a fact sheet released by the department, he said the Treasury’s Office of Foreign Assets Control (OFAC) issued a Broad General License (GL) to authorize certain transactions related to agricultural commodities, farm equipment, drugs and medical devices.

“The United States strongly supports United Nations efforts to bring Ukrainian and Russian grain to world markets and to reduce the impact of Russia’s unprovoked war against Ukraine on world food supplies and prices. … The agricultural and medical trade is not the target of sanctions imposed by the United States on Russia for its atrocities in Ukraine.”

The fact sheet pointed out that the provision of insurance or reinsurance for the transport of agricultural products was also not prohibited.

“The United States has imposed a ban on the importation into the United States of fish, seafood and their preparations originating in the Russian Federation. This ban does not limit the importation of fish, seafood and of their preparations originating in the Russian Federation from Russia to countries other than the United States,” he added.

He also said that US financial institutions could conduct transactions related to the items mentioned, adding that the state-owned Russian Agricultural Bank was not on OFAC’s Specially Designated Nationals list, but that transactions were subject to certain debt and equity restrictions.

The fact sheet reflected US policy, which exempts humanitarian, medical and agricultural products from sanctions, with certain restrictions.

The United States issued a memo in February saying its sanctions regime does not prohibit the import or export of agricultural products, drugs and medical devices to Afghanistan, the Wall Street Journal reported.

read more
Prescription drugs

Will allowing Medicare to negotiate prescription drug prices lead to cost savings?

Health care costs are notoriously high in the United States, and the price of prescription drugs is a major reason for this. Nationally, Medicare accounts for about one-third of prescription drug spending. To combat rising costs for this component of the program, legislation being drafted in Congress includes a price negotiation mechanism that could help reduce Medicare spending if enacted.

Medicare spending on prescription drugs has increased dramatically over the past 20 years

TWEET THIS

Spending on prescription drugs is higher in the United States than in other countries

The United States spends nearly three times the average of other developed countries per capita on health care, which is largely due to high drug costs. A 2021 study by the RAND Corporation, a nonprofit research organization, found that the cost of brand-name drugs in the United States was more than triple the cost of those same drugs in other developed countries. One reason is that there are loopholes that allow pharmaceutical companies to extend or create new patents in the United States, many of which are not actually new drugs. These patents lessen competition, limit the production of generic versions and thus allow companies to charge higher prices here compared to other countries. There are a number of other factors that contribute to other countries paying different prices for prescription drugs, but this largely comes down to the lack of state drug price regulation or negotiation. -United.

The United States pays more for prescription drugs than other OECD countries


How would Medicare negotiate prices?

Currently, Medicare does not have the right to negotiate prescription drug prices with manufacturers, forcing the government to pay relatively higher prices for drugs. Medicare Part D is an optional segment of the program that helps beneficiaries pay for prescription drugs. If the provisions being discussed to negotiate prices are signed into law, the US Department of Health and Human Services (HHS) would be authorized to negotiate prices for up to 10 drugs in 2025 and 20 drugs in 2028 and beyond.

The high costs are concentrated on a relatively small number of drugs; the 100 most expensive drugs account for nearly 50% of all Part D expenditures. The goal of price negotiation is to achieve a “maximum fair price” that more similarly matches the average international market price , which represents the average price in six countries: Australia, Canada, France, Germany, Japan and the United Kingdom. The agreed price would then be made available to insurers and organizations that sponsor Medicare Part D plans as well as commercial payers in the group and individual markets. If pharmaceutical companies do not comply with the negotiation process, a maximum excise tax of 95% would be invoked.

Would Negotiating Drug Prices Make a Difference for Medicare Beneficiaries?

Overall, allowing HHS to negotiate drug prices would reduce costs for both the federal government and consumers. A recent Congressional Budget Office (CBO) estimate of a similar plan to tackle drug prices showed savings of nearly $300 billion over the next decade.

The concept is already in practice in other federal government agencies that provide health services. The Veterans Health Administration, the Department of Defense, and Medicaid all have the power to negotiate drug prices, and they pay less than Medicare, on average, for top-selling brand name drugs. With prescription drug spending on the rise — which cost Medicare $116 billion in 2021 from $2 billion in 2000 — price negotiation would be a useful tool to reduce costs. In a recent report, the Center for American Progress wrote that “lowering drug prices through negotiation, inflationary discounts, and insulin and cost-sharing caps would allow people – especially those with chronic diseases and disabilities – to access the treatment they need”.

Conclusion

The price of prescription drugs in the United States is high and rising, with costly consequences for both consumers and the federal balance sheet. Allowing Medicare to negotiate drug prices is a promising policy lawmakers could consider to reduce health care spending, lower costs for consumers, and put our country on a stronger and more sustainable fiscal path.


Related: Infographic: Spending on Prescription Drugs Has Grown Exponentially Over the Past Decades


Image Credit: Photo by Willie B. Thomas/Getty Images

read more
Prescription drugs

Authorities seize $20 million worth of fentanyl disguised as prescription drugs from notorious cartel

The Drug Enforcement Administration (DEA) on July 5 seized approximately $20 million worth of fentanyl-containing pills believed to be linked to Mexico’s Sinaloa drug cartel, according to a DEA press release.

The seizure, carried out by the DEA’s Los Angeles Field Division High Intensity Drug Trafficking Area (HIDTA) Group 48, seized 1 million pills containing fentanyl, according to the news release. It was the largest fentanyl pill bust ever by the DEA in California. (RELATED: DEA Warns Law Enforcement to Prepare for Increase in Fentanyl ‘Massive Overdose Events’)

“These fake pills are designed to resemble real prescription pills down to size, shape, color and stamping,” the DEA said in its press release. “These fake pills usually replicate real prescription opioid medications.”

Prior to the seizure, DEA agents found drug couriers and hideout managers transporting drugs to other dealers in the area, according to the news release.

“Misleading marketing coupled with ease of access makes these seemingly harmless little pills a significant threat to the health and safety of all of our communities. A staggering number of teenagers and young adults are unaware that they are ingesting fentanyl in these fake pills and being poisoned,” DEA Special Agent in Charge Bill Bodner said in a statement Thursday.

Los Angeles is a hub for trafficking illegal drugs across the US-Mexico border due to its many international airports, freeways, and bus and train routes, according to the DEA. The DEA office in Los Angeles saw a 64% increase in fentanyl pills seized in the first four months of 2022, compared to the previous year.

The DEA claims that 40% of fentanyl-containing pills have a lethal dose, which is around 2 milligrams. Fentanyl is largely responsible for the nearly 108,000 drug overdose deaths in the United States in 2021.

The DEA declined further comment to the Daily Caller News Foundation.

Content created by the Daily Caller News Foundation is available at no cost to any eligible news publisher who can provide a large audience. For licensing opportunities of our original content, please contact [email protected]

read more
Medical products

Utah Medical Products (NASDAQ:UTMD) and Treace Medical Concepts (NASDAQ:TMCI) Financial Comparison


Utah Medical Products (NASDAQ:UTMDGet a rating) and Treace Medical Concepts (NASDAQ: TMCIGet a rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Risk and Volatility

Utah Medical Products has a beta of 0.24, meaning its stock price is 76% less volatile than the S&P 500. Comparatively, Treace Medical Concepts has a beta of -0.6, meaning its stock price is 160% less volatile than the S&P 500. .

Analyst Recommendations

This is a summary of recent ratings and recommendations for Utah Medical Products and Treace Medical Concepts, as reported by MarketBeat.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Utah Medical Products 0 0 0 0 N / A
Tracee Medical Concepts 0 0 4 0 3.00

Treace Medical Concepts has a consensus target price of $28.50, suggesting a potential upside of 75.82%. Given the likely higher upside of Treace Medical Concepts, analysts clearly believe that Treace Medical Concepts is more favorable than Utah Medical Products.

Insider and Institutional Ownership

71.4% of Utah Medical Products shares are held by institutional investors. By comparison, 34.8% of shares in Treace Medical Concepts are held by institutional investors. 6.6% of Utah Medical Products stock is held by insiders. By comparison, 41.9% of Treace Medical Concepts’ shares are held by insiders. Strong institutional ownership indicates that hedge funds, endowments, and large fund managers believe a stock will outperform the market over the long term.

Profitability

This table compares the net margins, return on equity and return on assets of Utah Medical Products and Treace Medical Concepts.

Net margins Return on equity return on assets
Utah Medical Products 30.34% 14.14% 13.03%
Tracee Medical Concepts -25.92% -28.57% -19.15%

Valuation and benefits

This table compares the gross revenue, earnings per share (EPS), and valuation of Utah Medical Products and Treace Medical Concepts.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
Utah Medical Products $49.05 million 6.09 $14.79 million $4.18 19.61
Tracee Medical Concepts $94.42 million 9.49 -$20.55 million ($0.50) -32.42

Utah Medical Products has higher revenue, but lower revenue than Treace Medical Concepts. Treace Medical Concepts trades at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

Summary

Utah Medical Products beats Treace Medical Concepts on 8 of 13 factors compared between the two stocks.

Utah Medical Products Company Profile (Get a rating)

Utah Medical Products, Inc. develops, manufactures and distributes medical devices for the healthcare industry. The Company offers fetal monitoring accessories, vacuum assisted delivery systems and other labor and delivery tools; Respiratory hoods for newborns DISPOSA-HOOD; and DELTRAN PLUS blood pressure monitoring systems. It also supplies GESCO umbilical vessel catheters; DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE Silicone Mouthguards; URI-CATH urinary drainage systems; NUTRI-CATHNUTRI-LOK feeding device; MYELO-NATE Lumbar Sampling Kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. Additionally, the Company offers the LETZ System for excision of cervical intraepithelial neoplasia and other lower genital tract lesions; FINESSE+ generators; loop, ball and needle electrodes; FILTRESSE spillways; other electrodes and specialized supplies and gynecological tools; Femcare trocars, cannulas, laparoscopic instruments and accessories; and EPITOME and OptiMicro electrosurgical devices. In addition, it provides Filshie Clip female surgical contraceptive devices; PATHFINDER PLUS endoscopic irrigation devices; suprapubic catheterization; LIBERTY Urinary Incontinence Treatment and Control Systems; ENDOCURETTE, a curette for the removal of uterine endometrial tissue; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of the uterus; and the LUMIN tool for manipulating the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components and other castings. It serves neonatal intensive care units, labor and delivery wards, women’s health centers in hospitals, outpatient clinics and physicians’ offices through direct customer service and a force sales representatives, independent consultants and manufacturer representatives. The company was incorporated in 1978 and is headquartered in Midvale, Utah.

Treace Medical Concepts Company Profile (Get a rating)

Treace Medical Concepts, Inc., an orthopedic medical device company, is engaged in the design, manufacture and marketing of medical devices for foot and ankle surgeons in the United States. It offers a lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with cosmetic and medical improvement. The company also provides the Precision Lapiplasty Mini-Incision System. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, Weil osteotomies, intercuneiform stabilization, inferior tarso-metatarsal joint fusions and autograft bone harvesting, as well as fusion MTP. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.



Receive daily news and reviews for Utah medical products – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Utah Medical Products and related companies with MarketBeat.com’s free daily email newsletter.

read more
Medical products

Drones ready to deliver medical products to Washington State in 2024

The drones will begin carrying medical supplies to addresses in Tacoma, Wash., starting in 2024, two companies behind the project announced Thursday. It’s the latest example of using unmanned aircraft to move critical cargo faster than conventional transportation.

Startup Zipline drone maker and healthcare provider MultiCare said the service would transport lab samples, medications and test kits among local Multicare facilities, the companies told CNET exclusively. MultiCare expects the partnership to mean that its healthcare providers, with their own on-demand delivery system, will be able to improve the care patients receive.

Project Tacoma still requires regulatory approval for flight operations details, including whether the Zipline drones will fly autonomously, as they do in the company’s other operations.

“Ensuring our providers have what they need, when they need it, is a critical part of providing affordable and accessible care to patients,” said Florence Chang, president of MultiCare, in a statement.

Project Tacoma marks the latest use of drones to speed up deliveries, which can be slowed by increasingly congested roads. The World Economic Forum expects the use of delivery trucks will increase by 78% by 2030 without alternative shipping approaches, adding 11 minutes to average travel times.

Drones are already in limited operation in the United States. Wing, operated by Alphabet, Google’s parent company, has begun deliveries in the Dallas-Fort Worth area of ​​Texas. In parts of North Carolina, Flytrex drones deliver food from Just Wings, Chili’s Grill & Bar and Maggiano’s Little Italy to homes. Amazon Prime Air plans to test drone deliveries south of Sacramento, California.

Based south of San Francisco Zipline has made nearly 345,000 deliveries to date, primarily with nationwide programs in Rwanda and Ghana, and delivers an average of one package every two minutes. It began an expansion into the United States last year, shipping packages for retail giant Walmart in Pea Ridge, Arkansas. In June, it began delivering medical supplies from a distribution center in Kannapolis, North Carolina, for Novant Health, Magellan Rx Management and Cardinal Health.

In June, Zipline cleared a regulatory hurdle in the United States by winning certification from the Federal Aviation Administration that allows flights up to 26 miles.

read more
Prescription drugs

State asks for help to quickly report fake prescription drugs

Director DPS Bayens.

The state is stepping up public awareness efforts in response to an influx of fake prescription drugs containing fentanyl that have appeared in the state.

Public Safety Commissioner Steven Bayens says the pills are produced primarily in Mexico.
“The pill presses used by cartels can create near-perfect reproductions of common prescription drugs. As a result, even our own agents are now trained to treat every prescription pill they encounter as if it contains fentanyl,” says Bayens.

Bayens says the procedures for mixing what goes into the pills aren’t as sophisticated as the production process – and that leads to deadly pills. “The Drug Enforcement Administration has discovered that four out of ten counterfeit pills submitted to their lab contain a lethal dose,” he says. “If we apply this data point to Iowa, over 28,000 lethal doses of fentanyl were seized. In the first six months only.

Bayens says the amount of fentanyl that is lethal can fit on a pencil lead. Too much fentanyl creates what is called a “hot batch”. He says you can help by reporting the discovery of the fake pills.

“The faster we can identify that a hot batch has made its way into a community. The sooner we can alert health officials, educate the public and begin enforcement actions aimed at stopping its deadly effects,” according to Bayens. Every tip that hits the hotline and is submitted to us via an anonymous email is distributed to one of our 17 field offices across the state.

He says the pills are dangerous to handle and you shouldn’t try to get rid of them yourself. Bayens says it’s also important for the lab to examine the pills to try to determine their composition. Anyone who finds a counterfeit pill is encouraged to call the Iowa Division of Narcotics Enforcement’s Anonymous Hotline at (800) 532-0052 or [email protected] and in case of emergency, dial 911.

Bayens says the most common pills are designed to look like the powerful painkiller oxycontin.
“These are smaller blue pills marked M 30. And these are actually the pharmaceutical brands of oxycontin. And so the vast majority of what we’re seeing right now and the vast majority of seizures appear to be oxycontin. They are stamped in blue about the same size and are marked M 30,” he says.

Gov. Kim Reynolds said the state is considering targeting young people to try to educate them more on the issue. “The Iowa Department of Health and Human Services will roll out an expansion of its multimedia public health campaign targeting tweens to young adults, which currently focuses on suicide prevention to include new messages about the dangers of fentanyl. says Reynolds.

The focus on fentanyl comes after overdose deaths in Cass and Shelby counties uncovered a fentanyl distribution ring in western Iowa and eastern Nebraska. For 24-hour confidential support and more information about fentanyl and counterfeit pills, or resources about opioids or other substance use disorders, visit www.YourLifeIowa.org.

read more
Medical supplies

For the medical supplies industry, the supply chain is back to business as usual

The medical supplies industry is returning to the supply chain strategies it used before COVID-19, despite current severe challenges, according to an expert in the field.

“The industry in general is back to exactly where it was before COVID,” says Michael Einhorn, president and CEO of Dealmed, a large independent distributor of medical supplies in New York, New Jersey, Connecticut and Pennsylvania. “There have been very few industry-wide changes. Much has been said about supplier diversity, nearshoring and friend-shoring. But the thing is, outside of those Band Aid supply fixes, there really hasn’t been much change in the healthcare industry. Everything is status quo. »

Einhorn has been a supporter of changes in supply chain management in the healthcare industry for years, and he sees the need as more pressing than ever.

“This industry still faces the greatest number of supply issues,” he said.

Fixes are hard to find though. Einhorn points to proposed legislation in Washington, DC, that would introduce a fast-track customs system where the appropriate government agencies would authorize the clearance of medical supplies before imports such as toys for faster entry. This, he says, is actually a sign that not much is changing in terms of sourcing and execution.

“If you think about it, a lot of products have to be made in China, or somewhere else overseas, so that doesn’t solve the proximity problem. A Fast Pass simply makes it easier for products to come from other countries. It is very revealing that it is as if nothing had happened. We just make it easy. It seems to me that the industry is operating with a just-in-time model, just like it was before COVID.

It’s not easy or quick to move production out of China, with a few exceptions. According to industry market research firm IBISWorld, there were 971 medical device manufacturing companies in the United States in January 2022, an increase of 1.9% from 2021.

He says much of the resistance to change is driven by the complications of manufacturing in the United States, including regulatory restrictions. Sometimes it’s legitimately easier to make items overseas, like nitrile gloves, because the raw material for them comes from Southeast Asia.

Overall, though, Einhorn says there aren’t currently compelling enough reasons for people to manufacture healthcare supplies in the United States. One reason is that many overseas manufacturers have long-term contracts with US-based Group Purchasing Organizations (GPOs), which are the de facto gateway for most medical supplies into the US, because they dominate the market. Another reason is that there are few financial incentives to do so.

“Everything is reimbursed. Medicaid doesn’t care. They’re just looking for the cheapest product, not necessarily the best product,” says Einhorn. “So what’s the point of buying something made in the USA or a premium product? There are very few incentives to change.

Einhorn continues to call for fundamental changes in the structure of health care delivery in the United States, with better manufactured products. He cites NATO’s Pandemic Response Trust Fund, which is responsible for maintaining an established stockpile of medical equipment and supplies to be able to provide immediate aid to Allies or partners in need. There, he said, the emphasis was more on the best than on the cheap. But overall, the challenges are daunting and require action from both the private and public sectors.

“It takes a bit of everything to make it work,” he says.

read more
Prescription drugs

Pamplin Media Group – West Linn man pleads guilty to distributing prescription drugs and steroids

Former dentist Salwan Wesam Adjaj is also facing COVID-19 relief fraud charges.

A 43-year-old West Linn man pleaded guilty in federal court Wednesday, July 13, to a charge of distributing controlled substances. The charge detailed the distribution of thousands of prescription drug pills as well as anabolic steroids.

Court documents from the U.S. Attorney’s Office for the District of Oregon said Salwan Wesam Adjaj, a former dentist who practiced endodontics in Sherwood, Clackamas and Portland, but whose license was suspended by the board of dentistry in Oregon in 2020, distributed an array of substances between March 2016 and August 2020. These drugs included tramadol, anabolic steroids, injectable testosterone, phendimetrazine, diazepam, alprazolam (Xanax), lorazepam, carisoprodol (Soma), zolpidem, and promethazine.

“Adjaj used his position as a dentist to obtain some of these drugs from a pharmaceutical manufacturer,” a press release from the U.S. Attorney’s Office said. “None of the drugs distributed by Adjaj were for legitimate medical purposes.”

Adjaj remains in detention pending sentencing in October. According to the US Attorney’s Office, he faces a maximum sentence of 10 years in prison, a fine of $500,000 and up to three years of probation.

In a separate case, Adjaj is also facing charges of identity theft and wire fraud for allegedly using nearly $8 million in COVID-19 relief funds for his personal use.


You rely on us to stay informed and we rely on you to fund our efforts. Quality local journalism takes time and money. Please support us to protect the future of community journalism.

read more
Generic drugs

Generic Inhalation and Nasal Spray Drugs Market 2022 Key Players, Demands, Trends and Forecast to 2030 – Instant Interview

Global “Generic Inhalation and Nasal Spray Market“Reports 2022 gives a key study on the industry status of Generic Inhalation and Nasal Spray Manufacturer with the specific statistics, meaning, definition, SWOT analysis, expert opinion and developments around the world. The research report also covers market size, price, sales, revenue, market share, gross margin, growth rate and cost structure. The report aims to give an additional sample of the latest scenario, the economic downturn and the impact of Covid-19 on the whole industry.

The Generic Drugs for Inhalation and Nasal Spray market report will provide forecasts based on real numbers and factual data to help you decide on your marketing plans. You will understand which are the top profit sectors from the overview presented in the report. You can then take advantage of these opportunities based on your developed strategies and strengthen yourself in the market. Information is collected from real-time sources such as customers, dealers, raw material suppliers, etc. For this reason, the gathered data is authentic and will provide comprehensive details about the Generic Inhalation and Nasal Spray market.

Generic Inhalation and Nasal Spray Market: Competitive Landscape

The Generic Drugs for Inhalation and Nasal Spray market report includes information on product launches, sustainability and outlook from key vendors including: (Teva, Sandoz (Novartis AG), Mylan, Allergan PLC, Cipla, Akorn, Apotex, Sun Pharma (Ranbaxy), Nephron Pharma, Beximco Pharma, Hikma (Roxane), XIANJU PHARMA, , )

Click Here for Free Sample Report of Generic Inhalation and Nasal Spray Drugs Market Report @ https://healthcaremarketreports.com/sample-request/inhalation-and-nasal-spray-generic-drugs-market/10877/? utm_source=Chaitali&utm_medium=SatPR

Generic Inhalation and Nasal Spray Market: Segmentation

The Generic Inhalation and Nasal Spray Drugs market is split by Type and by Application for the period 2022-2030, the growth between segments provides accurate artifices and forecasts for the sales by Type and by Application in terms of volume and value . This analysis can help you grow your business by targeting qualified niche markets.

By type:
Corticosteroids
Bronchodilators
Combinations
Decongestant sprays

By app:
Asthma
COPD
Allergic rhinitis

Generic Inhalation and Nasal Spray Market: Regional Analysis

The whole regional segmentation has been studied based on recent and future trends, and the market is forecast through the forecast period. The countries covered in the regional analysis of the Global Inhalation and Nasal Spray Generic Drugs Market report are USA, Canada & Mexico North America, Germany, France, UK, Russia , Italy, Spain, Turkey, Netherlands, Switzerland, Belgium and Rest of Europe in Europe, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, China, Japan, India, Korea South, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Saudi Arabia, United Arab Emirates, South Korea Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as part of the Middle East and Africa (MEA), and Argentina, Brazil and the rest of South America as part of South America.

Main points covered in the table of contents:

Market overview: It includes six sections, research scope, key manufacturers covered, market fragments by type, Generic Inhalation and Nasal Spray market shares by application, study objectives and years considered.

Market landscape:Here, Global Generic Inhalation and Nasal Spray Drugs Market Opposition is Dissected, by Value, Revenue, Transactions, and Pie Share by Organization, Market Rate, Fierce Circumstances Latest Landscape and Patterns, Consolidation, Development , obtaining , and parts of the overall industry of large organizations.

Manufacturer Profiles: Here, key players of the global Generic Inhalation and Nasal Spray Drugs market are considered dependent on region of deals, key elements, net benefit, revenue, cost, and creation.

Market Status and Outlook by Region: In this segment, the report examines net benefit, transactions, revenue, creation, global industry share, CAGR and market size by region. Here, the Global Generic Inhalation and Nasal Spray Drugs Market is thoroughly examined based on regions and countries like North America, Europe, China, India, Japan, and MEA.

Application or end user: This segment of the exploration study demonstrates how extraordinary end-customer/application sections are added in the global Generic Inhalation and Nasal Spray Drugs market.

Market forecast: Production side : In this part of the report, the creators focused on the conjecture of creation and creation esteem, the gauge of the main manufacturers and the estimation of the creation and creation esteem by type .

Research results and conclusion: This is one of the last segments of the report where the findings of the investigators and the end of the exploratory study are given.

Research Report on Generic Inhalation and Nasal Spray Drugs Market By Buy Direct Now @ https://healthcaremarketreports.com/purchase/inhalation-and-nasal-spray-generic-drugs-market/10877/;utm_source=Chaitali&utm_medium= SatPR

Answers to key questions in the report:

  • What will be the pace of development of the Inhalation and Nasal Spray Generic Drugs market?
  • What are the key factors driving the global Generic Inhalation and Nasal Spray market?
  • Who are the main manufacturers on the market?
  • What are the openings, dangers and contours of the market?
  • What are sales volume, revenue, and price analysis of top manufacturers of Generic Inhalation and Nasal Spray market?
  • Who are the distributors, traders and dealers of Generic Inhalation and Nasal Spray Market?
  • What are the Generic Inhalation and Nasal Spray market opportunities and threats faced by the vendors in the global Generic Inhalation and Nasal Spray industries?
  • What are Transactions, Revenue, and Value Reviews by Market Types and Uses?
  • What are reviews of transactions, revenue and value by business areas?

About Us

The healthcare industry is surely facing disruption, with global economies placing great importance on individual health. In this scenario, we expect our customers to get deep insights to propel their innovations in the right direction. We have closely followed the changes and modifications that occur in the field of health. According to our understanding, these alterations are active and unexampled.

Contact us

Healthcare Market Reports
99 Wall Street 2124 New York, NY 10005
E-mail: [email protected]
Our social networks: Facebook | LinkedIn | Twitter

read more
Medical supplies

Genesis Healthcare System signs Medline as primary distributor of medical supplies

Under the terms of the agreement, Genesis Healthcare System will have the ability to easily monitor key metrics such as item usage, contract compliance, pricing accuracy and spend by product categories through the advanced analysis from Medline.

“Medline is committed to doing what is right for the customer and their patients, understanding their challenges, and working together to find the best solution,” said Brian Moter, vice president of sales at Medline. “Our partnership with Genesis allows us to become an extension of their team, supporting their mission to provide quality, compassionate healthcare by providing their system with consistently superior and reliable service.”

Learn how Medline tailors its solutions across the continuum of care as a manufacturer and distributor by visiting https://www.medline.com/supply-chain/.

About Medline

Medline is a healthcare company; a manufacturer, marketer and solutions provider focused on improving overall healthcare operational performance. In partnership with health systems and institutions across the continuum of care, Medline provides the clinical and supply chain resources necessary for the long-term financial sustainability of delivering high-quality care. With the scale of one of the nation’s largest companies and the agility of a family business, Medline is able to invest in its customers for the future and respond quickly to a dynamically changing marketplace with solutions. personalized. Based at Northfield, Ill., Medline has more than 30,000 employees worldwide and does business in more than 125 countries and territories. Learn more about Medline at http://www.medline.com/.

Facebook
Twitter
LinkedIn
Youtube

SOURCE Medline

read more
Medical supplies

Liberia: World Hope International and Korlu-Bu Neuroscience donate various medical supplies to clinics in rural Montserrado County

Arthington – It was a time of joy and relief for health practitioners, including administrators, supervisors and nurses in rural Montserrado when World Hope International (WHI) in collaboration with its partners, including the Korle -Bu Neuroscience Foundation (KBNF) and the Department of Health through the Montserrado County Health Team, they donated various medical items.

A total of nine health facilities in the St. Paul River District have benefited from the donation with a total population of over 108,721 patients per year.

The donation was part of an extension of WHI and KBNF’s joint efforts with the Montserrado County Health Team to strengthen the health care delivery system.

On the first day, the team, led by World Hope International Country Director Mathew Ndote, presented the papers at clinics in Gbondoi and Bromley in Virginia.

Some of the donated materials include syringes and needles, protective gear, BP cuffs, IV tubing, Ambu bags and bandages, among others.

Speaking to reporters at the end of the first day of distribution, Mr Ndote said WHI was heavily involved in providing water, sanitation and hygiene in deprived communities and in the fight against human trafficking. human being.

However, through this partnership with KBNF, and in conjunction with the Department of Health through the Montserrado County Health Team, it is providing much-needed assorted medical items – primarily IPC materials and medications to facilities to ensure the safety of their staff while they manage patients; he noticed that something was missing.

He commended KBNF as the main donor for providing these necessary supplies, including shipment handling and warehousing services, while WHI provided the logistics to deliver the items while the CHT coordinated the activity, was supplying its staff and needed labor to support delivery to the targeted facilities.

He noted that although global health is a key pillar of WHI across the world, this year 2022 was the first time that WHI Liberia started its work in the health sector. He thanked the Ministry of Health for the cooperation and for providing the necessary donation support and enabling the environment to contribute to the health sector in Liberia.

“Our main concern is for women and children who find it difficult to travel to health facilities outside their villages and towns,” he said.

“So by bringing services closer to the people and bringing the health supplies that health workers who need them most can break down barriers to accessing health care in rural areas, we believe it will help a lot to save lives.”

On separate occasions, clinic administrators thanked WHI and KBNF for the articles and pledged to use them for their intended purpose.

“We are blessed today for the items you – WHI and KBNF have brought to us. We are so overwhelmed and want to say a big thank you for thinking of Gbondoi Health Center at a time when we need it most. from you,” Marion C. Bropleh, the head of the Gbondoi clinic boasted.

Mr. Augusta K. Musa, Bromley OCI said, “We are very grateful to you for bringing us the IPC materials and essential drugs. We pray that you will return and continue to be our partners.

Also speaking, Mr. Ben D. Wilson, the St. Paul River District Clinical Supervisor, speaking on behalf of CHO, praised the joint effort of WHI and KBNF and said the materials will fill some of the main shortcomings of these facilities. . He revealed that the nine government health centers in the district serve thousands of residents of this part of Montserrado.

Meanwhile, the distribution exercise has come to an end at the Arthington Community Clinic. The joint delegation included officials from WHI, KBNF and the Ministry of Health, including Tori Victoria Chan, WHI’s Global Health Director often based in Sierra Leone, Helen Charles, Operations Manager, KBNF, and Fania Kamara, Coordinator of the health of WHI.

In brief remarks, Ms. Chan said she was happy to be in Liberia to be part of the handover exercise. She praised the collaboration between KBFN and WHI and expressed hope that the materials will have a meaningful impact.

KBNF’s Operations Manager, Hellen Charles, expressed her joy in being part of the delivery team and promised the clinics of KBNF’s continued collaboration with WHI and the Department of Health to address some of the challenges faced. health facilities in rural areas and disadvantaged communities.

World Hope International is a Christian relief and development organization that works with vulnerable and exploited communities to alleviate poverty, suffering and injustice around the world.

The Korlu-Bu Neuroscience Foundation is a Canadian charitable organization that improves the delivery of quality medical care for the brain and spine in West Africa and beyond. KBNF’s vision is to alleviate the suffering of West Africans with a special focus on those affected by brain and spinal diseases and to address related health issues.

read more
Medical supplies

Replenishment of medical supplies in Ukrainian hospitals

NORTHERN UKRAINE — Samaritan’s Purse is helping bolster the Eastern European country’s medical systems with regular airlifts of supplies aboard its DC-8. They work with church partners to distribute these items to those who need them most.

Dr Alla MustafaievaVolunteer:

There is war in Ukraine right now. It’s very scary. It’s really hard to explain what’s going on right now. At the start of the Russian aggression, during the first days of the war, many people lost access to hospitals and pharmacies were closed. People had neither work nor money to buy medicine. Many people need psychiatric services. We have started to provide medical care and medicine to the refugees.

Halina RomanenkoDirector, Makariv Central District Hospital:

We really need this help right now given the very difficult situation in Ukraine. We cannot buy a lot of drugs and surgical consumables. We need them here, but we are also distributing these supplies to hospitals in busy locations.

Dr Alla:

Now, here at the church, we need medicine to send to the front line of the war, and we are distributing a range of medicine, pillows and instruments to the hospital in Makariv.

Dr. Tamara LatiukVolunteer:

There was an absolutely catastrophic shortage of medical supplies. Samaritan’s Purse provided many, and often. Your support with medical supplies helped us stock up on surgical supplies, infusion and infusion equipment, and equipment to prepare medication was very helpful.


Samaritan’s Purse is a non-denominational evangelical Christian organization that provides spiritual and physical relief to suffering people around the world. Since 1970, Samaritan’s Purse has helped meet the needs of people affected by war, poverty, natural disasters, disease and famine in an effort to share God’s love through His Son, Jesus- Christ. The organization serves the Church worldwide to promote the gospel of the Lord Jesus Christ.

Samaritan’s Purse International Disaster Response Team (DART) is committed to meeting the critical needs of victims of war, poverty, famine, disease and natural disasters. We are ready to respond at any time, whenever disaster strikes and wherever it occurs. DART specializes in providing water, food, shelter and medical care while sharing the Good News of Jesus Christ.

CONTACT: Melissa Nystrom, [email protected]


Read more news about nonprofits, humanitarian services, medical ministry, the refugee crisis, Ukraine and Russia on Missions Box.


read more
Medical supplies

Medical Supplies Market Analysis by Consumption Supply and Demand Analysis to 2028 | B. Braun Melsungen AG, Becton

Medical supplies market

Medical supplies exclude the manufacture and distribution of high-tech medical equipment and the retail sale of drugs.

SEATTLE, WASHINGTON, USA, July 11, 2022 /EINPresswire.com/ — Coherent Market Insights has published a new research study on the “Medical supplies marketwhich aims to provide an in-depth review of factors influencing global business introduction and outlook. The detailed information and overview of the Global Medical Supplies market report highlights latest trends in various regions Key market players will benefit from the business insights provided in this report The Medical Devices Market research report is an intelligence report that includes accurate and valuable data on market size, developing countries, market share, market and revenue forecast to 2028. It also provides insights into market development and capabilities.

Get quick access to the PDF brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1633

Furthermore, it will also include the opportunities available in the micro markets for the stakeholders to invest, a detailed analysis of the competitive landscape, and the product services of major players. Medical Supplies Company Analysis, Key Tactics Major Key Players Follow: B. Braun Melsungen AG, Becton, Dickinson and Company, Cardinal Health, Inc., Halyard Health, Inc., Johnson & Johnson, Thermo Fisher Scientific Inc., Boston Scientific Corporation, Baxter International Inc., and 3M Company, among others.

Report overview and scope:

The Global Medical Supplies Market analysis report provides a detailed analysis of the market size of various segments and countries in previous years as well as a forecast for the upcoming years. The Medical Supplies Market report presents a detailed competitive landscape of the global market. Market dynamics, drivers and segmentation by application, type, region and manufacturer are all covered in this report. With respect to regions and countries covered in the report, this Medical Devices Market report provides both qualitative and quantitative aspect of the industry.

The objectives of the study are:

✔ A comprehensive overview of major players operating in the Medical Supplies market and their corresponding data.

✔ It includes product portfolio, annual revenue, research and development expenditure, geographic presence, key developments in recent years and growth strategies.

✔ Regional analysis, which includes an overview of the dominant market and the corresponding market share.

✔ It also includes various socio-economic factors affecting the development of the market in the region.

✔ The report offers a comprehensive overview of the various individuals in the value chains such as raw material suppliers, distributors and shareholders.

Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1633

Key Opportunities:

The report examines the key opportunities in the Medical Supplies Market and identifies the factors that are and will continue to drive the growth of the industry. It takes into account past growth patterns, growth drivers, as well as current and future trends.

Regional Analysis: The Medical Supplies Market report is highly structured into region wise study. The comprehensive regional analysis done by the researchers highlights the key regions and their dominant countries accounting for substantial revenue share in the market.

Following are the various regions covered in the Medical Supplies market research report:

North America (United States, Canada and Mexico), Europe (Germany, United Kingdom, France, Italy, Russia, Spain and rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia, Southeast Asia, and rest of APAC), South America (Brazil, Argentina, Colombia and rest of Latin America), Middle East and Africa (Saudi Arabia, South Africa, Turkey, Nigeria , United Arab Emirates and Rest of MEA)

Answers to key questions:

1. What is the market size and CAGR of the medical supplies market during the forecast period?
2. What is the impact of growing demand on the growth of medical supplies market share?
3. What is the growing demand for the medical supplies market during the forecast period?
4. Who are the main suppliers in the market and what are their market shares?
5. What is the impact of the COVID-19 pandemic on the APAC Medical Supplies market?

To purchase the report, click here – https://www.coherentmarketinsights.com/insight/buy-now/1633

About Us:

Coherent Market Insights is a global market intelligence and advisory organization that provides syndicated research reports, custom research reports and advisory services. We’re known for our actionable insights and genuine reports in a variety of fields, including aerospace and defense, agriculture, food and beverage, automotive, chemicals and materials, and virtually any field and an exhaustive list of subdomains under the sun. We create value for our clients through our highly reliable and accurate reports. We are also committed to playing a leading role in providing insight in various post-COVID-19 sectors and to continuing to deliver measurable and sustainable results to our clients.

Mr Shah
Coherent Market Insights Pvt. ltd.
+1 206-701-6702
write to us here
Visit us on social media:
Facebook
Twitter
LinkedIn
Other

read more
Medical supplies

UAB provides veterinary medical supplies to Ghanaian university struggling with supply chain issues

In 2010, McKenzie was invited to accompany a team to visit the Kwame Nkrumah University of Science and Technology (KNUST) School of Veterinary Medicine in Kumasi, Ghana to assess its veterinary infrastructure and research ways to collaborate. KNUST faculty moved to the United States in 2011. KNUST and Tuskegee have since collaborated, exchanging faculty and staff and hosting graduate students.

Almost 10 years later, with KNUST in mind, McKenzie applied to the Fulbright US Scholar Program to teach. In November 2021, he was able to visit its campus as a Fulbright US Scholar. His specialty is the internal medicine of large animals, including horses, cows, sheep, goats and pigs, encompassing all aspects of their medical well-being. He has taught diagnostic and treatment techniques to students and some junior teachers.

While working in Ghana, his wife, Veronica McKenzie, contacted Ray Watts, UAB President‘ office asking if UAB could donate suture materials. KNUST needed current or expired suture materials for animal surgeries. COVID-19[feminine], as well as the war in Ukraine, affected the university’s supply lines. He usually gets his supplies through European companies and with the unfortunate events of the last few years, especially this year, those supplies have been drastically reduced. The veterinary college was looking for other sources of supply, McKenzie said.

From left to right, Dr. Esther Amemor, Head of the Clinical Studies Department; Dr. Rejoice Nyarku, speaker; Veronica McKenzie; Catherine McKenzie; Joseph Atawalna, Deputy Dean of KNUST-SVM; Vitus Burimuah, head of the pathobiology department at KNUST; David McKenzie, American Fulbright Scholar; and Raphael Folitse, founding dean of KNUST-SVM. (UAB)

Watts’ office connected to UAB Research Office, who may have facilitated the donation. Watts thanked “our wonderful people” at the Animal Resources Program for collecting and packing the supplies and facilitating the donation.

“Ms. McKenzie was delighted with everything we were able to share and said they would be extremely helpful to Dr. McKenzie and her colleagues in Kumasi,” Watts said. She and their daughter, Catherine, brought the supplies to the Ghana in May.

UAB provided suture materials and basic surgical materials for treatment and teaching, which were immediately put to use.

“These supplies have been a huge help,” McKenzie said. “We got supplies from other sources, including Tuskegee University. We had much needed textbooks and other veterinary supplies from UAB. We are very happy to have entered into this partnership with UAB, and I hope that we can continue in one way or another.

Kwame Nkrumah University of Science and Technology is one of West Africa’s leading universities, teaching subjects ranging from human and veterinary medicine to nursing, education and engineering to around 30 000 students. It is an important center for the training of scientists and technologists not only for Ghana but for other African countries and parts of the world.

This story originally appeared on the UAB News Website.

read more
Prescription drugs

Florida Governor DeSantis Takes Steps To Lower Prescription Drug Prices

TALAHASSEE – Calling for more “transparency” in prescription drug costs, Gov. Ron DeSantis issued an executive order on Friday aimed at increasing oversight of drug benefit managers.

The executive order will in part require audits of drug benefit managers who provide services under the state’s Medicaid managed care program and state employee health insurance program.

Pharmacy benefit managers act as something of an intermediary and play roles such as representing insurers in negotiations with pharmaceutical companies and pharmacies.

“It’s an incredibly opaque process,” DeSantis said during an appearance in Cape Coral to announce the executive order. The audits, for example, will include “a detailed review of potential inflation in dispensing fees and payments to drug manufacturers, insurers, and pharmacies, as such regarding a Medicaid managed care plan,” the executive order says. .

“The purpose of this audit is to ensure that all costs incurred by the State of Florida are justified.”

The executive order also requires state agencies to insert certain terms into new, renewed, or extended contracts that involve pharmacy benefit managers.

For example, one of those stipulations would prevent “clawbacks,” which the executive order says involve situations where pharmacy benefits managers keep money that is clawed back from overpayments to pharmacies.

DeSantis signed a bill (HB 357) last month that also seeks to increase oversight of drug benefit managers.

The bill planned to give the Office of Insurance Regulation more authority over drug benefit managers.

Small pharmacies, which have long complained about drug benefit managers, lobbied for the bill.

read more
Medical supplies

An in-depth study exploring the medical supplies market – Designer Women

The Global Medical material The market report offers an overview of the industry including definitions, applications, classifications and chain structure. The report provides a comprehensive assessment of the market studied, including key trends, historical data, current market scenario, opportunities, growth drivers, potential roadmap, and market players’ strategies. The report further includes regional analysis to assess the global presence of the Baby Car Seat Market.

In order to simplify industry analysis and forecast estimation for the Medical material Market, our research report provides a well-defined market scope and a systematically developed research methodology.

Access a sample report – marketreports.info/sample/72978/Medical-Supplies

Global Medical Supplies Market: Segment Analysis

Each market segment studied is thoroughly evaluated in the research study. The segmentation analysis discussed in the report presents the major opportunities available in the market across major segments. Here are the segments covered in the report:

Regional analysis:

The Global Medical material The market is segmented into Regional segmentation of the market includes North America (United States and Canada), Europe (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), Asia Pacific (China, India, Japan, Korea, Indonesia, Taiwan, Australia, New Zealand and Rest of Asia Pacific), Latin America (Brazil, Mexico and Rest of Latin America), Middle East and Africa (GCC, North Africa, South Africa and Rest of Middle East & Africa).

Key highlights of the Global Medical Supplies Market report include:

  • Market Overview, Industry Development, Market Maturity, PESTLE Analysis, Value Chain Analysis
  • Growth Drivers and Barriers, Market Trends and Market Opportunities
  • Porter’s Five Forces Analysis and Business Analysis
  • Market forecast analysis for 2022-2030
  • Market segments by geographies and countries
  • Market segment trend and forecast
  • Market analysis and recommendations
  • Price analysis
  • Key Market Drivers
  • Company analysis of the medical supplies market: market share and company positioning, company profile, recent industry developments, etc.

Key players:

This section of the report includes an accurate analysis of major players with company profile, market value, and SWOT analysis. The report also includes manufacturing cost analysis, raw material analysis, major suppliers of the product, mergers and acquisitions, expansion, etc. The following companies are rated in the report:

Johnson & Johnson, Baxter, Fresenius, Boston Scientific, Medtronic, BD, 3M, Terumo Corporation, B. Braun, Smith & Nephew, Abbott, CR Bard, Novartis, ConvaTec, Medline, Teleflex, Halyard Health, Nitto Medical, Coloplast, Smiths Group, Weigao, BSN Medical, Lohmann & Rauscher, Ansell

Product Type SegmentationInjection and InfusionWound CareBlood and DialysisMedical Implantation EquipmentDisposable Garments/Incontinence Supplies/Surgical SuppliesIndustry SegmentationHome Healthcare and Nursing HomesHospitals and Other Medical Facilities

Check Instant Discount- marketreports.info/discount/72978/Medical-Supplies

Why market reports?

  • We use the latest market research tools and techniques to authenticate statistical figures
  • Availability of custom reports
  • Research analysts who are experts and experienced in market research approaches
  • Prompt and timely customer support for domestic and international customers

Buy the full report @ marketreports.info/checkout?buynow=72978/Medical-Supplies

About Us:

Market Reports offers a comprehensive database of syndicated research studies, custom reports, and consulting services. These reports are created to help make smart, instant and crucial decisions based on detailed and in-depth quantitative information backed by in-depth analysis and industry insights.

Our dedicated in-house team ensures that reports meet client requirements. We aim to provide valuable service to our customers. Our reports are based on extensive industry coverage and ensure that we focus on the specific needs of our clients. The main idea is to enable our customers to make an informed decision, keeping them and ourselves informed of the latest market trends.

Contact us:

Carl Allison (Business Development Manager)

Market reports

phone: +44 141 628 5998

Email: [email protected]

Website: www.marketreports.info

read more
Prescription drugs

The governor of Florida wants to reduce the cost of prescription drugs

CAPE CORAL, Fla. — Florida Governor Ron DeSantis took the stage at Cape Coral High School on Friday to announce a plan to lower the cost of prescription drugs for state residents.

DeSantis announced he would sign an executive order that would allow the state to hold prescription benefit managers, or PBMs, accountable for the prices people are ultimately charged for their drugs, and open the door to reforms. He said it would also help small, independent pharmacies that want to stock these drugs.

WATCH: Florida governor announces pharmacare plan

Florida Governor Ron DeSantis holds a press conference in Cape Coral

DeSantis said he asked Simone Marstiller, secretary of the Agency for Healthcare Administration, to review PBMs and help find a way to ensure cost-cutting measures are in place.

“They do a lot more than set prices,” Marstiller explained. “They handle the pre-authorization. They have to approve getting your prescription, even after your doctor decides you need it.”

Marstiller said the executive order would be used as the basis for comprehensive prescription industry reform.

BNC News

Simone Marstiller, secretary of the Agency for Healthcare Administration, speaks during a press conference on July 8, 2022.

The governor also said he was studying a provision in federal law that would allow states to buy drugs from Canada and was working with federal agencies to enable that provision. He submitted a proposal to the FDA and submitted a Freedom of Information Act request to the agency to find out the status of the proposal.

“[The FDA] may very well not be able to meet a 20-day deadline,” Marstiller said of the wait. “We have not obtained any commitment from the FDA to do this.

DeSantis said a warehouse in Polk County is “ready to go” to receive the drugs as soon as that approval is given, but he hinted there could be a legal battle in the near future to get the drug started. program.

When discussing the upcoming school year, DeSantis said he would block any attempt to require a vaccination mandate in public schools.

AHCA officials will meet in Tallahassee on Friday to discuss a proposed rule that would block Medicaid coverage for hormone therapy, puberty-blocking drugs and related treatments for transgender patients.

read more
Prescription drugs

Police: Traffic check finds syringes and prescription drugs

Signs of impairment during a traffic stop Tuesday night led to the discovery of several syringes and prescription drugs, police said.

Jasmine E. Diab, 38, has been charged with possession of narcotics, possession of drug paraphernalia, possession of prescription drugs only and driving under the influence, according to police.

Around 9:30 p.m., officers stopped a vehicle near State Route 347 and West Hathaway Avenue, police said.

According to a probable cause statement, the driver of the vehicle was identified as Diab, who exhibited signs of drug impairment, including profuse sweating and rapid, uncontrollable body movements.

Police said they observed on both of Diab’s arms what they believed to be “trace marks” of apparent drug use.

A check of Diab’s records showed she had never received a driver’s license, police said.

According to the probable cause statement, a search of Diab’s vehicle revealed a piece of aluminum foil with burn marks and residue, a partially burnt blue pill believed to be a counterfeit fentanyl pill, several syringes containing brown liquid and several prescription-only drugs. , including suboxone strips, hydroxyzine pamoate tablets 50mg and lorazepam tablets.

Diab was incarcerated in Pinal County Jail on the charges, police said.

Read more about the arrests here.

read more
Medical supplies

“Live their best and healthiest life”: delivering medical supplies to remote islands of Kiribati

It’s no exaggeration to say that pharmacist Moannara Benete literally holds one of the most important positions in the Pacific. Kiribati’s 21 inhabited islands are spread across some 3.5 million square kilometers of ocean, and as head of the pharmacy team at the Kiribati Ministry of Health and Medical Services, Moannara is focused on provision of medical supplies for all the inhabitants of his country; no matter where they live.

This was already a huge challenge before COVID-19, and the pandemic has only amplified these challenges. Medical supplies have been hard to come by and there have been significant delays in their arrival. This has led to an increase in orders for urgent medical supplies, which has driven up prices.

“Procurement of medical supplies is an important part of most health care services”, said Moannara Benetefrom his office in Tarawa, the capital of Kiribati. “Our goal is to improve the overall health of the population by procuring and purchasing quality, cost-effective medical supplies. A well-managed supply program supports economic and social development by keeping people as healthy as possible.

The logistics of managing pharmaceutical supplies on 21 islands spread over 3.5 million square kilometers of ocean is a huge challenge.
Photo: Conor Ashleigh/World Bank

Take control of health service delivery

The World Bank supports Kiribati’s commitment to advancing Universal Health Coverage so that all I-Kiribati can access health services when they need them. A key part of this work is to help track development partner contributions to health programs, so that they are recognized as part of the integrated plans and budgets managed by the Department of Health and Medical Services. By doing so, the department is then able to make the most of all available resources, ensure it understands where support is coming from and when, and take control of health service delivery. in a more effective and holistic way.

While many can access health care when they need it on Kiribati’s main island of Tarawa, it is much more difficult to ensure clinics and pharmacies on the outer islands are stocked with sufficient supplies and equipment.

“I’m really happy with the progress made by the pharmacy team. We have limited resources, but we work well as a team and there is a lot of enthusiasm for what we do,” explains Moannara. “We are improving supply chain management, and now, for the first time, we also have a comprehensive national list of essential medical supplies – which includes medicines, equipment and consumables.”

“Health center staff are now using tablets to track what is coming in and going out. It really helped us develop a better picture of what we need and when we need it.

Kiribati's Chief Pharmacist, Moannara Benete, says the right supply chain and distribution of medical supplies will benefit everyone in Kiribati.  Photo: Rimon Rimon/World Bank
Kiribati’s Chief Pharmacist, Moannara Benete, says the right supply chain and distribution of medical supplies will benefit everyone in Kiribati.
Photo: Rimon Rimon/World Bank

Improving supply chains

Moanara took up a position with the Department of Pharmacy of the Kiribati Ministry of Health and Medical Services in 2011 after earning a degree in pharmacy in Fiji. In 2019, she completed a Masters in Public Health from the University of Melbourne, Australia. She says her studies helped shape her vision for improving the healthcare system at home.

“It made me think that the pharmacy sector was more than just a curative department. I realized that it sits at the center of health service delivery in many ways – spanning the spectrum of preventive, curative, restorative and palliative care needs in this country,” said Moannara. “If we can get the supply chain and distribution in place, then everyone across the islands will benefit.”

Access to contraceptives

One area of ​​particular passion for Moannara is her team’s work on sexual and reproductive health.

“Sexual and reproductive health commodities have traditionally been hard to come by here in Kiribati. We have been dependent on the support of development partners,” she explains. “And with the borders closing due to COVID-19, it became even harder for us to get enough and there was a shortage.

“Yet our the data shows us that the number of married women with access to contraceptives has increased over the past decade, so if we can make sure the supplies are on the shelves, we know people will use them.

Doctor Jennifer ButlerDirector for the Pacific and Representative of the United Nations Population Fund (UNFPA), which supports this sexual and reproductive health work, says improving access to modern contraceptives and life-saving maternal health drugs is a job vital.

“It’s about improving access to contraceptives, increasing visibility of availability – so people know where to get contraceptives – and building more sustainable systems,” said Dr. Butler. “This is essential work with a strong focus on gender equality, human rights and prosperity for all; and is essential for achieving universal health coverage.

Moannara Benete is committed to building the capacity of Kiribati's health system so that all I-Kiribati can access health services when they need them.  Photo: Aislinn Healy/World Bank
Moannara Benete is committed to building the capacity of Kiribati’s health system so that all I-Kiribati can access health services when they need them.
Photo: Aislinn Healy/World Bank

Live their best, healthiest life

Moannara believes ensuring equal access to health services is a big challenge for Kiribati, but one she and her team are ready to meet.

“Our pharmacy team is committed to building the capacity of our healthcare system. We’re driven by opportunities to learn as we go, and we’re certainly learning a lot. Leadership and effective and transparent decision-making are also very important,” said Moannara.

“We want to make sure that everyone has the opportunity to live their best life in the best state of health; no matter who they are or where they live.

World Bank support to the Kiribati Ministry of Health and Medical Services is provided in part by Advanced Universal Health Coveragea multi-donor trust fund set up by Australia Department of Foreign Affairs and Trade in 2015 to support the strengthening of health financing and service delivery systems in countries in East Asia and the Pacific. Other partners include Gavi, the global fundand the Bill and Melinda Gates Foundation.


Partner content

This article was first published by The World Bank April 27, 2022

read more
Medical supplies

Sunflower Network is raising money to send drones, medical supplies and a fully equipped ambulance to war-torn Ukrainian cities

Sunflower Network members work on the ground in war-torn areas of Ukraine.

The sunflower network is made up of many college-aged students or recent graduates.

After Russia invaded Ukraine on February 24, Dustin Ross, a former University of Michigan student, spent a month trying to figure out how to help Ukrainians in need.

Most organizations, however, only wanted monetary donations. Desiring to find a way to help directly, Ross traveled to Eastern Europe to see the situation for himself.

He spent several weeks in Romania, Poland and Ukraine, talking to refugees and learning how to build an emergency supply of food, hygiene, medical and other items in the besieged territories – where some 40 million people are affected. by war.

Ross learned about an international network ready to help and how much Ukraine needed critical supplies to save lives. In a country with a destroyed and disrupted supply chain, even basic necessities like deodorant and feminine products were essential to secure.

[Read the latest coverage from Ukraine]

To get directly involved, Ross launched Sunflower Network, a pending 501(c)(3) nonprofit organization that includes an ever-expanding network of people in the United States and abroad who bring in essential supplies. to Ukraine.

Eve Wasvary
Eve Wasvary

The network is made up of many college-age students or recent graduates, including Eve Wasvary of Franklin, a 20-year-old student at the University of Michigan, who is currently doing internships in Tel Aviv and is affiliated with the University of Michigan. Hillel.

“I saw pictures [of the network’s work] through a mutual friend,” says Wasvary, who recently joined Sunflower Network and is now involved in fundraising efforts. In these photos, she saw Ross handing out gym bags filled with medicine and basic necessities to Ukrainians. Water purification systems and civil protection equipment were also delivered.

Inspired, she wanted to find a way to help. “They go directly to them,” she says of the supplies. “Sunflower Network has an Amazon Wishlist so you can purchase merchandise directly.” This helps donors know where their donations are going, she explains.

Members of the network unload medical supplies in Ukraine.
Members of the network unload medical supplies in Ukraine. Nathan Vicar | Detroit Jewish News
Sunflower Pride

As a symbol of Ukrainian national identity and pride, the sunflower has a deeper meaning than just a clever name for a network. With several members based in the Detroit metro area, the work spans international waters and includes three partners in Ukraine.

These Ukraine-based partners are making deliveries, helping find homes for displaced people, and even securing and distributing medical supplies, among other vital services.

“Sunflower Network has partners who understand what supplies are needed, and they get them around the world to different regions,” Wasvary explains. “Then they distribute them in the worst regions of Ukraine.”

This includes hard-hit cities like Mariupol, Kharkiv, Odessa and the Donbass region.

Recently, Sunflower Network distributed $25,000 worth of supplies to partners in Kyiv, Lviv and Zakarpattia. Now they are looking to acquire medical equipment for trauma victims, such as haemostatic bandages and tourniquets.

They also double their goals. The network’s third mission to Ukraine, on July 12, aims to raise $52,250. A private donor also matches all dollar donations through July 8.

As well as purchasing vital supplies, the aim is to transport a fully equipped ambulance from Ireland to Ukraine. Sunflower Network also plans to buy five drones with the funds, which help locate injured people in dangerous areas.

Supplies of all kinds are needed in this war-torn country.
Supplies of all kinds are needed in this war-torn country.
Maintain War Consciousness

Wasvary says Ukraine needs help more than ever.

“I tried to raise awareness of the plight of these areas,” she says of towns like Mariupol, where up to 95% of the city is estimated to have been destroyed and people have hard to find drinking water or basic medicines. like antibiotics.

It is important for people to remember that the war continues, she explains, and that some regions continue to fall into a worse and more dangerous state.

“Now that I’m out of school, we hear a little about it, but not enough,” Wasvary says of the dwindling media coverage of the war. “I want people to know what’s going on.”

Together, she explains, “we can make such a difference.”

Even if people aren’t in a position to donate financially or send supplies, just being aware of the ongoing Russian-Ukrainian crisis helps propel the mission further. It’s a chain of events, Wasvary says, that sends the message from one person to another.

“Staying informed and understanding what’s going on, learning about what’s going on in the world…that’s the most important thing.”

To learn more about Sunflower Network and its mission, visit sunflowernetwork.io.

read more
Medical products

Providing lifesaving medical products and expert advice for over 32 years

Healthgear Medical & Safety team teaches customers how to properly and safely use their medical products

Founded by James W. Mills, CSF, CFO, Healthgear Medical & Safety has served the District of Algoma and Sault Ste Marie for over 32 years, with competitive pricing and the widest product line in the North. They carry all types of medical products for individuals, hospitals and nursing homes.

Born with spina bifida, Jim had a strong desire to help others with their mobility issues from an early age. Also a former competitive swimmer and provincial weightlifter, Jim strives to stock all the best sports medicine products, braces and health supports, for both able-bodied and disabled athletes.

Doctors and physiotherapists refer their patients to Healthgear Medical & Safety because of the certified staff and wide variety of products.

Healthgear Medical & Safety sells items such as:

  • blood pressure monitors,
  • walkers,
  • compression hose,
  • TENS,
  • lifting chairs,
  • ostomy supplies,
  • bath safety equipment,
  • FIRST AID,
  • pain control devices,
  • scooters
  • and stair railings,

Not only that, but they also service all makes and models with their comprehensive aftermarket service, with parts and reasonable hourly rates.

Healthgear Medical & Safety will show you the correct usage of your device or product with every purchase, so you know you’re getting the right information.

All customers get a very private full experience when purchasing their product, whether it is custom made knee brace, foot orthotics, back brace, ankle support , wrist or cervical. If you need your medical product delivered, there is no charge in the District of Algoma.

A solidarity company

For five consecutive years, Healthgear Medical & Safety has been voted the top medical provider in the Sault by opinion polls. Healthgear Medical & Safety is an authorized provider for WSIB, Social Agencies, NIHB Program and can bill most insurance companies where applicable. They can make home and hospital visits when needed.

Healthgear Medical & Safety is a community-minded company. During the pandemic, Jim and staff have been able to secure thousands of dollars in supplies donated to nonprofits here in Sault Ste Marie and abroad. When hospitals and nursing homes struggled to find fair prices on PPE supplies, Healthgear Medical & Safety staff were able to source these items from the United States. They always had ample supplies for the public and never ran out, while maintaining fair prices and offering free shipping.

Healthgear Medical & Safety is here to serve the residents of Sault Ste Marie and the District of Algoma.

They are open Monday through Friday from 8:30 a.m. to 5:30 p.m. and Saturday from 9 a.m. to 1 p.m., and also offer free shipping anywhere in the Algoma area. After hours, call 705-257-8049 for emergency appointments or fittings. They are located across from Memorial Gardens at 262 Queen Street East.

You can also visit them online here.

read more
Prescription drugs

Reviews | On prescription drugs, is Joe Manchin about to do the right thing?

The effort to save some of the programs of Build Back Better, the now-defunct centerpiece of President Biden’s national agenda, is so dependent on Senator Joe Manchin III that some in Washington call him Build Back Manchin. Yet the West Virginia Democrat has so often shattered the dreams of Democrats that many have given up hope that he would agree to anything.

But now there are new indications that negotiations are moving forward, and in ways that could rekindle several Democratic goals. It’s a reminder that no matter how desperate things seem, nothing is what it seems in the Senate, a murky, impenetrable place.

Senate Majority Leader Charles E. Schumer (DN.Y.) released a proposed bill allowing Medicare to negotiate prescription drug prices, which emerged from talks with Manchin. The bill has been given to the Senate parliamentarian to ensure it meets the conciliation requirements to allow the filibuster to be circumvented so that it can be passed by a simple majority.

The Democrats will need it, because so far precisely zero Senate Republicans support the bill. That could change, however, as allowing drug price negotiation has long been almost absurdly popular.

The bill would do the following:

  • Require the Department of Health and Human Services to negotiate prices for commonly used drugs, which will almost certainly reduce their cost.
  • Cap out-of-pocket drug costs for Medicare beneficiaries at $2,000 per year.
  • Limit the amount that drug companies can increase annually on existing drug prices to the rate of inflation.
  • Extending assistance to seniors earning up to 150% of the poverty line to afford medication (currently those earning up to 135% of poverty receive such assistance).

A lobbyist for PhRMA, the drug companies trade group, criticized the plan, which is a good indication that it would indeed bring prices down.

Manchin has frequently cited inflation as a justification for scrapping Democratic spending bills, but those proposals are a way to address inflation. The Prescription Drug Bill limits annual price increases, and other spending that savings could fund would help ease the burden of inflation, particularly the Affordable Care Act’s extended subsidies (see below).

Not to mention the political advantage. Every election, Democrats promise to rein in the abysmal price of prescription drugs (and more than a few Republicans do too). This desire then collides with the enormous lobbying power of the pharmaceutical industry, which is why Americans continue to pay far more for drugs than the citizens of any other country.

Ensuring that, then, would be a serious achievement, after a year in which Democratic infighting and BBB paralysis have helped define the party.

What’s more, the Medicare prescription drug movement also offers a tantalizing possibility: It could open the door for Manchin to strike a broader deal that also extends the ACA’s expanded subsidies.

The expanded grants, which were originally passed in the 2021 covid-19 bailout, are set to expire at the end of this year. They were meant to be extended as part of BBB, but Manchin killed that.

Expiring now would mean millions of people would see their premiums go up, and a few million more could lose their coverage altogether. Given that Democrats have spent a decade winning the ACA argument, while slowly expanding it toward universal health care, such a massive regression would be a total disaster, both substantively and politically.

Fortunately, NBC News reports that Manchin is open to extending the grants, though he doesn’t seem enthusiastic about it.

Here’s the thing, though: if Manchin is willing to do it, it absolutely can be done within the parameters he has set himself.

Here’s why: Most reports suggest Manchin seems open to a revived, scaled-back BBB that raises about $1 trillion, both by undoing some GOP tax cuts in 2017 and with Medicare prescription drug reform. (which would save the government money).

Manchin wants to invest half of that trillion dollars in deficit reduction. That would leave about $500 billion for public and social spending.

If about $300 billion of that were dedicated to funding the clean energy transition, through tax incentives and other means — a key part of the BBB that Manchin seems open to — that would leave about $200 billion. dollars for extension of ACA grants.

Larry Levitt, executive vice president of health policy at the Kaiser Family Foundation, says it’s entirely possible to fund the vast majority of extended grants with that amount. The cost of extending them to all would be estimated at $220 billion, so it would be feasible to reduce it to $200 billion, perhaps by reducing these subsidies for those eligible on the highest incomes.

“You could definitely extend the ACA grants and still help the vast majority of enrollees with $200 billion,” Levitt told us. “The numbers certainly add up for a package that lowers drug prices and keeps premiums in check under the ACA.”

So Manchin can have it all! He can have a reformed tax code, climate tax incentives, lower prescription drug prices and expanded ACA subsidies — cutting costs for people he says are being hammered by inflation — and he can have hundreds of billions of dollars in deficit reduction to boot.

All Manchin has to do is take yes for an answer.

read more
Medical products

Prescriptions for medical cannabis products increased almost tenfold in 2021

According to figures released by the Care Quality Commission (CQC), prescriptions for unauthorized medical cannabis in the private healthcare sector have increased by nearly 1,000% over a 12-month period.

The health and social services regulator’s report — ‘Managing Controlled Medications Safer: 2021 Annual Update‘, published in July 2022 – indicates that 37,634 cannabis medical products (CBMPs) were prescribed by non-NHS health services between January and November 2021, compared to 3,636 over the same period in 2020.

Conversely, during the same period, NHS prescribing of CBMP in England was so low that data could not be reported.

“The number of items prescribed in the NHS is so small that it could potentially affect patient confidentiality,” the report said.

On April 25, 2022, in response to a written question on the assessment made of the adequacy of access to medical cannabis for those eligible, Pharmacy Minister Maria Caulfield said: “Licensed cannabis medicines are regularly available on the NHS.

“However, clinical guidelines from the National Institute for Health and Care Excellence demonstrate a clear need for more evidence to support routine prescribing and funding decisions for cannabis products not authorized for medical use. until this evidence base is built, prescribers will remain reluctant to prescribe and no decisions can be made by the NHS on routine funding.

In July 2020, a CQC report found that in 2019 – the first year CBMPs were legally available – 18 NHS prescriptions were issued in England.

Then, in October 2020, the National Institute for Health Research confirmed that no government-funded medical cannabis trials were underway, despite a call for applications.

Several private health clinics capable of providing CBMPs have been established since the legalization of medical cannabis in November 2018.

At the time of publication of the latest CQC update, there were 15 registered providers of unlicensed CBMP in England, with more being assessed for registration.

Sapphire Medical Clinic was the first dedicated medical cannabis clinic in the UK to be registered by the CQC on October 3, 2019.

Commenting on the recent increase in CBMP prescriptions, Simon Erridge, Head of Research and Access at Sapphire Medical Clinics, said: “Since 2020, we have seen an 846% increase in the number of patients accessing our specialist service. .

“The prescribing of unlicensed cannabis medicines through the NHS has not seen the same growth. The most important reason behind this is the National Institute for Health and Care Excellence guideline issued in 2019, which has not showed sufficient clinical benefit over the costs then associated with these drugs.

“There is also a lack of randomized controlled trials showing the effectiveness of CBMPs compared to other licensed drugs.”

Read more: Medical cannabis has yet to live up to the hype

read more
Medical supplies

Global Southeast Asia Disposable Medical Supplies Market Size, Share, Growth, Analysis to 2032

Southeast Asia Disposable Medical Supplies Market

Southeast Asia disposable medical supplies market is dominated by Indonesia with ¼ share: Persistence Market Research

PUNE, MAHARASHTRA, INDIA, July 6, 2022 /EINPresswire.com/ — Traditionally, the disposable medical supplies industry has focused on usability, compliance and quality to meet health and safety standards. However, in addition to the increase in demand, environmental concerns are on the rise. As a result, the industry is seeing a renewed interest in low cost and environmentally friendly products.

With recorded sales worth US$6 billion in 2021, the Southeast Asia Disposable Medical Supplies Market is expected to witness a high growth rate in the coming years owing to the growing preference for low-cost disposable medical supplies amid the COVID-19 pandemic.

Maintaining health and hygiene has become the top priority for the prevention of communicable diseases. Disposable supplies come in aseptic packaging which limits the risk of cross-contamination and can help stop the spread of infections, save money and manage hospital resources. Growing awareness of personal hygiene and safety has accelerated the demand for disposable medical supplies.

Get a sample copy of this report @ https://www.persistencemarketresearch.com/samples/33019

One of the most promising opportunities for improving care and reducing costs is moving care delivery to the home. Key players are launching and adapting models to move primary, acute and palliative care to homes. Home care can avoid the need for more expensive treatments in hospitals and other institutional settings for vulnerable patients. Disposable medical supplies provide support not only for care of acute and chronic medical conditions, but also for disease prevention and lifestyle choices.

Many key manufacturers are leveraging their capacity for innovation and ingenuity to open up a world of possibilities for healthcare professionals and patients to deliver affordable services and improve patient outcomes.

Company Profiles:

Medtronic Plc.
Cardinal Health, Inc.
3M Company
Molnlycke Health Care AB
NIPRO Corporation
Ansell Healthcare LLC
Halyard Health, Inc.
Medline Industries Inc.
McKesson Corporation
Sempermed USA, Inc.
GE Healthcare
Johnson & Johnson
ThermoFisher Scientific Inc
Smiths Plc Group
Ambu A/S
Royal Philips SA

Methodology request @ https://www.persistencemarketresearch.com/methodology/33019

Key insights from market research

Hypodermics and Radiology holds nearly 17.8% market share by value in the disposable medical supplies market in Southeast Asia.

With a market share of 26.2% in 2021, cardiovascular procedures dominate the application segment.

Hospitals hold nearly half of Southeast Asia’s overall market share for disposable medical supplies.

Indonesia is the No. 1 country in Southeast Asia for disposable medical supplies and accounted for 1/4 market share in 2021.

“Increased prevalence of hospital-acquired infections and rising health and hygiene awareness will drive demand for disposable medical supplies in Southeast Asia,” says an analyst at Persistence Market Research.

Market competition

Major manufacturers of disposable medical supplies are focusing on partnerships with emerging companies to expand into the Southeast Asian market and reach a wider customer base to meet growing demand.

Moreover, major market players have embraced expansion as a business growth strategy.

For example, in September 2021, Lankenau Heart Institute, part of Main Line Health, signed a long-term strategic partnership agreement with Philips, using integrated solutions related to cardiovascular diseases.

What does the report cover?

Persistence Market Research offers a unique perspective and actionable insights into the Southeast Asia disposable medical supplies market in its latest study, presenting a historical demand assessment from 2017 to 2021 and projections for 2022 to 2032.

The research study is based on the product (sterilization consumables, wound care products, dialysis products, infusion products, hypodermic and radiology products, intubation and respiratory supplies, surgical procedure kits and trays, supplies blood management and diagnostics and general disposables), application (cardiovascular, cerebrovascular, dental, laparoscopy, gynecology, urology, orthopedics and others) and end user (hospitals, outpatient surgery centers, clinics, diagnostic centers, long-term care centers and nursing homes) in Southeast Asian countries.

Access the full report @ https://www.persistencemarketresearch.com/checkout/33019

Southeast Asia Disposable Medical Supplies Market – Report Highlights

A Detailed Overview of the Parent Market of the Southeast Asia Disposable Medical Supplies Market
Changing Southeast Asia Disposable Medical Supplies Market Dynamics in Industry
In-depth segmentation of the disposable medical supplies market in Southeast Asia
Historical, current and projected Southeast Asia Disposable Medical Supplies market size in terms of volume and value
Recent industry trends and developments in the Southeast Asia disposable medical supplies market
Competitive Landscape of Southeast Asia Disposable Medical Supplies Market
Strategies for key players and products offered
Potential and niche segments, promising growth geographies
A neutral perspective on the performance of the disposable medical supplies market in Southeast Asia
Must-have information for Southeast Asia Disposable Medical Supplies market players to maintain and improve their market footprints

Access exclusive PMR reports-

rehabilitation equipment market
The global rehabilitation equipment market is expected to reach a figure of approximately US$13,400 million in 2022 and is expected to show a robust CAGR during the assessment period.

diabetic socks market
Global diabetic socks market was valued at US$42.3 million in 2016 and is expected to grow at a healthy CAGR above 3.8% during the forecast period 2017-2025.

Persistence Market Research Pvt Ltd Atul Singh
people with reduced mobility
+1 646-568-7751
write to us here
Visit us on social media:
Twitter
LinkedIn

read more
Prescription drugs

The Woods at Parkside releases guide to prescription drug addiction

GAHANNA, OHIO, USA, July 5, 2022 /EINPresswire.com/ — The Woods at Parkside has released a guide on how to become addicted to prescription drugs. It reviews the risks, why people become addicted, the most popular drugs they become addicted to, and how to seek help.

People do not plan to become addicted to their prescription medications, but can often become addicted to the feeling of their pain relief. Groups that are at higher risk for prescription drug addiction include:

• Advanced age
• Female gender
• Poor or fair general health
• Drink daily
• Use of the drug for non-medical purposes

Many of the drugs that people take and become addicted to are usually associated with prescription drugs given after surgery or to help treat a mental health condition. The five most common prescription drugs that people become addicted to are:

1. Opioids: Given to help manage severe pain.
2. Anti-anxiety drugs: prescribed to reduce or prevent anxiety.
3. Sedatives: Helps people sleep after painful procedures.
4. Barbiturates: Used as sedatives to achieve deep, restorative sleep.
5. CNS stimulants: Central nervous system stimulants for ADHD.

Drugs that are addictive usually give someone a pleasurable experience that they want to continue having. They often solve the problems the person had by relieving pain or making it easier to sleep. However, as the body adapts to the medication, it may give someone less pleasure and not solve the problem, which is when someone can increase their dose.

Some signs of prescription drug addiction include:

• Steal prescription drugs
• Forge Ordinances
• Sell prescriptions or prescription drugs
• Have mood swings
• Make bad decisions or bad judgments
• Request refills sooner than needed
• Consult different doctors to get more prescriptions

The Woods at Parkside is a residential detox and recovery facility that can help people with addictions in Gahanna, Ohio. The staff includes doctors, nurses, and therapists who work together to create a treatment plan that helps drug-related challenges. If someone or someone they know is struggling with drug addiction, they can visit the Woods at Parkside website to learn more about treatment options.

William Slover
The Woods at Parkside
write to us here

read more
Medical supplies

PERFORMANCE HEALTH DONATE 4 MEDICAL SUPPLY TRUCKS TO UKRAINE

“At Performance Health, we are a company of people who value people. Our hearts and support go out to the people of Ukraine. We know this donation is needed and will be used to help many who are suffering,” said Joy GalloPurchasing Manager, Performance Health.

As a member of $500,000 donation, Performance Health partners with Vector, their global logistics provider. Vector is part of an ongoing effort to support Ukraine providing essential supplies through product customer partnerships and financial donations. Additionally, a Ukrainian businessman made several financial donations to help offset the logistical costs of transporting medical donations.

Containers of supplies totaling more than 120 pallets were picked up from the Performance Health distribution center in Indianapolis, shipped to Chicagothen flew to Ukraine. The Ukrainian Embassy joined in the project of chartering the aircraft, due to the need to ship the products. The plane made several trips to deliver all the products.

Once in the country, the first priority for donations is the Ukraine military, the rest going to the locals Ukraine hospitals. Medical supplies include scarves, hand sanitizer, disinfectant wipes, nitrile gloves, masks and more.

This donation is a continuation of efforts to support Ukraine. In March of this year, Performance Health announced that it did not manufacture or have direct suppliers in Russia Where Belarus. Moreover, they no longer buy raw materials either directly or indirectly from Russia. Their teams worked actively to find alternative suppliers of raw materials.

About performance health

Based at Warrenville, Ill.with major operations in Akron, Ohio, Performance Health is a leader in consumer healthcare and the world’s largest manufacturer and marketer of products for the rehabilitation, physical therapy and sports medicine markets. The Company’s products are sold to leading healthcare facilities and practitioners such as physical therapists, athletic trainers and chiropractors, and directly to consumers through all major physical and online retail channels. Its market leading brands include THERABAND, Cramer, Sammons Preston, Medco and Roylan. More information is available at www.performancehealth.com.

Contact
Rachel Keoppel
[email protected]

SOURCE Performance Health

read more
Medical products

Swabs Market Expected to Drive Future Growth by 2030 | Puritan Medical Products, Sarstedt, MWE – Brits in Kenya

Swabs Market Report Coverage: Key Growth Drivers and Challenges, Regional Segmentation and Outlook, Key Industry Trends and Opportunities, Competitive Analysis, COVID-19[feminine] Impact analysis and projected recovery, and market sizing and forecasting.

Latest research launched on Global swab market, it provides a detailed analysis with presentable graphs, charts and tables. This report covers an in-depth study of the Swabs Market size, growth and share, trends, consumption, segments, application and forecast 2030. Through qualitative and quantitative analysis, we help you to carry out an in-depth and comprehensive research on the global swabs market. This report has been prepared by experienced and knowledgeable market analysts and researchers. Each section of the research study is specially prepared to explore key aspects of the global Swabs market. Buyers of the report will have access to accurate information PESTLE, SWOT and other types of analysis on the global swabs market. In addition, it offers very precise estimates on the CAGR, market share and market size of key regions and countries.

Major Key Players profiled in the report include:
Puritan Medical Products, Sarstedt, MWE, SARSTEDT, Clean Cross, GPC Medical, Citotest Labware Manufacturing, Q-TIPS, ELMEX

Download Free Sample PDF including COVID19 Impact Analysis, Full TOC, Tables & Figures @
Get a FREE sample PDF copy of the report @ https://marketstrides.com/request-sample/swab-market

Do not miss the trading opportunities on Swab Market. Talk to our analyst and get key industry insights that will help your business grow when you create sample PDF reports.

Segmental analysis:
The report categorized the global swabs market into segments comprising product type and application. Each segment is assessed based on its share and growth rate. Additionally, analysts have studied the potential regions that could prove rewarding for Swab makers in the coming years. The regional analysis includes reliable predictions about value and volume, helping market players to gain insightful insights into the overall Swab industry.

Market is split by Type, can be split into:
Absorbent cotton, Non-absorbent cotton

The market is split by Application, can be split into:
Pharmaceutical, Microbiological, Laboratory, Others

Share your budget and get an exclusive discount @
Check the discount for this report: https://marketstrides.com/check-discount/swab-market

The report authors have analyzed the developing and developed regions considered for research and analysis of the global Swabs market. The regional analysis section of the report provides an in-depth study of different regional and country-level Swab industries to assist players in planning effective expansion strategies.

Regions Covered in Global Swabs Market:
The Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa)
North America (United States, Mexico and Canada)
South America (Brazil, Argentina, Colombia, etc.)
Europe (Turkey, Germany, Russia UK, Italy, France, etc.)
Asia Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia and Australia)

Years considered to estimate the market size:
Historical year: 2019-2020
Year of reference : 2021
Estimated year: 2022
Forecast year: 2022-2030

Detailed TOC of Swabs Market Report 2022-2030:
Chapter 1: Swabs Market Overview
Chapter 2: Economic impact on industry
Chapter 3: Market competition by manufacturers
Chapter 4: Production, revenue (value) by region
Chapter 5: Supply (production), consumption, export, import by regions
Chapter 6: Production, Revenue (Value), Price Trend by Type
Chapter 7: Market analysis by application
Chapter 8: Manufacturing cost analysis
Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers
Chapter 10: Marketing Strategy Analysis, Distributors/Traders
Chapter 11: Analysis of market effect factors
Chapter 12: swab market Provide
Continued……

Get Buy this Swabs Market Report 2022-2030: Choose License Type

What market dynamics does this report cover?
The report shares key information on:
Current market size
Market forecasts
Market opportunities
Main Drivers and Constraints
Regulatory scenario
Industry trend
New product approvals/launch
Promotion and marketing initiatives
Price analysis
Competitive landscape
It helps companies make strategic decisions.

Does this report offer customization?
Personalization helps organizations better understand specific market segments and areas of interest. Therefore, Market strides provides customized reporting information based on business needs for mission-critical calls.

About Us:

Market Strides is a global aggregator and publisher of market intelligence development reports, stock reports, database directories and economic reports. Our repository is diverse, covering virtually every industry sector and even more so all categories and sub-categories within the industry.

Our pre-integration strategy for publishers is perhaps what sets us apart in the market. The publishers & their market share, the reports are meticulously validated by our panel of internal consultants, before being posted on our website. These in-house consultants are also responsible for ensuring that our website features only the most up-to-date reports.

You have a question ? Ask our experts

Market Strides has a team of professionals who assist you in many advanced industry-specific trends, content and test different strategies and implement the most productive one for the business.

For more information, Email – [email protected]

Contact us: +1 856 677 8909 (USA)

Follow us on social networks:

Facebook || LinkedIn || Twitter || pinterest || tumblr || instagram || Medium

Other list of trend reports:
https://sjindependent.org/regional-news/hcm-software-market-comprehensive-study-explores-huge-growth-in-future-cornerstone-ondemand-webhr-zoho-corporation/
https://www.tgbbj.com/global-home-healthcare-software-market-trends-and-developments-forecast-by-2030/
https://sjindependent.org/report/microwave-ablation-systems-market-industry-size-in-depth-qualitative-insights/
https://www.designerwomen.co.uk/apheresis-market-size-2022-analysis-by-2030-asahi-kasei-medical-nikkiso-fresenius-kabi/

read more
Medical supplies

Best Statistical Growth of Emergency Medical Supplies Market Expected to Increase Significantly from 2022 to 2028 Bayer Corporation, Becton and Dickinson Company

The titled global market reports provide “Emergency Medical Supplies Market” Comparative analysis before and after the covid-19 market and also suggests strategies to overcome the impact of a pandemic by providing products favorable to customer needs and demands. In addition, the report presents details of the major manufacturers focusing on measures to promote the Emergency Medical Supplies market in their target industry. The objectives of the study are to offer key strategies for potential investors to understand growth opportunities and potential challenges in the market. this too understand Growth, Size, Share, Historical Progression, Future Projections, Cost, Revenue and Value Chain Analysis. The report presents growth figures using industry facts and figures.

A sample report can be viewed by visiting (Use corporate email id for higher priority) at: https://www.worldwidemarketreports.com/sample/796561

Global Emergency Medical Supplies Market Segmentation By Key Companies:

  • Bayer Corporation
  • Becton and Dickinson Company
  • Johnsons and Johnsons
  • Braun Melsung
  • Stryker Corp.
  • Medtronic
  • Asahi Kasei Society
  • Koninklijke Phillips
  • GE Healthcare
  • Smith and nephew

Global Emergency Medical Supplies Market Segment By Type:

  • Infection control products
  • Diagnostic and monitoring equipment
  • Therapeutic breathing apparatus
  • Cardiac equipment
  • Wound care supplies
  • Patient handling equipment
  • Others

Global Emergency Medical Supplies Market Segment By Application:

  • Cardiac care
  • Respiratory care
  • Trauma
  • Others

Get a preview of the study, request a sample now @ https://www.worldwidemarketreports.com/sample/796561

What is included in the free sample report:

➤ A brief presentation on market research and business overview
➤ Market size and share analysis
➤ Major market players with analysis of sales, revenue and business strategies
➤ Market growth drivers and restraints
➤ Market Opportunities and Challenges
➤ Detailed research methodology

Considering the geographical landscape of the Emergency Medical Supplies Market:

The Emergency Medical Supplies market report provides information on the market area, which is sub-categorized into sub-regions and countries/regions. In addition to the market share in each country and sub-region, this chapter of this report also contains information on profit opportunities.

➤ North America (United States, Canada and Mexico)
➤ Europe (UK, Germany, France, Russia and Italy)
➤ Asia-Pacific (China, Korea, Japan, India and Southeast Asia)
➤ South America (Brazil, Colombia, Argentina, etc.)
➤ The Middle East and Africa (Saudi Arabia, United Arab Emirates, Nigeria, Egypt and South Africa)

This report offers actionable growth insights and in-depth study comprising secondary research, primary interviews with industry stakeholders, competitors, validation and triangulation with regional Worldwide Market Reports database. Experts have detailed primary records with market players across the value chain in all regions and industry experts for qualitative and quantitative insights.

Purchase this research study report for quick access @ https://www.worldwidemarketreports.com/buy/796561

The report covers an in-depth analysis of key market players in the market along with their business overview, expansion plans, and strategies.

The report provides a comprehensive view of the market, including value chain analysis, historical analysis, current market size estimation, opportunities, technological advancements, product developments, market drivers and restraints. market, as well as constraints that will occur in the years to come. . The report also includes sales and industry chain analysis with a comprehensive overview of key players in the Asia-Pacific Emergency Medical Supplies industry.

Secondary research:

This research study made extensive use of secondary sources, directories and databases. Other secondary sources included company annual reports, press releases, investor presentations, white papers, certified publications, articles from recognized authors, manufacturer associations, trade directories and databases. of data.

Primary research:

Various sources from the supply and demand side were queried during the primary research process to obtain qualitative and quantitative insights for this report. Key sources included industry experts from core and related industries, as well as preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations from all segments of this industry’s value chain. . To obtain and verify critical qualitative and quantitative information, in-depth interviews were conducted with various key informants, including key industry participants, subject matter experts, C-level executives from key market players, and industry consultants. sector.

Market Size Estimate:

The total size of the Emergency Medical Supplies market has been estimated and validated using top-down and bottom-up approaches. These methods have also been widely used to estimate the size of various market sub-segments. The following research methodologies were used to estimate the market size: Extensive secondary research was used to identify major industry players.

How will this report be worth your money?

➤ Giving a comprehensive overview of emergency medical supplies markets
➤ Research and analysis of the competition of emergency medical supplies
➤ It will help gain a different perspective to approach a crisis when needed
➤ Data driven statistics that will help to track the growth of Emergency Medical Supplies market segment or product category
➤ A comprehensive analysis of the Emergency Medical Supplies Market which will give the reader a broader perspective to perform a SWOT analysis
➤ Presents contextual case studies from the past and current scenarios as well as
➤ Advice from the emergency medical supplies markets expert

Do you have a question or specific requirements? Submit your query here @ https://www.worldwidemarketreports.com/quiry/796561

In conclusion, the Emergency Medical Supplies Market report presents the descriptive analysis of the parent market supported elite players, present, past and artistic movement information that is able to function as a profitable guide for all business competitors in the emergency medical supplies industry. Our team of expert research analysts have been trained to provide in-depth marketing research reports on each individual industry, which can be helpful in knowing the industry data in the most accurate way.

For more details,
Contact us please:

Mr Shah
Global Market Reports,
Tel: USA +1-415-871-0703
UK +44-203-289-4040
Japan +81-50-5539-1737
Email: [email protected]
Website: https://www.worldwidemarketreports.com/

read more
Prescription drugs

Sanofi, Abbott Laboratories, Takeda Pharmaceutical, Apotex, Aurobindo Pharma – Designer Women

The latest competent intelligence report released by WMR with the title “Growing Demand and Opportunities for the Global Sleeping Pills (Prescription Drugs) Market 2022“provides a sorted picture of the Sleeping Pills (Prescription Drugs) industry by analyzing research and information gathered from various sources that has the ability to help global market decision makers play a significant role in impacting progress on the global economy.The report presents and highlights a dynamic view of the overall scenario in terms of market size, market statistics and competitive situation.

At present, the market for sleeping pills (prescription drugs) is present all over the world. The research report presents a comprehensive judgment of the market which consists of Future Trends, Growth Factors, Consumption, Production Volume, CAGR Value, Careful Opinions, Profit Margin, Price and Industry Validated Market Data. This report helps individuals and market competitors to predict future profitability and make critical decisions for business growth.

A sample report can be viewed by visiting (Use corporate email id for higher priority) at: https://www.worldwidemarketreports.com/sample/773428

Scope of Sleeping Pills (Prescription Drugs) Market:

Emerging Trends, The Sleeping Pills (Prescription Drugs) Market report provides a comprehensive picture of the future demands and opportunities that are beneficial for individuals and market players. This report determines the market value and growth rate based on key market dynamics along with growth enhancing factors. The entire study is based on latest industry news, market trends and growth probability. It also consists of in-depth analysis of the market and competitive scenario along with SWOT analysis of well-known competitors.

Major Players involved in the Global Sleeping Pills (Prescription Drugs) Market are:

✤Sanofi
✤ Abbott Laboratories
✤ Takeda Pharmaceutical
✤ Apotex
✤ Aurobindo Pharma
✤ Actellon Pharmaceuticals
✤ Allegiant Health
✤ Chemical Cayman
✤ Ambitropin
✤ Hayao

Segmentation by type:

✤ Zolpidem
✤ Eszopiclone (Lunesta)
✤ Ramelteon (Rozerem)
✤ Ativan (lorazepam)
✤ Adapin (doxepin)

Segmentation by applications:

✤ Hospital pharmacy
✤ Retail Pharmacy

Get the PDF brochure here by clicking: https://www.worldwidemarketreports.com/sample/773428

Global Sleeping Pills (Prescription Drugs) Market Regional Analysis:

The research study separated the global Sleeping Pills (Prescription Drugs) industry into segments including Product Type, Application, and Vertical to broaden the overall understanding of the industry. This assessment was made based on size, share and CAGR. In addition, a regional analysis has been carried out by the experts highlighting the growth potential of key regions and countries. The report also includes accurate and reliable figures based on the consumption and production of sleeping pills (prescription drugs) in key regions.

North America: United States, Canada, Mexico, etc.
Asia Pacific: China, Japan, Korea, India and Southeast Asia
Middle East and Africa: Saudi Arabia, United Arab Emirates, Egypt, Turkey, Nigeria and South Africa
Europe: Germany, France, United Kingdom, Russia and Italy
South America: Brazil, Argentina, Colombia, etc..

The report helps to provide a broader introduction to the market and also helps to address the detailed research methodology for calculating the market size and forecast. Secondary data sources are used and primary inputs are taken for data validation. This section also helps in the outline of the different segments that have also been covered as part of the report. Additionally, research methodology reviews tend to provide the calculation to determine the inclinations of the global market.

Get customization and ask about the discount: https://www.worldwidemarketreports.com/quiry/773428

Some of the main points of the table of contents cover:

Chapter 1: Techniques and Scope

1.1 Definition and forecast parameters
1.2 Methodology and predictive parameters
1.3 Sources of information

Chapter 2: Summary of recent trends

2.1 Regional trends
2.2 Product trends
2.3 End-use trends
2.4 Trade trends

Chapter 3: Overview of Sleeping Pills (Prescription Drugs) Industry

3.1 Industry fragmentation
3.2 Industry Landscape
3.3 Supplier Matrix
3.4 Technological and innovative landscape

Chapter 4: Sleeping Pills (Prescription Drugs) Market, By Region

Chapter 5: Company Profiles

5.1 Presentation of the company
5.2 Financial elements
5.3 Product landscape
5.4 SWOT analysis
5.5 Systematic Perspectives

Chapter 6: Assumptions and Acronyms

Chapter 7: Research Methodology

Chapter 8: Contact (Continue . . .)

Purchase of Sleeping pills (prescription drugs) Market report to: https://www.worldwidemarketreports.com/buy/773428

Finally, Sleeping Pills (Prescription Drugs) Market 2022 report provides industry development roadmap, industry insights source, research findings, appendix and conclusion. The report offers precise clarification of the market by highlighting the manufacturing procedure of the market, competitors in the market, classification of vendors and merchants, implementation of innovation, and business enhancement designs. All these details will reassure customers about future plans and actions to compete with other players in the market. In addition, the most recent market improvements are displayed.

Contact us:

Global Market Reports,
Tel: USA +1-415-871-0703
UK +44-203-289-4040
Japan +81-50-5539-1737
Email: [email protected]
Website: https://www.worldwidemarketreports.com/

read more
Medical supplies

Kate Garraway fans rally to collect Derek’s life-saving medical supplies she left in a taxi

Kate Garraway was helped by fans to find the lost property of Derek Draper. (Getty)

Kate Garraway thanked fans who helped her recover husband Derek Draper’s vital medical supplies that were lost in a black cab after an urgent call.

The Hello Brittany The presenter was driving Draper home from the hospital for a weekend visit, but tweeted on Friday that she had left a briefcase containing all of her essential medication and kit in the black cab they were traveling in.

Read more: Ben Shephard ‘overwhelmed with grief’ after sudden loss of close friend

She wrote: “@BC_Lostproperty to help!! Just took Derek home in a black mobility cab from the hospital for a weekend visit – and left a briefcase with all his meds and kit out front! The driver recognized me but may not know he is there – please watch and get in touch – urgently needed!!”

Appearing in a new episode of Love Your Garden, Kate Garraway was shown sharing her new garden with her husband Derek Draper who remains in a wheelchair after his highly publicized battle with COVID-19.

Kate Garraway’s husband, Derek Draper, still needs constant care. (IVT)

Draper spent a year in hospital after becoming the UK’s worst-affected surviving COVID patient and although he returned home earlier this year, he still needs round-the-clock care and support. regular hospital treatment.

Garraway fans were quick to support her with suggestions on how to find lost items and order emergency prescriptions, but luckily the message reached a fan who was able to locate the missing case.

They tweeted: “I know the driver Kate as he mentioned he picked me up with you and your husband tonight. I’m trying to contact you right now.”

Read more: Kate Garraway says she and Derek Draper are relearning how to be a couple

A relieved Garraway confirmed on Sunday that the fan’s helper had managed to retrieve the urgently needed supplies, and also thanked the driver.

Kate Garraway attends the 2022 Prince's Trust Awards at Theater Royal Drury Lane on May 24, 2022 in London, England.  (Photo by Karwai Tang/WireImage)

Kate Garraway finally got the case back. (Wireframe)

She tweeted: “It was returned! Thank you to everyone who reached out – the message reached the lovely driver Robert who returned it – phew and thank you all. #Happy Sunday everyone

One fan commented, “The power of Twitter.”

Another added: “Absolutely amazing news Kate.”

Garraway wrote a book, The power of hopeon the experiences of his family who have been hit hard by COVID and have also made two ITV documentaries, Finding Derek and Take care of Derekwho have won awards.

She and Draper share two children and she said she still had hope that her husband would one day recover from his illness.

Watch: The touching moment Kate Garraway met a nurse who treated Derek Draper for the first time

read more
Medical products

Comparison of Globus Medical (NYSE: GMED) and Utah Medical Products (NASDAQ: UTMD)


Globus Medical (NYSE: GMEDGet a rating) and Utah Medical Products (NASDAQ:UTMDGet a rating) are two medical companies, but which is the best investment? We will compare the two companies based on their risk strength, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Volatility and risk

Globus Medical has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. In comparison, Utah Medical Products has a beta of 0.24, suggesting that its stock price is stock is 76% less volatile than the S&P 500.

Profitability

This table compares the net margins, return on equity and return on assets of Globus Medical and Utah Medical Products.

Net margins Return on equity return on assets
Globus Medical 14.77% 11.95% 10.69%
Utah Medical Products 30.34% 14.14% 13.03%

Institutional and insider ownership

67.2% of Globus Medical shares are held by institutional investors. By comparison, 71.4% of Utah Medical Products’ shares are held by institutional investors. 16.5% of Globus Medical shares are held by insiders of the company. By comparison, 6.6% of Utah Medical Products’ stock is held by company insiders. Strong institutional ownership indicates that large fund managers, hedge funds, and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommendations for Globus Medical and Utah Medical Products, as provided by MarketBeat.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Globus Medical 0 1 9 0 2.90
Utah Medical Products 0 0 0 0 N / A

Globus Medical currently has a consensus target price of $83.18, suggesting a potential upside of 44.11%. Given the likely higher upside of Globus Medical, stock analysts clearly believe that Globus Medical is more favorable than Utah Medical Products.

Benefits and evaluation

This chart compares revenue, earnings per share, and valuation of Globus Medical and Utah Medical Products.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
Globus Medical $958.10 million 6.13 $149.19 million $1.36 42.44
Utah Medical Products $49.05 million 6:30 p.m. $14.79 million $4.18 20.27

Globus Medical has higher revenues and profits than Utah Medical Products. Utah Medical Products trades at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Summary

Globus Medical beats Utah Medical Products on 7 out of 13 factors compared between the two stocks.

About Globus Medical (Get a rating)

Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders in the United States and around the world. It offers spine products, such as traditional fusion implants comprising screw and pedicle rod systems, plating systems, intervertebral spacers and corpectomy devices for the treatment of degenerative conditions, deformities, tumors and trauma; treatment options for motion-preserving technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologics including allografts and synthetic alternatives. The Company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails and external fixation systems; and solutions for the hip and knee joints, including modular hip stems and acetabular cups, as well as posterior stabilization and cruciate ligament retention knee arthroplasty implants. In addition, it distributes human cells, tissues, and cell and tissue products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

About Utah Medical Products (Get a rating)

Utah Medical Products, Inc. develops, manufactures and distributes medical devices for the healthcare industry. The Company offers fetal monitoring accessories, vacuum assisted delivery systems and other labor and delivery tools; Respiratory hoods for newborns DISPOSA-HOOD; and DELTRAN PLUS blood pressure monitoring systems. It also supplies GESCO umbilical vessel catheters; DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE Silicone Mouthguards; URI-CATH urinary drainage systems; NUTRI-CATHNUTRI-LOK feeding device; MYELO-NATE Lumbar Sampling Kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. Additionally, the Company offers the LETZ System for excision of cervical intraepithelial neoplasia and other lower genital tract lesions; FINESSE+ generators; loop, ball and needle electrodes; FILTRESSE spillways; other electrodes and specialized supplies and gynecological tools; Femcare trocars, cannulas, laparoscopic instruments and accessories; and EPITOME and OptiMicro electrosurgical devices. In addition, it provides Filshie Clip female surgical contraceptive devices; PATHFINDER PLUS endoscopic irrigation devices; suprapubic catheterization; LIBERTY Urinary Incontinence Treatment and Control Systems; ENDOCURETTE, a curette for the removal of uterine endometrial tissue; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of the uterus; and the LUMIN tool for manipulating the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components and other castings. It serves neonatal intensive care units, labor and delivery wards, women’s health centers in hospitals, outpatient clinics and physicians’ offices through direct customer service and a force sales representatives, independent consultants and manufacturer representatives. The company was incorporated in 1978 and is headquartered in Midvale, Utah.



Get news and reviews for Globus Medical Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Globus Medical and related companies with MarketBeat.com’s free daily email newsletter.

read more
Prescription drugs

Alberta safe supply report criticized for bias and focuses on prescription drugs

Content of the article

An Alberta legislative committee exploring the issue of safe drug supply has released a report that critics say is biased and focuses too much on the overprescription of opioids.

Advertisement 2

Content of the article

The 57-page report of the Select Select Committee to Review Secure Procurement includes eight recommendations, although adopting a secure procurement program is not one of them.

Associate Minister for Mental Health and Addictions Mike Ellis said in a statement that the government would “carefully consider” the findings.

“As we continue to implement a recovery-oriented system of care in Alberta, work is already underway that aligns with some of the committee’s recommendations,” the statement said.

A spokesman for the UCP caucus, which handles the committee’s investigations, did not respond to a request for comment after the report was released this week without any government announcement.

Safe supply is known as a harm reduction practice in which some drug users are provided with a legal, regulated supply of drugs to help them avoid entering the illicit toxic drug market.

Advertisement 3

Content of the article

At least three of the report’s eight recommendations relate to prescription opioids. One calls on the Government of Alberta to prevent “harmful pharmaceutical practices such as the widespread prescribing of full agonist opioids, often used in safe supply practice, which can lead to community diversion and increased addiction and overdoses.

The Edmonton Area Medical Staff Association (EZMSA), which launched an opioid poisoning committee in response to Alberta’s drug poisoning crisis, said the report’s focus on diversion of prescription opioids ignores the current reality.

“While the first wave of the opioid crisis may be linked to pharmaceutical marketing tactics and opioid prescribing incentives, since 2012 there has been ongoing education about restrictions and monitoring of opioid prescribing. opioids by regulatory colleges across Canada,” the EZMSA said. .

Advertisement 4

Content of the article

“In fact, since these programs were instituted, the rate of dispensing of opioids has shown a dramatic decline across Canada.

According to the province’s Substance Use Surveillance System, which tracks drug poisoning deaths, 95% of opioid-related deaths in 2021 were due to non-pharmaceutical opioids.

“More regulation on prescribing will not impact the current poisoning crisis – preventable deaths will continue to occur,” EZMSA said.

EZMSA provided a written submission to the Safe Procurement Committee and although the association is listed as a stakeholder, the submission was not included in the final report.

Dr. Bonnie Larson, a professor of family medicine at the University of Calgary who practices primary care and addiction medicine, echoed EZMSA’s concerns.

Advertisement 5

Content of the article

She said the recommendations focus on a controlled medical environment, opioid prescribing and diversion prevention, as well as increased law enforcement involvement.

“While we once hoped we could get support to prescribe a safer supply of opioids to people who really need them, this report is not reassuring,” Larson said. “I think it’s actually increased the fear in our community of being disciplined by the government or the government pressuring the college to (surveil) the prescribers.”

Two of the committee’s recommendations call on the government to allow “replacement within the framework of a treatment plan under strict medical supervision in the clinic” and collaborate with the College of Physicians and Surgeons to “ensure that physicians are informed of the criteria for prescribing appropriate opioids.

Advertising 6

Content of the article

About two-thirds of the report consists of a heavily critiqued review by staff at the Center for Applied Research in Mental Health and Addiction at Simon Fraser University (SFU).

While the review found ‘no evidence showing benefits’ of a safer drug supply, more than 50 researchers and clinicians signed an open letter criticizing SFU’s work as ‘extremely low quality’ .

“It’s a biased report, as we knew,” Larson said of the committee’s final report. “It relies on commissioned non-scientific information.”

Accusations of bias have been leveled against the committee since its inception in December 2021.

In February, four New Democrat MPs from Alberta resigned from the committee over concerns that the UCP had “clear intentions of staging a protracted political coup” against harm reduction policies. They also criticized the lack of diversity among the presenters.

Advertising 7

Content of the article

The UCP caucus said the NDP was indulging in its own political stunt by stepping down.

The committee’s work was also rejected by several experts and advocates, including the British Columbia Center on Substance Use, Moms Stop the Harm and Each and Every, who declined to appear before the committee. They raised concerns about the lack of representation of people to whom safe supply is prescribed, the lack of an academic community conducting primary research on safe supply, and the lack of safe supply prescribing physicians.

Other recommendations in the report call on the government to establish a provincial pain management strategy and step up police efforts to guide people towards recovery using “alternatives to the criminal justice system.”

[email protected]

Twitter.com/JunkerAnna

Advertisement 1

comments

Postmedia is committed to maintaining a lively yet civil discussion forum and encourages all readers to share their views on our articles. Comments can take up to an hour to be moderated before appearing on the site. We ask that you keep your comments relevant and respectful. We have enabled email notifications. You will now receive an email if you receive a reply to your comment, if there is an update to a comment thread you follow, or if a user follows you comments. See our Community Guidelines for more information and details on how to adjust your email settings.

read more
Medical products

Disposable Hemostats Market Statistical Forecast, Trade Analysis 2022 – DaySpring Medical Products, Bard Medical, Alpha Industries, Towne Brothers, Fine Science Tools, Ydm, Hu-Friedy, Ted Pella, Teleflex Medical – Instant Interview

The Latest published a market study on Disposable hemostat Market provides an overview of current market dynamics in the Disposable Hemostat space, as well as what our survey respondents – all outsourcing decision makers – predict the market will look like in 2028. The study divides the market in terms of revenue and volume (if applicable) and price history to estimate size and trend analysis and identify gaps and opportunities. Some of the actors covered by the study are DaySpring Medical Products, Bard Medical, Alpha Industries, Towne Brothers, Fine Science Tools, Ydm, Hu-Friedy, Ted Pella, Teleflex Medical

Prepare to identify the pros and cons of the regulatory framework, local reforms and its impact on the industry. Find out how the leaders in disposable hemostat are staying ahead with our latest survey analysis

Click for Sample PDF Copy of Disposable Hemostat Market Research Here @ https://www.maccuracyreports.com/report-sample/459498

Main highlights of the study as well as the most frequently asked questions:

1) What makes this disposable hemostat review so unique?

Market Factor Analysis: In this economic downturn, the impact on various industries is enormous. Moreover, the increase in the gap between demand and supply resulting from the slow supply chain and production chain has made the market interesting to observe. It also discusses technological, regulatory and economic trends affecting the market. It also explains the key drivers and regional dynamics of the global market and current trends within the industry.

Market concentration: Includes C4 Index, HHI, Disposable Hemostats (YoY) Market Share Benchmarking, Major Companies, Emerging Players with Heatmap Analysis

Market entropy: The randomness of the market highlights the aggressive steps players are taking to overcome the current scenario. Developmental activities and milestones such as expansions, technological advancements, mergers and acquisitions, joint ventures, launches are highlighted here.

Patent Analysis: Comparison of patents issued by each player per year.

Peer review: An assessment of players by financial metrics such as EBITDA, net profit, gross margin, total revenue, segmented market share, assets, etc. to understand the management efficiency, functioning and state of liquidity.

2) Why are only a few companies featured in the report?
Industry standards such as NAICS, ICB, etc. are considered the most important manufacturers. The focus is more on SMEs that are emerging and evolving in the market with their product presence and improved technology modes, the current version includes players such as DaySpring Medical Products, Bard Medical, Alpha Industries, Towne Brothers, Fine Science Tools, Ydm, Hu-Friedy, Ted Pella, Teleflex Medical etc and many more.

**Companies reported may vary due to rebranding/merger etc.

Access full report description, table of contents, table of figures, chart, etc. : https://www.maccuracyreports.com/report-sample/459498

3) What details will the competitive landscape provide?
A chapter on the value proposition to assess the disposable hemostats market. 2-page profiles of all listed companies with 3-5 year financial data to track and compare company overview, product specifications, etc.

4) What did all the regional segmentations cover? Can a specific country of interest be added?
The countries included in the analysis are North America, United States, Canada, Mexico, Europe, Germany, France, United Kingdom, Italy, Russia, countries Nordics, Benelux, Rest of Europe, Asia, China, Japan, South Korea, Southeast Asia, India, Rest of Asia, South America, Brazil, Argentina , Rest of South America, Middle East and Africa, Turkey, Israel, Saudi Arabia, United Arab Emirates and Rest of Middle East and Africa
** Countries of primary interest can be added if missing.

5) Is it possible to limit/adapt the scope of the study to the applications we are interested in?
Yes, the general version of the study is broad, but if you have a limited application in your scope and target, the study can also be customized just for those applications. It now covers Aeronautics, Airports & Other applications.

** Depending on the requirement, delivery time may vary.

To mainly understand the global Disposable Hemostats market dynamics, the global Disposable Hemostats market is analyzed across major regions of the world. Custom study by specific region or country can be provided, usually customer prefer below

  • North America: United States of America (USA), Canada and Mexico.
    • South and Central America: Argentina, Chile, Colombia and Brazil.
    • Middle East and Africa: Kingdom of Saudi Arabia, United Arab Emirates, Turkey, Israel, Egypt and South Africa.
    • Europe: United Kingdom, France, Italy, Germany, Spain, NORDIC countries, BALTIC countries, Russia, Austria and rest of Europe.
    • Asia: India, China, Japan, South Korea, Taiwan, Southeast Asia (Singapore, Thailand, Malaysia, Indonesia, Philippines and Vietnam, etc.) and rest
    • Oceania: Australia and New Zealand

Basic segmentation details
Types of Deep Disposable Hemostats: Disposable straight hemostat, Disposable curved hemostat, other.

Main Applications/End Users of Disposable Hemostat: Hospital, Clinic, Family, Other

Geographical analysis: North America, USA, Canada, Mexico, Europe, Germany, France, UK, Italy, Russia, Nordics, Benelux, Rest of Europe, Asia, China, Japan, South Korea, South Asia – East, India, Rest of Asia, South America, Brazil, Argentina, Rest of South America, Middle East and Africa, Turkey, Israel, Saudi Arabia, United Arab Emirates and Rest of Middle East and Africa and rest of the world

For an in-depth analysis of the Disposable Hemostats market size, a competitive analysis is provided, which includes Revenue (M USD) by Players (2022-2028) and Market Share (%) by Players (2022 -2028) supplemented by the concentration rate.

Full Purchase of 2022 Disposable Hemostat Report at Revised Suggested Price @ https://www.maccuracyreports.com/checkout/459498

Actual figures and in-depth analysis of the Disposable Hemostats market size estimate and trends available in the full version of the report.

Thank you for reading this article, you can also shop by section or opt for a regional report limiting the scope to North America, ANZ, Europe or MENA countries, Eastern Europe. is or the European Union.




read more
Medical supplies

St. Luke’s Community Clinic shares medical supplies with locals and third world countries – Royal Examiner

While the local school district’s new budget isn’t exactly what the Warren County School Board was originally looking for, they voted 5-0 on Wednesday, June 29 to approve it so that Warren County Public Schools Warren (WCPS) can continue to operate without interruption.

During the special school board meeting, School Board Chair Kristen Pence, Vice Chair Ralph Rinaldi, and members Antoinette Funk, Andrea Lo, and Melanie Salins unanimously adopted WCPS’ budget for the fiscal year. 2022-2023, which totals approximately $69 million and includes approximately $53.2. million dollars for its operating fund, nearly $12.4 million for capital improvements and nearly $3.4 million for the cafeteria fund.

The new operating budget is lower than what the school district originally passed and then sought approval from the Warren County Board of Supervisors (BOS), as the BOS voted unanimously on Tuesday, June 28 to fund Temporarily WCPS operations at 75% due to tax concerns. So while WCPS had requested nearly $71 million for its FY23 school operating fund—bringing its total FY23 budget request to nearly $92 million—the school division has so far agreed to adopt the total budget of $69,007,344 for the upcoming school year.

WCPS Superintendent Christopher Ballenger at the June 29 special school board meeting.

That amount, WCPS Superintendent Christopher Ballenger said, is enough to allow the district to continue operations beginning July 1. “If we didn’t have a budget of course on Friday we couldn’t open our doors,” he told the school. Plank. “It at least keeps our doors open.”

As part of the FY23 budget, WCPS employees will receive a 5% salary increase, including an experience step, as well as $1,000 bonuses provided by the State of Virginia. WCPS Chief Financial Officer Robert Ballentine said employees can expect to receive these bonuses by the end of the year.

State bonuses will be in addition to pandemic-related bonuses for WCPS employees. Full-time employees who worked during the 2021-2022 school year — and who return for the upcoming school year — will receive a net bonus of $1,500; this includes recent retirees. Part-time WCPS employees during the 2021-2022 school year will receive $750, while employees hired after December 31, 2021 will be eligible for half the full-time and part-time bonuses.

After some back and forth over the past month between boards, BOS agreed on Tuesday to allow WCPS to transfer $125,000 between school board budget categories to help cover its one-time employee bonuses, which are expected to total approximately 1.7 million dollars and are in the majority. funded by funds remaining from vacancies from the last school year, mid-year turnover, new employees entering on a lower pay scale, etc.

The approved FY23 WCPS operating fund also covers funding for 15.5 new positions, grounds maintenance, student transportation and technology, among other things, according to the supervisor’s budget document.

The school board and BOS plan to continue working together to finalize WCPS’ FY23 budget. Both Pence and Ballenger told the Royal Examiner earlier this week that they remain hopeful of improved communication between their councils.

“I am pleased that we now have the opportunity to talk about this budget in more detail and discuss its impact on the school system so that an informed decision can be made regarding the division’s FY23 budget,” Ballenger wrote. in an email.

“I look forward to the conversations ahead of us between the school board budget subcommittee and the board of supervisors,” Pence wrote.

At the special school board meeting on Wednesday, Funk said members of the board’s budget committee were discussing the budget and options presented at the BOS meeting on Tuesday and hoped to meet with members of the BOS budget subcommittee next week. .

Lo said members of the school board’s budget committee also discussed how to establish better communication between themselves and members of the BOS budget subcommittee “to ensure that our goals are aligned with the goals of the supervisors so that we work together”.

Rinaldi said there should be a timeline developed and adopted to settle the FY23 budget. “I think it’s important to start our plan for the fall,” he added.

Other action
The school board unanimously agreed to ask BOS to increase the WCPS technology category in the FY22 budget operating fund by $140,476. WCPS received a grant from the Federal Communications Commission ( FCC) to install Wi-Fi connectivity on its school buses. To spend the grant money, an additional credit must be received by the BOS. Ballenger said the grant money is for the installation of a Wi-Fi radio system to enable direct communications between buses and schools. “We are getting closer to having [this system] fully implemented for this year,” he added.

Going back, Pence said, the school board at an earlier meeting had voted to approve the purchase and use and to date had not made that additional appropriation.

For this type of grant, WCPS Chief Financial Officer Ballentine explained that WCPS must first spend the money before getting the federal reimbursement, “which is currently in the works,” he said.

Because of that, the county has already advanced, so to speak, the money to pay for it. So that request would essentially be to reimburse the county for local funds that were advanced to pay for the system, and then WCPS will be reimbursed with federal funds, Ballentine said.

In a proactive move, school board members asked Ballentine if they should change the way they make these requests to the BOS. For example, when notified of receiving a grant, should the school board then go to the BOS and explain that the grant is coming, what will be done with the funds, and at that time request a credit increase of that specific amount. The school board would then be able to issue a contract and accept the grant.

“The way I see it, that would be, in an ideal world, the best way to handle this,” Ballentine said. “It’s asking for permission rather than forgiveness.”

Following a motion from Rinaldi asking the BOS to increase the 68,000 Technology category of the school board’s operating budget for the 2021-2022 fiscal year by $140,476, with a second from Funk, the board voted 5 -0 to approve.

Additionally, WCPS Director of Staff Shane Goodwin (above) presented the 2022 staff report to the school board on Wednesday for approval.

Goodwin also updated the school board on the number of vacancies facing WCPS for the upcoming school year. As of June 29, WCPS must fill a total of 39 positions: 29 teachers, eight teaching assistants, and two central office positions (new director of communications and community engagement and an assistant superintendent for instruction).

“We have all worked hard to ensure that we find the best candidates for our students in our classrooms and at each of our facilities,” Goodwin said.

Prior to the vote on the staff report, school board member Salins asked if board members could be present at exit interviews for outgoing WCPS staff. Goodwin said he would like to ask Dr.
Ballenger to work with the band “and we’ll find a way to present that in a format that you would like.”

Salins asked again: “Is there a way for us to take into account the advice of the [Warren County] The supervisory board gave us [during its June 28 meeting] and actually doing physical interviews with departing staff in hopes that we can stop them from leaving and just sort out any issues they might have? »

“The practice that’s in place now goes back quite some time,” Goodwin replied. “I’m sure we have the flexibility to adjust this as you see fit or as needed.

“Of course, I would love to have the opportunity for us to retain people because we wouldn’t have to recruit,” Goodwin said. “We would be happy to look into this as long as it falls within our policy which you have all approved. If necessary, we could create a new one. We would be happy to do this together.

Following a motion from Funk with a second from Salins, the school board voted 5-0 to approve the 2022 staff report, which included four resignations, one retirement and 12 appointments.

To watch the meeting in its entirety, go to: https://wcps.new.swagit.com/videos/176504


read more
Medical products

Essentials of Preparing for Medical Product Inspection

DAVID L. CHESNEY is the Managing Director of DL Chesney Consulting, LLC, providing GMP and GCP compliance consulting and training services to clients worldwide. Previously, he served for more than twenty years as Vice President, Strategic Compliance Services for PAREXEL Consulting. Prior to joining PAREXEL Consulting, he worked for twenty-three years with the FDA as an investigator, supervising investigator, director of investigations, and ultimately district manager in San Francisco, managing all FDA operations in California. North, Nevada and Hawaii. Chesney holds a master’s degree in jurisprudence, focusing on pharmaceutical and medical device law, from Seton Hall University School of Law, a bachelor’s degree in biology from California State University, Northridge, as well as three years of graduate studies in biology at CSU Northridge and CSU San Diego. Chesney is a member of the Parenteral Drug Association, where he serves on the faculty of the PDA Training and Research Institute. He is a guest lecturer for the Maine Regulatory and Ethics Training Center, University of Maine School of Law, and is also active with the Food and Drug Law Institute and RAPS.

read more
Prescription drugs

I was banging my head to get prescription drugs, reveals Ozzy Osbourne

OZZY Osbourne has confessed that his drug addiction was so out of control that he hit his head with planks of wood to get prescriptions.

Wild rocker Oz, now 73, banged his skull so he could stock up on painkillers.

3

Ozzy Osbourne, pictured with his faithful wife Sharon, was beating himself up so he could get painkillersCredit: Getty

And the Black Sabbath star discovered that his tolerance to substances was so high that an anesthetist needed at least twice the amount of sedatives to put him to sleep.

Ozzy also opened up about how he still struggles with addiction issues, recently buying over £600 worth of marijuana for no reason.

Ozzy said: “I used to take a piece of wood and hit myself on the head, so they gave me a bottle of pain pills.”

Ozzy explained that it was “normal” practice during his addiction days and when the interviewer asked him, “Don’t normal people hit their heads with wood?”

Ozzy Osbourne plans to build his own 'rehab wing' at the mansion
Ozzy Osbourne sparks outrage by revealing he kills cats and birds in his backyard

Ozzy, famous for biting off the head of a bat, replied, “Normal people aren’t Ozzy.

“We are fucking clowns.” He admits that the drugs helped him sleep.

“You don’t have to think about falling asleep. You close your eyes and you’re done.” The fucking lies I was telling (to get high).

“Someone once told me that to be a good liar you have to have a good memory and mine is horrible.”

Ozzy also recalled how his tolerance for substances was so high that an anesthetist couldn’t put him to sleep with a full dose.

“I once had surgery a long time ago when I was doing all this shit. The guy who put the stuff on said, ‘How long have you been doing this music?

“And I said so many years…and I kept talking. And he said to me: ‘And why aren’t you sleeping yet?’

“He gave me two full syringes.”

Recover Ozzy says he struggles to stay sober. She was recommended marijuana, which is legal in Los Angeles, for pain relief and sleep issues.

Ozzy discovered that his tolerance for substances was so high that an anesthetist needed at least twice the amount of sedatives to get him to sleep.

3

Ozzy discovered that his tolerance for substances was so high that an anesthetist needed at least twice the amount of sedatives to get him to sleep.Credit: Getty
Ozzy is convinced that he is above his cravings and his addiction

3

Ozzy is convinced that he is above his cravings and his addictionCredit: Getty – Contributor

He admitted, “I recently did a little experiment with marijuana.

“I got it and thought why did I buy this? Four ounces?” “I don’t know. I can’t smoke. I just had COVID so I can’t smoke anyway.

“I just had one of those ‘That would be nice’ thoughts. I agreed. He just said ‘thank you’…$800 later! ‘I’ve never smoked one.’

Ozzy is convinced that he is above his cravings and his addiction.

“What takes me away from that now is that I know myself and I got real with myself.

“One of the main reasons I kissed my family is because I’m not out of my fucking face anymore.”

Speaking on US digital radio Sirius XM, Ozzy said a recent third surgery to fix his back, neck and leg problems would bring him back to the stage.

“I hope and pray that I feel better. Not 100%. Just enough that I can move around better. I hope the world likes the album.

“I hope I can do more concerts.”

He just released new single Patient Number 9 about a man in a mental asylum struggling with mental health.

read more
Generic drugs

PBMs inflate the cost of generic drugs. They must be mastered

JThese are not comfortable days in Washington for pharmacy benefit managers, the highly consolidated group of intermediaries who straddle the drug supply chain. The Federal Trade Commission and Capitol Hill want to know how obscure PBM business practices are impacting pharmaceutical costs. This is good news for just about everyone, including generic drug users.

PBMs administer prescription drug benefits on behalf of health insurers, large employers and other payers. They have become important players behind the scenes in determining patient access to medicines and how much pharmacies are paid.

As health economists, we have documented the anticompetitive practices of pharmaceutical benefit managers related to generic drugs. Using their position as intermediaries between payers, producers and drug dispensers, PBMs often require pharmacies to sign contracts giving them their lowest price, which discourages pharmacies from undercutting the price of PBMs with cash prices, although pharmacies could still make a profit doing so. Complex and opaque business practices allow PBMs to hide their profit margins from outside scrutiny.

advertising

The result is that patients and payers are overcharged on the order of 20% for generic drugs, resulting in billions of dollars in overpayments. And that doesn’t count the overpayment that results when PBMs exclude low-cost generics from formularies – the list of drugs covered by Medicare – if PBMs can collect high enough discounts by putting the branded version on forms instead.

Although generic drugs account for 92% of all prescriptions, they only account for 16% of retail drug spending. This is a huge achievement and the cornerstone of the pharmaceutical patent and innovation system established by Congress in 1984 through the Hatch-Waxman Act. The promise of cheap generics was the explicit “reimbursement” that justified granting patent protection for expensive drugs for a limited time. As such, a market that is manipulated to inflate generic prices could affect both drug affordability and drug innovation by altering the balance between the yields of innovative drugs today and access. at low cost to these innovations when the patents expire.

advertising

Recognizing the stakes, the FTC recently voted unanimously to launch an investigation into the operation of PBMs. The agency also pledged to “step up enforcement” of any “illegal kickbacks and rebate schemes” that prevent patients from accessing cheaper drugs. Meanwhile, a group of Republicans in the U.S. House of Representatives are urging the U.S. Government Accountability Office to investigate PBMs, and legislation introduced weeks ago by the Sense. Maria Cantwell (D-Wash.) and Charles Grassley (R-Iowa) would give the FTC even great authority to regulate the PBM market.

The efforts come as news of a whistleblower lawsuit filed against the largest PBM, CVS Caremark, detailed a scheme involving deals with pharmaceutical companies that allegedly sought to block generic competition for more than one dozen widely prescribed brand name drugs. CVS says the lawsuit is without merit.

There is no doubt that PBMs must be brought under control to protect consumers and keep branded and generic drug markets healthy. The Cantwell/Grassley bill is a good start: It would ban certain anti-competitive practices and increase transparency by requiring PBMs to submit annual reports to the FTC about their sources of revenue and how they treat PBM affiliates differently from independent pharmacies.

But more can and should be done. Possibilities include:

  • Reform rebate contracts
  • Setting PBM fees per transaction rather than calculating them as a share of drug costs
  • Give employers and government purchasers stronger audit rights to understand the actual prices paid by PBMs and insurers to pharmacies
  • Reflect the true full cost to the health system of placing generics on formulary levels

Another option is to reduce barriers to entry into the PBM market to increase competition. The three largest PBMs – CVS Caremark, Express Scripts and OptumRx, operating under the umbrella of major insurers Aetna CVS Health, Cigna and UnitedHealth Group respectively – control 79% of the PBM market.

The FTC should further investigate the impact of consolidation and vertical integration on the PBM market. It should also pay more attention to whether other intermediaries in the drug supply chain – wholesalers, pharmacies and health plans – are acting in the best interests of patients.

Policy makers also need to shed light on the opacity of prices and transactions between participants in the distribution system.

It’s also time to look at a more radical market-based approach to continue saving money for consumers. A transparent and competitive cash market for low-cost generic drugs would allow consumers to decide whether they want to fill their prescriptions using insurance or cash. Cash-only pharmacies, like Blueberry Pharmacy and Mark Cuban’s Cost Plus Drug Company, cut out middlemen like PBMs, but for these approaches to thrive, all pharmacies would need to be protected from PBM’s “lowest price” contracts. – which actively discourage pharmacies from implementing low cash prices – and variation in state-level pharmacy laws may need to be addressed.

Americans pay too much for generic drugs because of a PBM-manipulated payment system. The system needs to be cleaned up now before the biggest success story of US drug pricing – generics – turns into something completely different.

Erin E. Trish is co-director of the USC Schaeffer Center for Health Policy and Economics. Karen Van Nuys is executive director of the Value of Life Sciences Innovation program at the Schaeffer Center. Robert Popovian is director of science policy at the Global Healthy Living Foundation. Trish has served as a consultant and litigation expert on matters affecting the hospital, health insurance, health information technology and life sciences sectors. Van Nuys has consulted for companies in the life sciences sector. Popovian is a consultant and advisor to the biopharmaceutical industry, healthcare coalitions and PBMs, and is the founder of Conquest Advisors, a strategic advisor for biopharmaceutical companies.

read more
Medical products

Pediatric Pulse Oximeter Market Statistical Forecast, Trade Analysis 2022 – Devon Medical Products, Carewell, Acare, Heal Force, Bistos, Medplant, IN4 Technology, Armstrong Medical, Advanced Instrumentations, Holtex, Medical Econet, Tenko Medical Systems, Solaris Medical Technology, Sunset Healthcare Solutions – Indian Defense News

The Pediatric Pulse Oximeters The report is an in-depth examination of the overall global Pediatric Pulse Oximeters consumption structure, development trends, sales techniques, and major nations sales. The research covers well-known vendors in the global Pediatric Pulse Oximeter industry along with market segmentation, competition, and macroeconomic climate. A comprehensive analysis of Pediatric Pulse Oximeters takes into account a number of aspects, including a country’s population and business cycles, as well as market-specific microeconomic consequences. The global market study also includes a specific section on the competition landscape to help you better understand the Pediatric Pulse Oximeter industry. This information can help stakeholders make informed decisions before investing.

Key Players in Pediatric Pulse Oximeters including:

Devon Medical Products, Carewell, Acare, Heal Force, Bistos, Medplant, IN4 Technology, Armstrong Medical, Advanced Instruments, Holtex, Medical Econet, Tenko Medical Systems, Solaris Medical Technology, Sunset Healthcare Solutions

Sample Free Report + All Related Charts & Graphs @ https://www.maccuracyreports.com/report-sample/400582

The report is categorized into several sections which consider competitive environment, latest market events, technological developments, countries and regional details related to Pediatric Pulse Oximeters. The section that details the pandemic impact, recovery strategies and post-pandemic market performance of each player is also included in the report. Major opportunities that may support Pediatric Pulse Oximeters are identified in the report. The report focuses specifically on near-term opportunities and strategies to realize one’s full potential. Crucial uncertainties for market players to understand are included in the Pediatric Pulse Oximeters report.

Due to these issues, the pediatric pulse oximeter industry has been hampered. Due to the small number of significant companies in the industry, the field of pediatric pulse oximeters is heavily targeted. Customers would benefit from this research as they would be informed about the current scenario of pediatric pulse oximeters. The latest innovations, product news, product variants, and in-depth updates from industry specialists who have effectively exploited the position of pediatric pulse oximeters are all included in this research study. Many companies would benefit from a research study of Pediatric Pulse Oximeters to identify and expand their global demand. Micro and macro trends, significant developments, and their usage and penetration among a wide variety of end users are also included in the Pediatric Pulse Oximeters segment.

Market analysis done with statistical tools also helps to analyze many aspects including demand, supply, storage costs, maintenance, profit, sales and production details of the market. In addition, the global Pediatric Pulse Oximeter research report provides details about Pediatric Pulse Oximeter share, import volume, export volume, and company gross margin.

Pediatric Pulse Oximeter Segmentation by Type:

Wrap sensors, clip sensors.

Pediatric Pulse Oximeter Segmentation by Application:

Hospitals, EHPAD, Clinics, Others

The Pediatric Pulse Oximeters report answers a few key questions:

  • What is the expected growth of global pediatric pulse oximeters after the discovery of a vaccine or treatment for covid-19?
    • What new business practices can be implemented post-pandemic to remain competitive, agile, customer-centric, and collaborative in the world of pediatric pulse oximeters?
    • Which specific sectors are expected to drive the growth of the Global Pediatric Pulse Oximeters Market?
    • What are the key government policies and interventions implemented by the world’s leading pediatric pulse oximeter countries to drive the adoption or growth of pediatric pulse oximeters.
    • How have the market players or leading global pediatric pulse oximeter companies dealt with the challenges faced during the pandemic?
    • What growth opportunities do global pediatric pulse oximeters offer?

Access full report description, table of contents, table of figure, chart, etc. @ https://www.maccuracyreports.com/reportdetails/reportview/400582

Report Highlights:

  • The report provides pediatric pulse oximeter industry demand trends in the first and second quarters of 2021.
    • Individual circumstances of pediatric pulse oximeter segments are discussed in the report.
    • The report contains forward-looking information about risks and uncertainties.
    • The report studies the consumer driven sectors of Pediatric Pulse Oximeters.
    • Business scenarios for products and services in particular segments are detailed in the report along with regulations, taxes and tariffs.
    • Trends which are impacting Pediatric Pulse Oximeters in recent years are discussed in the report.
    • The report studies the potential impact of the Covid-19 pandemic on the Pediatric Pulse Oximeters sector economy and the performance of market players in the same context.

Contents:

1 Scope of the report
1.1 Market Overview
1.2 Research objectives
1.3 Years considered
1.4 Market research methodology
1.5 Economic indicators
1.6 Currency considered
2 Executive summary
3 Global Pediatric Pulse Oximeters by Players
4 Pediatric Pulse Oximeters by Regions
4.1 Pediatric Pulse Oximeter Size by Regions
4.2 Americas Pulse Oximeter Size Growth
4.3 APAC Pediatric Pulse Oximeter Size Growth
4.4 Europe Pediatric Pulse Oximeter Size Growth
4.5 Middle East & Africa Pediatric Pulse Oximeter Size Growth
5 Americas
6 APACs
7Europe
8 Middle East and Africa
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market trends
10 Global Pediatric Pulse Oximeter Predictions
Analysis of the 11 key players
12 Research findings and conclusion

Please click here today to purchase the full report @ https://www.maccuracyreports.com/checkout/400582

MR Accuracy Reports is the world’s largest publisher and has published over 2 million reports worldwide. Fortune 500 companies work with us. Also help small players to know the market and focus on advice.




read more
Medical supplies

Cardinal Health launches Zipline drone delivery for drugs and medical supplies

Zipline’s fixed-wing drones deliver medical supplies to North Carolina. [Image courtesy of Zipline]

Cardinal Health (NYSE:CAH) today began aerial delivery of pharmaceuticals and medical supplies via a Zipline drone in North Carolina.

Zipline based in San Francisco earned FAA Part 135 air carrier certification for long-haul flights earlier this month. The company made its first commercial deliveries on June 22 with a maiden flight of 16 nautical miles.

Flights starting today depart from Zipline’s hub in Kannapolis, North Carolina, on behalf of Cardinal Health as well as Novant Health and Magellan Rx Management.

Zipline said the hub can serve customers in a 7,800 square mile area in as little as 15 minutes, with emissions 98% lower than traditional delivery options.

“We envision a future in which goods move almost instantaneously,” said Zipline Founder and CEO Keller Rinaudo. Press release. “With Novant Health, Magellan Rx Management and Cardinal Health, we are making this a reality. In the process, we are setting the bar for care and convenience with instant logistics.”

Cardinal Health flights to Cannon Pharmacy Main are intended to make it easier for patients to get the products they need.

“We are committed to working diligently to help ensure that our healthcare provider customers have access to the right medicine at the right time for their patients, and an effective distribution strategy is required to achieve this,” said Josh Dolan, Senior Vice President of Pharmaceutical Operations at Cardinal Health. in the press release. “Through our work with Zipline, we are able to expand our world-class distribution services with innovative delivery methods that will help our customers meet the changing needs of their patients – now and in the future.”

Cardinal Health (Dublin, Ohio) is the eighth largest medical technology company in the world, according to Medical design and outsourcingof the latest Big 100 ranking by revenue.

Zipline flights make Phoenix-based Magellan Rx Management the only national pharmacy benefits manager to deliver prescription drugs directly to patients at home using drones.

At Novant Health, Zipline will deliver specialty medications to patients in the healthcare network. Novant and Zipline, based in Winston-Salem, North Carolina, have launched the first emergency logistics drone operation for the pandemic response in 2020 with contactless deliveries of essential medical supplies and personal protective equipment .

The zip line is also delivering health and wellness products to Walmart customers in Northwest Arkansas.

read more
Generic drugs

Generic Drugs Undergo Rigorous FDA Review

Image

Perhaps you have already had this experience: you go to fill a prescription and the pharmacist mentions that there is a generic available. You’ve noticed that generic drugs often cost less and wonder: how can I be sure they’re as safe and effective as brand name drugs?

By applying the rigorous standards established by law, the United States Food and Drug Administration ensures that generic drugs are as safe and effective as the brand name drugs they copy. Today, approximately 9 out of 10 prescriptions filled in the United States are for generic drugs.

Generics are as safe and effective as their branded counterparts

Imagine a copy of something that should work just as well as the original. It is a generic drug.

Generic drugs are formulated to work like their brand name counterparts. An FDA-approved generic drug must:

  • Have the same active ingredients as the brand name drug. The active ingredients make the drug effective for a particular disease or condition. For example, atorvastatin calcium is the active ingredient in Lipitor cholesterol treatment.
  • Have the same strength, dosage form, route of administration, and conditions of use as its brand name counterpart. If the brand name drug is a capsule and is taken orally, for example, the generic drug must also be a capsule taken orally.
  • Treating the same illnesses or conditions.

Generic drugs must also be “bioequivalent” to their brand name counterpart. This means that the generic drug reaches the part of the body where it works at the same time and in the same amount as the brand name drug.

Just like brand name drugs, generic drugs must meet the same high standards of quality and manufacturing. These and other requirements allow the FDA to ensure that when patients take a generic drug, it is an appropriate substitute for its brand name counterpart.

Generic drugs may look different

Intellectual property sometimes prevents generic drugs from looking exactly like their brand name counterparts.

Although a generic and its brand name counterpart must share the same active ingredient(s), some formulation differences between a generic and its brand name counterpart may be permitted. For example, some generic drugs are not required to have the same inactive ingredients, such as colors and flavors, as their brand name counterparts. (An inactive ingredient is any component of a drug product other than the active ingredient.)

This can lead to certain differences in taste and appearance, for example. The FDA considers all of these differences before determining whether to approve a generic drug.

Generic drugs could cost less

Generic drug makers generally don’t have to repeat the extensive clinical studies that backed the approval of a brand name drug. Instead, generic drugs must meet the requirements outlined above. Generally, generic drug manufacturers do not pay for advertising, marketing or promotion. These are some of the reasons why generic drugs are often less expensive.

How to know if a generic drug is available

Not all drugs have currently approved generics. To find out if there is a generic version of your brand name medication available:

  • Ask your pharmacist.
  • Use the [email protected] database.
  • Search for generic drugs using the FDA’s online Orange Book.
  • View the most recent monthly approvals for First Generics.

If you have a question about a drug, you can call the FDA. The FDA’s Division of Drug Information (DDI) is ready to answer your drug-related questions to help keep you and your family safe. DDI pharmacists are available by email, [email protected], and by phone, 1-855-543-DRUG (3784) and 301-796-3400.

read more
Prescription drugs

PROBE AND ACT ON PRESCRIPTION DRUGS ABUSE

By The Citizen Reporter

It has been noted with dismay in recent years that an increasing number of people are abusing prescription drugs in the country. This, it goes without saying, should be cause for grave concern.

The Ministry of Health and government drug supply chain departments should act urgently to reverse this trend before it spirals out of control.

The list of prescription drugs that authorities have issued a red flag on includes valium, pethidine, morphine powder, ketamine and tramadol. Globally, these are some of the leading names in prescription drug abuse right now.

Today, in many parts of the world, the abuse of prescription drugs is leading to the death of an increasing number of people. In our country, there was an alert in 2018 following a crackdown on drug addiction in general. A good starting point is that the government has recognized the problem.

It turns out that Tanzania has not been immune to the global rapid response syndrome which has seen many young people, including students, and some stressed professionals resort to the abuse of prescription drugs as a quick fix. ultimate. It is not easy to obtain prescription drugs without the help of medical staff at hospital pharmacies.

Drug addiction is already a serious problem in Tanzania. Official reports show that Tanzania struggles with between 250,000 and 500,000 people who abuse heroin. The government could take several steps to address this growing problem.

Advertising

The first step will obviously be to tighten the drug supply and investigate those suspected of abusing and/or negligently using their position in medical facilities to hand over prescription drugs to the wrong patients.

It is also necessary to put in place stricter regulations on the distribution of these drugs.

Finally, the Department of Health should conduct awareness campaigns to dispel misconceptions that there is no serious danger in abusing prescription drugs.

ELDERS DESERVE RESPECT

It is time for us in Tanzania to ask what we have done and are doing to protect vulnerable older people and prevent their abuse. Questions have sometimes been raised about our commitment to preventing and responding to elder abuse.

The frequent killings of red-eyed elderly women in some parts of the country are perhaps the most damning evidence of brutality against elders in Tanzania. These women are brutally killed, especially in Mwanza, Shinyanga and Tabora areas, suspected of being witches, which of course is ridiculous.

Do older people get the respect they deserve in hospitals, public offices or on public transport? It’s a relevant question because it’s not uncommon to see nurses and other healthcare workers insulting old people of grandparenting age.

On public transport, it is now the norm for young people to remain glued to their seats even when they see elderly people standing there, unable to maintain their balance, thanks to the reckless driving synonymous with daladalas.

read more
Medical supplies

Mining Company Donates 190 Offices, Medical Supplies, Education, Health Sectors

Speaking shortly after receiving the donation, Sengerema District Administrative Secretary Allan Augustine expressed his gratitude for the company’s continued contribution to the community in the district, noting that such efforts make SMCL a exemplary corporate citizen.

“We are happy to be here today to receive these items from SMCL. Through their many Corporate Social Responsibility (CSR) projects over the years, developed in close collaboration with Sengerema District, Sotta has proven to be an exemplary corporate citizen,” said Augustine.

The handover ceremony was attended by senior officials from Sengerema district as well as SMCL board members, including two government-appointed directors, Prof. Raphael Chibunda, Dr. Joas Kabete and Leonard Mususa.

SMCL Managing Director and Director Damien Valente said, “Today marks our third CSR handover event of the year, and we are extremely grateful to the Sengerema District for their participation. We are also pleased that today’s CSR handover ceremony coincided with a visit to Nyanzaga by SMCL directors.

SMCL has shown a strong commitment to schools in its local community, having already built three new classrooms at Ngoma Secondary School and having already funded the construction of toilets at the school.

In April 2022, SMCL completed the handover of six toilets at Chikomero Island Primary School in Sengerema District.

Sotta also supported the district health system with its awareness campaign and vaccination campaign against COVID-19.

SMCL is a joint venture between the Government of Tanzania (16%) and Nyanzaga Mining Company Limited (84%), a subsidiary of OreCorp Tanzania Limited, to develop the $670 billion South Ngoma Project in Sengerema District , following the granting of a Special Mining Title on December 13, 2021.

The project is now on track to be the first large-scale gold mine to be built in Tanzania in over a decade and the first-ever large-scale mine in Sengerema district.

read more
Prescription drugs

Prescription Drug Consumption Market Size, Share and Forecast to 2028 | Pfizer, Roche, Sanofi, Johnson & Johnson, Merck & Co. (MSD) – Designer Women

The Global”Prescription Drug Consumption Market » The report provides an in-depth analysis of emerging trends, market drivers, development opportunities and market restraints that may impact the market dynamics of the industry. Each market sector is examined in-depth in Market Research Intellect, including products, applications, and competitive analysis.

The report was created using three different recognition systems. The first step requires conducting in-depth primary and secondary research on a wide range of topics. Approvals, ratings and findings based on accurate data obtained by industry specialists are the next steps. The research derives an overall estimate of the market size using top-down methodologies. Finally, the research assesses the market for a number of sections and sub-sections using information triangulation and market separation techniques.

The main purpose of the report is to educate business owners and help them make a wise investment in the market. The study highlights regional and sub-regional perspectives with corresponding factual and statistical analysis. The report includes the latest first-hand data, obtained from the company’s website, annual reports, industry-recommended journals, and paid resources. The Prescription Drug Consumption report will help business owners understand the current market trend and make profitable decisions.

Profiled Market Leaders:

  • Pfizer
  • rock
  • Sanofi
  • Johnson & Johnson
  • Merck & Co. (MSD)
  • Novartis
  • AbbVie
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • Amgen
  • Astra Zeneca
  • Bristol Myers Squibb
  • Eli Lily
  • Suits you
  • Bayer
  • Novo Nordisk
  • Allergan
  • County
  • Boehringer Ingelheim
  • Takeda

Report Analysis and Segments:

Prescription drug consumption is segmented by product type, application and geography. All segments of the prescription drug consumption are carefully analyzed based on their market share, CAGR, value and volume growth, and other important factors. We have also provided Porter’s and PESTLE’s five forces analysis for further study of prescription drug use. The report also outlines recent developments undertaken by major market players, including new product launches, partnerships, mergers, acquisitions, and other latest developments.

Based on Product Type, prescription drug consumption is segmented into –

On the basis of application, consumption of prescription drugs is segmented into –

The report provides information about the following pointers:

1️⃣ Market Penetration: Complete information on the product portfolios of major players in the prescription drug industry.

2️⃣ Product Development/Innovation: Detailed information on upcoming technologies, R&D activities and product launches in the market.

3️⃣ Competitive Assessment: In-depth assessment of market strategies and geographic and business segments of major market players.

4️⃣ Market development: comprehensive information on emerging markets. This report analyzes the market for various segments across geographies.

5️⃣ Market Diversification: Comprehensive information on new products, untapped geographies, recent developments and investments in prescription drug consumption.

Schedule a consultation call with our analysts/industry experts to find a solution for your business @ https://www.marketresearchintellect.com/ask-for-discount/?rid=419994

Various analyzes covered:

A regional assessment of prescription drug consumption was carried out in six key regions, namely North America, Asia-Pacific, Europe, Latin America, and the Middle East and Africa. Moreover, the report also provides in-depth information about ongoing research and development activities, revenue, innovative services, real demand and supply status, and pricing strategy. In addition to that, this report also provides details on consumption figures, export/import supply and gross margin by region. In short, this report provides a valuable source of advice and clear direction for the trader and the party interested in the market.

North America (US, Canada)
Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
Latin America (Brazil, Mexico, Others)
The Middle East and Africa

Frequently Asked Questions:

  • What are the main drivers of global prescription drug consumption?
  • What are the major challenges in the global consumption of prescription drugs?
  • Who are the key market players?
  • What has been the effect of the COVID-19 pandemic on global prescription drug consumption?
  • What are the latest market trends?
  • What is the compound annual growth rate of global prescription drug consumption?

About Us: Market Research Intellect

Market Research Intellect provides syndicated and customized research reports to clients across various industries and organizations with the aim of providing functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing & Construction, Chemicals & Materials, Food & Beverage, and more. These reports provide an in-depth study of the market with industry analysis, market value of regions and countries, and industry-relevant trends.

Contact us:
Mr. Steven Fernandes
Market research intelligence
New Jersey (USA)
Tel: +1-650-781-4080

Email: [email protected]

Website: –https://www.marketresearchintellect.com/

read more
Prescription drugs

Top 20 most expensive prescription drugs in 2022

If you thought inflation was high, wait until you hear about rising specialty drug prices. A recent AARP report indicates that they are increasing at more than three times the rate of inflation. To see how you’ll be affected, we’ve put together this list of the 20 most expensive prescription drugs in 2022.

Rising drug costs are heartbreaking because prescription drugs were already expensive. Luckily, we’ve found a way to save up to 80% on your prescriptions. Tap or click here to see Kim’s favorite way to save money at the drugstore.

Depending on the medications you need, your prescriptions could cost thousands of dollars, reports AARP. Review the list below to see if any of your medications are listed. If so, brace yourself for tough financial times ahead.

These are the 20 most expensive prescription drugs in 2022

Worried about needing to buy the most expensive drug in the United States? It’s an understandable fear. When you hear about inflation impacting prescription costs, you can start Googling “List of Expensive Drugs,” “Highest Prescription Drugs,” or “Expensive Prescription Drugs in the U.S. ” to see if you have any problems.

Don’t waste hours researching. Use this helpful tip as a starting point. After all, we always have what you need here at Komando HQ. We also tell you which critical mistakes you should avoid, like these 10 worst ways to save money.

Scroll down to see the most expensive common prescription drugs in the US

Thanks to our sponsor GoodRx for the data. (More on that later.)

Drug name Maker What it treats Monthly cost (based on duration of treatment)
Zokinvy Eiger BioPharmaceuticals Hutchinson-Gilford syndrome progeria, which causes premature aging $89,480
Myalept Amryt Pharmaceuticals, Inc. Leptin deficiency in people with generalized lipodystrophy $77,496
Mavenclad EMD Serono, Inc. Multiple sclerosis $63,993
Ravicti Therapeutic Horizon Urea cycle disorders $57,998
Actimmun Therapeutic Horizon Osteopetrosis and chronic granulomatous disease $55,310
Oxervate Domped Neurotrophic keratitis, which makes the corneas less sensitive $50,874
Takhzyro Takeda Angioedema, a condition that causes swelling under the skin $48,233
juxtapid Amryt Pharmaceuticals, Inc. Homozygous familial hypercholesterolemia, which can lead to heart disease $47,897
Gatex Takeda Short bowel syndrome $42,913
Chenodal Travere Therapeutic Gallstones $42,570
Acthar Gel Mallinckrodt Pharmaceuticals Lupus, rheumatoid arthritis, multiple sclerosis, infantile spasms, eye conditions and psoriatic arthritis $41,459
Orladeyo BioCryst Pharmaceuticals Hereditary angioedema $38,427
Tegsedi Akcea Therapeutic Nerve damage caused by hereditary transthyretin amyloidosis $36,707
Ayvakit Medication Master Plan Gastrointestinal stromal tumors $35,213
Qinlock Decipher Pharmaceuticals, LLC Tumors of the gastrointestinal tract $35,199
Korlym Therapeutic Corcept High levels of cortisol in the body $34,620
Vitrakvi Bayer Pharmaceuticals Cancerous tumors with abnormally fused genes $33,784
Recorlev Xeris Pharmaceuticals, Inc. Endogenous Cushing’s syndrome (decreases the amount of cortisol in the body) $32,400
cortrophin gel ANI Pharmaceuticals, Inc. Rheumatic disorders, collagen diseases and dermatological diseases $31,851
Tibsovo Servier Pharmaceutical Acute myeloid leukemia, blood and bone marrow cancer $30,083
Data from GoodRx, our sponsor.

Have you seen any familiar names on that US drug price list? Unfortunately, you need one of the most expensive prescription drugs.

All hope is not lost

You can still save money on the most expensive popular generic drugs. You can talk to your doctor about sample packs, check out mail-order pharmacies, or research government assistance programs. Tap or click here for five ways to save money on your prescription (or get it for free).

Never think you are alone. There are free ways to save money on lifesaving drugs. We haven’t even figured out the best way to save money on prescription drugs. There’s also a free database you can use to find discounts. (Kim love this!)

Save money on the most expensive prescription drugs in the US

So you’ve just looked at our list of the most expensive prescription drugs. You’re starting to feel nervous since you saw your prescription on it. Take a deep breath and get ready for a silver lining.

Use GoodRx to get your medications at the best price. To find deep discounts, search for your drugs in its search bar and see what prices you can find at nearby pharmacies. You don’t need to register or share any personal information: This is a free tool that compiles the various prescription prices you can find in pharmacies across America.

Use this link to let GoodRx know that Kim sent you there. No matter how much inflation makes your prescription prices skyrocket, you have a safe place to land. GoodRx offers deep discounts on expensive prescription drugs, so you can have peace of mind when shopping.

read more
Medical supplies

Local Ukrainian group sends medical supplies to Ukraine

A group of local Ukrainians who have called the Bay Area their home for a few years now, are doing all they can to help hospitals in their country which are seeing an overflow of patients due to the current Russian invasion.


What do you want to know

  • Local Ukrainians work together to help those in their home country
  • The group is largely made up of healthcare workers
  • They hope to have a positive impact on the lives of those still living in Ukraine

Sergeiy Kushchayev heals people for a living.

“I’m a neuroradiologist at Moffit Cancer Center,” he said. “I was a neurosurgeon in Ukraine for 10 years.”

He immigrated to the Bay Area with his family over ten years ago. After seeing events unfold in his country, he felt he had to do something.

“A few days after Putin’s invasion of Ukraine,” he said, “we got together and created a group of volunteers to help our country.”

The group is mainly made up of healthcare workers and is made up of Ukrainians who did not know each other just a few months ago.

Andriy Marusyk is one of the band members.

“A very interesting kind of story,” he said. “Once the active phase of the war began, Ukrainians started talking to each other to figure out how we could help.”

Collectively, they have contacted hospitals across the country to find surgical items they can ship.

“Anything to do with bone fractures and wound repair,” Marusyk told Bay News 9.

It’s a process they take very seriously.

The group is committed to communicating with doctors in Ukraine to find out what they need and to ensure they receive shipments. Kushchayev said what he is most grateful for is the support he has found here to help those in his beloved country.

“Everyone is trying to do their best for our country and now we are just one family,” he said. “We have created something valuable for our Ukrainian people and people who are hurting right now, so it’s so happy to have the opportunity to help.”

A war halfway around the world continues to bring strangers together across the Bay Area.

With manufacturing of jabil offering free shipping, this group has been able to send two shipments of medical devices so far, they plan to ship as many supplies as possible for as long as the country faces need.

To support the group and find out how you can help, just click here.

read more
Prescription drugs

Nearly half of world’s rivers poisoned by over-the-counter and prescription drugs: study

Nearly half of the world’s rivers are poisoned by over-the-counter and prescription drugs, according to new research.

They range from antibiotics, antidepressants and painkillers to oral contraceptives, hay fever pills and tranquilizers.

The River Clyde in Scotland is the most polluted in the UK from a pharmaceutical point of view, with carbamazepine, an epilepsy drug, being the most common in almost 70% of UK rivers.

New research has found that nearly half of the world’s rivers are poisoned by over-the-counter and prescription drugs. In this photo, oxycodone painkillers prescribed to a chronic pain patient are displayed on March 23, 2016 in Norwich, Connecticut.
John Moore/Getty Images

Of 54 sampling sites in the UK, drugs were detected in 50, with only four in the remote Snowdonia region of Wales being clean.

These levels are potentially toxic to humans. Fish and other wildlife are also under threat, endangering ecosystems. Drugs that target hormones, for example, have induced sexual changes in marine animals.

The study found that more than 43% of sites had “concerning” amounts of active pharmaceutical ingredients (APIs), including 23 that exceeded those considered “safe”.

It was based on 1,052 locations in 104 countries around the world, the largest analysis of its kind.

Corresponding author Alejandra Bouzas-Monroy, Ph.D. student at the University of York, said, “This is the first truly global assessment of the impacts of single pharmaceuticals and pharmaceutical mixtures in river systems.

“Our results show that a very high proportion of rivers worldwide are threatened by pharmaceutical pollution.

“We should therefore do much more to reduce the emissions of these substances into the environment.”

They are released into the environment during production, use and disposal. They are more likely to be found in surface waters such as streams, rivers, lakes, reservoirs and wetlands.

The findings indicate that contamination is a global problem damaging rivers from the Thames to the Amazon.

Bouzas-Monroy said: “More than 1,900 APIs are used to treat and prevent disease in humans. It is inevitable that these substances will be emitted into the natural environment.

“There is growing concern that exposure to these APIs may negatively affect ecosystem health because they are designed to interact with receptors and biochemical pathways in humans.

“Many are retained in non-target organisms and have the potential to cause toxicological side effects.”

River Clyde in Scotland
The River Clyde (pictured) in Scotland is the most pharmaceutically polluted in the UK, with the epilepsy drug carbamazepine being the most prevalent in nearly 70% of UK rivers, new research has found.
Alistair McIntyre/Pixabay

Studies on the lake have shown that “the pill” and other synthetic estrogens cause hormonal disruption.

Diclofenac, a popular painkiller, has caused a noticeable decline in vulture populations on the Indian subcontinent, leading to potential impacts on human health.

Antidepressants have been shown to affect the behavior of fish, which could disrupt the food chain making them more vulnerable to predators.

It is feared that the presence of antimicrobial compounds in the environment could contribute to the selection of drug-resistant bacteria, fueling the emergence of deadly superbugs.

Bouzas-Monroy said: “The lack of global API monitoring data means that for many parts of the world we have no idea of ​​the level of potential impacts.

“Therefore, we used a unique dataset of concentrations of 61 high-use APIs in rivers from 104 countries to perform the first truly global holistic assessment of their potential ecotoxicological effects.”

The British team discovered that pharmaceutical pollution contaminates water on all continents. In North America, sulfamethoxazole and caffeine had the highest concentrations.

A total of 54 sampling sites were selected in the UK. Drugs were detected in all – except four in the remote Snowdonia region of Wales. The most contaminated was the River Clyde in Glasgow.

The most frequently detected drug in UK waterways was carbamazepine prescribed for epilepsy, found at 69% of sites.

Co-author John Wilkinson, also from the University of York, said: “There are 19.5 million people living in the cities where we have done monitoring work in the UK – London, Leeds, York, Glasgow, North Wales and Belfast. That’s almost a third of the population.”

polluted rivers of the world
World (A) and European (B) map showing the average hazard quotients (RQ) of the mixtures for each sampling campaign in the study by Wilkinson et al. (2022) Global Monitoring Project. Blue = HQ between 0 and 0.1, green = HQ between 0.1 and 1, orange = HQ between 1 and 5, yellow = HQ between 5 and 10, and red = HQ > 10. The campaigns in Iceland and Venezuela did not detect any compounds.
SETAC

The availability of API ecotoxicity data has increased significantly in recent years as the pharmaceutical industry becomes more transparent.

Bouzas-Monroy said: “Twenty-three APIs had concentrations for at least one sampling location above concentrations where an effect on organisms might be expected.

“Ten of those identified, including molecules used to treat depression, bacterial infections, epilepsy and anxiety, as well as hormone treatments and stimulants, were found to be at levels of ecotoxicological concern.”

Characterizing the 61 APIs may just be “the tip of the iceberg” as there are almost 2,000 in circulation, according to the study. Actual impacts on aquatic systems are expected to be higher.

Bouzas-Monroy said: “The rivers that have been monitored will not only contain APIs but also other pollutants such as industrial chemicals, pesticides and metals.”

She added: “We present for the first time a comprehensive assessment of the potential ecotoxicological impacts of APIs on aquatic ecosystems.

“We demonstrate that approximately 43.5% of river locations globally have concentrations where ecotoxicological effects might be expected, with some locations expected to experience effects across multiple trophic levels and endpoints.

“If we are to achieve the 17 UN Sustainable Development Goals, especially Goal 6, ‘Clean Water and Sanitation’, we must urgently address the global problem of pharmaceutical pollution.”

The regions of the world most affected are those that have been the least analysed: sub-Saharan Africa, South America and parts of South Asia.

Less than a quarter of wastewater is treated – and the technology is unable to filter most pharmaceuticals.

It is hoped that increased monitoring will lead to strategies that limit the effects.

A cutting-edge scan in York identified propranolol, a beta-blocker for heart disease, and loratadine which is taken for allergies. Others included the common antibiotics sulfamethoxazole and ciprofloxacin for bacterial infections.

They can disrupt the reproductive abilities of organisms, alter behavior or physiology – and even alter heart rhythm.

The amount of drugs seeping into waterways will increase by two-thirds before 2050, endangering freshwater ecosystems.

The study was published Wednesday in Environmental toxicology and chemistry.

This story was provided to Newsweek by Zenger News.

read more
Medical products

Personal Mobility Devices Market Size, Scope and Forecast

New Jersey, United States – The personal mobility device market The research report examines the market in detail over the predicted period. The research is divided into sections, each of which includes analysis of market trends and changes. Drivers, limitations, opportunities, and barriers, as well as the impact of numerous aspects on the industry, are all variables of market dynamics.

The report provides participants with essential information as well as specific recommendations for gaining a competitive advantage in the global business world. It studies how different players compete in the global market and shows how they compete differently. The market size for the Personal Mobility Devices market is calculated using a projected period included in the research study. Current market status and trends, along with business growth drivers, industry share, sales volume, interesting BI dashboards, and market forces are all explored.

Get Sample Full PDF Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.verifiedmarketresearch.com/download-sample/?rid=37564

Key Players Mentioned in the Personal Mobility Devices Market Research Report:

NOVA Medical Products, Performance Health, Drive DeVilbiss Healthcare, Medline Industries Invacare Corporation, Carex Health Brands Kaye Products Rollz International, GF HEALTH PRODUCTS and Briggs Healthcare

Our analysts have performed a qualitative and quantitative analysis of the microeconomic and macroeconomic components of the Personal Mobility Devices market. This study will also help to understand changes in Personal Mobility Devices market industrial supply chain, manufacturing processes and costs, sales scenarios and market dynamics.

This analysis highlights significant mergers and acquisitions, business expansion, differences in goods or services, market structure, competitive conditions in the Personal Mobility Devices market and market size by participant.

Personal Mobility Devices Market Segmentation:

Personal Mobility Devices Market, By Product

• Wheel chairs
• Scooters
• Walking aids

Inquire for a discount on this Premium Report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=37564

Scope of the Personal Mobility Devices Market Report

ATTRIBUTES DETAILS
ESTIMATED YEAR 2022
YEAR OF REFERENCE 2021
FORECAST YEAR 2029
HISTORICAL YEAR 2020
UNITY Value (million USD/billion)
SECTORS COVERED Types, applications, end users, and more.
REPORT COVER Revenue Forecast, Business Ranking, Competitive Landscape, Growth Factors and Trends
BY REGION North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
CUSTOMIZATION SCOPE Free report customization (equivalent to up to 4 analyst business days) with purchase. Added or changed country, region and segment scope.

Answers to key questions in the report:

1. Who are the top five players in the personal mobility device market?

2. How will the personal mobility device market evolve in the next five years?

3. Which products and applications will capture the lion’s share of the personal mobility device market?

4. What are the drivers and restraints of the Personal Mobility Devices Market?

5. Which regional market will show the strongest growth?

6. What will be the CAGR and size of the Personal Mobility Devices market throughout the forecast period?

For more information or query or customization before buying, visit @ https://www.verifiedmarketresearch.com/product/personal-mobility-devices-market/

Visualize the Personal Mobility Devices Market Using Verified Market Intelligence:-

Verified Market Intelligence is our BI platform for market narrative storytelling. VMI offers in-depth forecast trends and accurate insights on over 20,000 emerging and niche markets, helping you make critical revenue-impacting decisions for a bright future.

VMI provides a global overview and competitive landscape with respect to region, country and segment, as well as key players in your market. Present your market report and findings with an integrated presentation feature that saves you over 70% of your time and resources for presentations to investors, sales and marketing, R&D and development of products. VMI enables data delivery in Excel and interactive PDF formats with over 15+ key market indicators for your market.

Visualize the Personal Mobility Devices Market using [email protected] https://www.verifiedmarketresearch.com/vmintelligence/

About Us: Verified Market Research®

Verified Market Research® is a leading global research and advisory firm that for over 10 years has provided advanced analytical research solutions, personalized advice and in-depth data analysis to individuals and businesses seeking accurate research, reliable and up to date. data and technical advice. We provide insight into strategic and growth analytics, the data needed to achieve business goals, and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecasts, capitalize on future opportunities, and maximize efficiency by working as a partner to deliver accurate and valuable insights. The industries we cover span a wide spectrum, including technology, chemicals, manufacturing, energy, food and beverage, automotive, robotics, packaging, construction, mining and the gas. Etc.

At Verified Market Research, we help in understanding holistic market indicator factors and most current and future market trends. Our analysts, with their deep expertise in data collection and governance, use industry techniques to gather and review data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject matter expertise and years of collective experience to produce informative and accurate research.

Having served over 5000 clients, we have provided reliable market research services to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the world’s leading consulting firms such as McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for companies around the world.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research®

USA: +1 (650)-781-4080
UK: +44 (753)-715-0008
APAC: +61 (488)-85-9400
US toll free: +1 (800)-782-1768

E-mail: [email protected]

Website:- https://www.verifiedmarketresearch.com/

read more
Medical supplies

Naperville groups join forces to send medical supplies to Ukraine

NAPERVILLE, IL – Five Naperville-area organizations have joined together to help raise funds to send medical supplies to Ukraine.

The Naperville Sister Cities Commission worked with the city’s Chamber of Commerce, Edward-Elmhurst Health, KidsMatter and Marquette Companies to provide medical supplies to refugees fleeing parts of Ukraine. Now they are focused on delivering these supplies to military hospitals in Ukraine’s capital, Kyiv.

“Members of the Naperville Sister Cities Commission watched the ongoing military invasion of Ukraine with the same shock and helplessness as many in Naperville and around the world,” said Patty Gustin, Naperville City Councilwoman and Representative of the Commission, in a press release.

Gustin added: “As this ongoing humanitarian crisis evolves, we know one thing will remain in the days and week ahead.[s]. The Ukrainians need our help.”

Sister Cities Commissioner Peter Foyo, who is an honorary adviser to Ukraine, said in a press release: “We have already started sending materials, but every day we receive requests for additional help. Every little bit helps us secure what we desperately need. . Please give all you can.

Funds donated to the effort will help provide bandages, gloves, gowns, ultrasound equipment, scalpels, defibrillators and other items that will be used to help treat injured soldiers. Click on the link to donate to help Ukraine.

read more
Prescription drugs

Nearly HALF of the world’s rivers contain dangerous levels of prescription drugs

When you think of river pollution, visions of plastic bottles and packaging are likely to come to mind.

But a new study has warned that almost half of the world’s rivers are also full of prescription drugs.

York University researchers found unsafe levels of drugs, including antidepressants, antihistamines and painkillers, at 43.5% of 1,052 sites tested in 104 countries.

“Our results show that a very high proportion of rivers worldwide are threatened by pharmaceutical pollution,” said study co-author Alejandra Bouzas-Monroy.

“We should therefore do much more to reduce the emissions of these substances into the environment.”

Nearly half of the world’s rivers are full of over-the-counter and prescription drugs, a new study has warned. Pictured: a river in Nairobi

York University researchers found unsafe levels of drugs, including antidepressants, antihistamines and painkillers, at 43.5% of 1,052 sites tested in 104 countries.

York University researchers found unsafe levels of drugs, including antidepressants, antihistamines and painkillers, at 43.5% of 1,052 sites tested in 104 countries.

Which countries have the world levels?

The sites with the highest levels were located in Africa – with a river in Nairobi having the highest levels of all the sites, the researchers said.

“The locations with the highest mixing HQs were located in Africa and were primarily associated with three sampling campaigns (Lagos in Nigeria, Nairobi in Kenya and Bukavu in the Democratic Republic of Congo) where garbage disposal, points of sewage discharge, dumping of sewage raw materials by vacuum trucks, and pharmaceutical manufacturing activities were observed,” the researchers wrote.

In Asia the highest levels were in Lahore, in South America in La Paz and in Europe in Tubingen.

More than 100,000 tons of pharmaceuticals are consumed worldwide each year, according to the European Environmental Bureau (EEB).

During their production, use and disposal, pharmaceutical drugs are released into rivers, where they can have adverse effects on organisms, including fish and aquatic plants.

In the study, the team set out to understand the extent of this pharmaceutical pollution in the world.

“This is the first truly global assessment of the impacts of single pharmaceuticals and mixtures of pharmaceuticals in river systems,” Ms. Bouzas-Monroy said.

The team took water samples from 1,052 sites in 104 countries, including the UK, Australia, France and the US.

The results revealed that 43.5% of sites had “concerning” levels of 23 active pharmaceutical ingredients (APIs).

This included substances from antidepressants, antimicrobials, antihistamines, benzodiazepines and painkillers.

The sites with the highest levels were located in Africa – with a river in Nairobi having the highest levels of all the sites, the researchers said.

“The locations with the highest mixing HQs were located in Africa and were primarily associated with three sampling campaigns (Lagos in Nigeria, Nairobi in Kenya and Bukavu in the Democratic Republic of Congo) where garbage disposal, points of sewage discharge, dumping of sewage raw materials by vacuum trucks, and pharmaceutical manufacturing activities were observed,” the researchers wrote.

In Asia the highest levels were in Lahore, in South America in La Paz and in Europe in Tubingen.

Worryingly, previous studies have shown how exposure to high levels of APIs can affect organisms, including fish and algae.

“For example, concentrations of antibiotics in surface waters have been shown to exceed the PNEC [predicted no‐effect concentrations] European and Chinese surface values,” the researchers explained.

“The anticonvulsant carbamazepine has been reported to occur at levels of concern for acute and chronic effects in fish, daphnids and algae in Africa, China and Israel.

In Asia the highest levels were in Lahore, in South America they were in La Paz and in Europe (map shown) they were in Tubingen, Germany.

In Asia the highest levels were in Lahore, in South America they were in La Paz and in Europe (map shown) they were in Tubingen, Germany.

“Stimulants have been highlighted as a group of concern in terms of aquatic impacts in Poland, Israel, China and Italy.”

The researchers hope their findings will encourage nations to take better action to tackle pharmaceutical pollution in rivers around the world.

“Overall, the results show that API pollution is a global problem that likely negatively affects the health of the world’s rivers,” the team concluded.

“Work is urgently needed to resolve the issue and bring concentrations down to an acceptable level.”

Worryingly, studies have shown that the presence of antibiotics in the environment contributes to the development of antimicrobial resistance (AMR), one of the major emerging threats to human health today.

“The burden of AMR in terms of lost lives, morbidity, healthcare costs and lost productivity is far greater than currently available statistics suggest – 25,000 deaths in 2007 – and projections estimate a 15% of AMR morbidity in Europe by 2050 with 390,000 deaths,” the EEB said.

FISH IN RURAL BRITISH WATERWAYS CONTAIN COCAINE AND KETAMINE: 2019 STUDY

Fish in British waterways contain cocaine, ketamine, methamphetamine, pesticides and drugs, a 2019 study found.

Kings College scientists working with the University of Suffolk took water samples from 15 sites in five rivers around Suffolk.

The authors said they “surprisingly” found cocaine in every sample, while the party drug ketamine and other pharmaceuticals were also found in freshwater shrimp.

Dr Leon Barron of King’s College London said: ‘Such a regular occurrence of illicit drugs in wildlife was surprising.

“We might expect to see them in urban areas such as London, but not in smaller, more rural catchments.

“The presence of pesticides which have long been banned in the UK also poses a particular challenge as the sources of these remain unclear.”

In the 56, different substances were detected – and the drug of abuse, cocaine, was most commonly found along with lidocaine.

Lidocaine has legal uses as a local anesthetic in dentistry, but is also often used illegally to “cut” cocaine, as it produces cocaine-like numbness of the gums, tricking users into thinking they are taking cocaine which has a similar effect.

Lead author Dr Thomas Miller of King’s College London said: “Although the concentrations were low, we were able to identify compounds which may be of concern to the environment and, importantly, which may pose a risk to wildlife.”

read more
1 2 3 7
Page 1 of 7